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The endoplasmic reticulum is a rich source of enzymes involved in the metabolism of
xenobiotics/drugs. Two enzymes, NADPH-cytochrome P450 oxidoreductase and a
carboxylesterase, have been studied.
The microsomal flavoprotein NADPH-cytochrome P450 oxidoreductase functions as a
'shuttle' in the transfer of electrons from NADPH to the physiological acceptors
cytochromes P450. Exogenous acceptors, such as paraquat and quinone containing
compounds, can also be reduced. To assess the role of P450 reductase in free radical
cytotoxicity via redox cycling of compounds, the rat enzyme was expressed in both S.
typhimurium and E. coli. S.typhimurium expressing P450 reductase were found to be
more sensitive to the cytotoxic effects of paraquat and menadione but not to the
anticancer drug doxorubicin. Similarly, the growth inhibitory effects of paraquat and
menadione were found to be enhanced in the P450 reductase expressing bacteria. Using
superoxide dismutase and catalase as markers of the oxidative stress inducible regulons
soxRS and oxyR, it was found that in E. coli there was no difference in the induction of
these enzymes between the expressing and non-expressing strains.
P450 reductase contains the cofactors FAD and FMN as well as being able to bind
NADPH and interact with P450s and membranes. In order to probe the evolution and
function of this protein, proposed domains of the enzyme have been expressed in E.coli
with a 6x-Histidine tag and purified by a single step using nickel-agarose
chromatography. The putative FMN and FAD/NADPH domains were found to bind their
respective cofactors independently. However, FMN and FAD binding in these domains
was found to be less than the expected ratio of 1 mole flavin: 1 mole protein. The
FAD/NADPH domain catalysed the one electron reduction of a variety of compounds.
This portion of the protein was unable to efficiently reduce cytochrome c or P450.
However, the FMN and FAD/NADPH domains could be combined to produce a
functional system that was active in the reduction of cytochrome c and cytochrome P450
(as judged by the oxidation of the CYP1A1 substrate 7-ethoxyresorufin). The FMN
domain containing the hydrophobic membrane anchor was a potent inhibitor of
reconstituted monooxygenase activity.
A human liver carboxylesterase was purified to electrophoretic homogenity after a two
step procedure involving DEAE-cellulose and hydroxylapatite chromatography. The
purified protein had an apparent molecular weight of 59kDa. and was glycosylated with
mannose residues. The enzyme had high specific activity to a variety of carboxylesterase
substrates and was inhibited by the serine hydrolase inhibitor, phenylmethylsulphonyl
fluoride, and the specific carboxylesterase inhibitor Z>w-4-nitrophenylphosphate. The
amino-terminal sequence showed high homology to a carboxylesterase cloned from
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other mammalian species. Western blot analysis with an antibody to the pure protein
showed that the enzyme was only expressed in the liver and its level varied by only 2.5
fold across a panel of human liver microsomes. The carboxylesterase was shown to be a
target for autoantibodies in the sera of patients with the immune mediated disease
halothane hepatitis. Immunohistochemical analysis found the protein to be located in the
ccntrilobular region of liver sections.
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1.1 General Aspects of Drug metabolism.
1.1.1 Historical Perspectives.
The origins of drug metabolism are to be found in the first half of the
nineteenth century. Later in that century all the major pathways of drug
metabolism were elucidated i.e. oxidation; reduction; hydrolysis; conjugation
with glycine, sulfuric acid and glucuronic acid; acetylation and mercapturic
acid synthesis (reviewed by Bachman and Bicknell, 1985). The discovery by
Ure (1841) on the biotransformation of benzoic acid into hippuric acid may be
considered as the birth of drug metabolism.
Conjugation reactions were the first to be discovered since the conjugating
agent endows the xenobiotic with distinct physicochemical properties which
facilitate their separation. On the other hand oxidative or phase I metabolites
belong to a great variety of chemical classes, have little in common and their
identification was difficult with the methodologies available at that time. The
early studies employed were based on administering the xenobiotic to man or
an animal and following its fate through analysis of urine. The anti¬
malarial quinine and the analgesic morphine which have been used
effectively for centuries served as model compounds for many of the
pioneering studies.
In early drug metabolism studies the chemical compound rather than the
organism was at the centre of the scientific interest. The fact that a foreign
compound was altered because it had been introduced into a system which
was able to perform chemical reactions was looked upon more as a
biochemical curiosity rather than a physiologically meaningful process
(Bachman and Bicknell, 1985). However, in the late nineteenth century this
attitude began to change when it was found that metabolites of aromatic
compounds were much less toxic than their parents (Baumann, 1876; Nencki
and Boutmy, 1892). This led to the synonym 'detoxication mechanisms'
which preceded the modern term of 'drug metabolism'. The former term
was changed after the discovery of toxication reactions in the 1930's
(Kinosita, 1937 and Sasaki and Yoshida, 1935). Together with his earlier work
and a later publication (Williams, 1947; Williams, 1959), Williams brought
together the main theories that had been accumulating for over fifty years
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about the physiolgical role of detoxication mechanisms/ drug metabolism.
These theories included; 'The Chemical Defense Hypothesis' of Sherwin
(1922) which described oxidations, reduction and conjugations as rendering
drugs more soluble thus aiding their excretion and 'The Decreased
Lipophilicity Hypothesis' of Schuller (1925) which stated that conjugations
lead to the decreased lipophilicity of the drug which in turn results in altered
distrubution, shifting the drug to the extracellular phase. These early
theories resulted in Williams's model of the "Biphasic Metabolism of Drugs',
which is outlined below in section 1.1.2.(Williams 1959).
The methodology available at a given time dictates what can be achieved in
the study of a scientific discipline. As the methodology improves we are able
to study the subject of interest in increasing detail, thus following a basic
reductionist philosophy. This is clearly exemplified in the study of drug
metabolism. Initial studies looked at the fate of a xenobiotic by the whole
organism and then eventually specific organs. It wasn't until the 1950s with
the development of isolation techniques of subcellular compartments that the
field of drug metabolism really took off (see section 1.1.4). The advancement of
protein purification techniques further aided the study of xenobiotic
metabolism in that the specific enzymes, that were catalysing the reactions,
could be isolated and studied. Now in the age of recombinant DNA technology
we are able to clone the cDNAs and genes for the enzymes that are involved in
drug metabolism. Through the use of heterologous expression systems
functional and structural analysis of individual enzymes can now be studied
in more detail. Furthermore, by studying gene promoter sequences the
regulation and tissue specific expression of these enzymes can be examined.
1.1.2 The Biphasic Metabolism Of Drugs.
The present day views of drug metabolism are highlighted in Figure 1.1 and,
as described above, first outlined by Williams (1947, 1959). The first phase can
result in the inactivation of a drug, the conversion of an initially inactive
compound into an active drug or the conversion of an active drug into another
active drug. The second phase of drug metabolism consists of conjugating
reactions, most of which convert active compounds into inactive excretory
products. Phase I reactions generally bring about the introduction of a
suitable functional group into the drug molecule. This changes the drug, in
2
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Figure 1.1. The biphasic metabolism of drugs.
most cases, to a more polar form and hence a more readily excretable form.
The product of phase I metabolism may then act as the substrate for phase II
metabolism, resulting in conjugation with endogenous substrates, increased
water solubility and polarity and drug elimination from the body in either the
urine or bile.
Oxidation, reduction, hydrolysis, hydration and isomerisation are all
examples of phase I metabolism. These reactions are mediated by a number
of enzyme systems including alcohol dehydrogenase, xanthine oxidase, the
microsomal flavin containing monooxygenase, carboxylesterase, epoxide
hydrolase and the cytochrome P450 monooxygenase system. This latter
system plays a central role in the oxidative metabolism of structurally diverse
xenobiotics and also plays an important role in the synthesis and degradation
of many endogenous biosynthetic intermediates. This system will be
discussed in more detail in section 1.2.1. Studies on NADPH cytochrome P450
oxidoreductase, an integral component of the P450 monooxygenase system
will be the basis of chapters 3 and 4. Serum as well as microsomal
carboxylesterases are involved in the hydrolysis of ester containing
compounds. These enzymes are not only important for the inactivation of
drugs but in the metabolism of pro-drugs into their active moieties. The
purification and characterisation of a human hepatic microsomal
carboxylesterase is the basis of the work presented in chapter 5.
Phase II metabolism or conjugation also involves a diverse group of enzymes
acting on a diverse group of compounds. Both foreign compounds and many
natural metabolites of the body containing suitable chemical groups such as
OH, NH2 and COOH, the products of phase I metabolism, will undergo
synthetic conjugation reactions. The conjugated products of phase II
metabolism are more water soluble and excreted in the the bile or urine.
Examples of phase II reactions include glucuronidation, catalysed by the
UDP-glucuronyl trnsferases; glycosidation catalysed by the UDP-
glycosyltransferases; sulfation, catalysed by the sulfotransferases;
methylation, catalysed by the methytransferases; acetylation, catalysed by the
acetyltransferases and glutathione conjugation, catalysed by the glutathione
S-transferases.
The further metabolism of glutathione conjugates which leads to cysteine
conjugates and mercapturic acids is considered by some workers as an
additional phase of metabolism. For example, metabolism of glutathione
conjugates may take place by the intestinal microflora which can result in
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reabsorption of the compound and further metabolism in the liver. More
recently the term "phase III" has been applied to describe the elimination of
glutathione conjugates from the cell by an ATP-dependent glutathione S-
conjugate export pump (Ishikawa, 1993). Whether these examples can be
considered as a further phase of drug metabolism is open to debate.
1.1.3. Localisation of Drug Metabolic Pathways.
In early drug metabolism studies, foreign compounds were administered to
animals or human subjects and reaction products looked for or identified in
the urine. The localisation of drug metabolic pathways initially involved
techniques such as hepatectomy of laboratory animals and perfusion of the
liver and kidneys (reviewed by Conti and Bicknell, 1977). These original
studies led to the conclusion that the liver was the major site of drug
metabolism. In a quantitative sense the liver is the main organ responsible
for both phase I and phase II drug metabolism reactions, although this is by
no means the only organ involved. Drug localisation and metabolism in a
given tissue is dependent on many factors including the physico-chemical
properties of the drug, chemical composition of the organ and the presence of
uptake mechanisms which may allow the drug to be 'trapped'. Other organs
where metabolic reactions have been observed include skin, gastrointestinal
tract, gastrointestinal flora, lung, blood, brain, kidney and placenta.
Most of our fundamental knowledge regarding the molecular mechanisms of
drug metabolism have been derived from studies on the liver. The
development of systems for the disruption of mammalian cells (Potter and
Elvehjem, 1936) and of centrifugal methods for the preparation of
enzymatically functional cellular organelles (Claude, 1941; Scheider, 1949)
facilitated approaches to examining in vitro metabolism of xenobiotics. The
first study utilising subcellular organelles was carried out by Mueller and
Miller (1948). They showed that N-demethylation and aromatic ring
hydroxylation occurred on aerobic incubation of dimethyl-1-4-
aminoazobenzene with pyridine nucleotide treated rat homogenates.
The majority of phase I reactions are carried out by enzymes located in the
endoplasmic reticulum of hepatic cells (Brodiee£ al., 1955; Gillette, 1963). On
homogenisation of cells the endoplasmic reticulum is disrupted giving rise to
small vesicles. These can be separated from the homogenate by high speed
centrifugation and give rise to the fraction known as microsomes. Phase II
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reactions are found to occur predominantly in the cytoplasm. The one major
exception to this being glucuronidation which is carried out by the UDP-
glucuronosyltransferases in the endoplasmic reticulum.
1.1.4 The endoplasmic reticulum.
Electron microscopy studies of hepatocytes reveal the endoplasmic reticulum
to be present throughout the cytoplasm as an extensive network of tubules,
vesicles and lamellae (Loud, 1968; Weibel et al., 1969). In the liver it is found
that the morophological characteristics of the endoplasmic reticulum vary
from region to region (Loud, 1968). On average the endoplasmic reticulum
occupies 15% of the total cell volume and has a volume 2.5 times that of the
nucleus and 65% that of the mitochondria. Compositional studies of rat liver
microsomes reveal the membrane of the endoplasmic reticulum to be
approximately 70% protein and 30% lipid (of which 85% is phospholipid) by
weight (Glaumann and Dallner, 1968). Microsomes have also been found to
contain cholesterol (0.6 mg/g liver), triglycerides (0.5 mg/g liver), small
amounts of cholesterol esters, free fatty acids and vitamin K (Depierre and
Dallner, 1975). Located on the endoplasmic reticulum are ribosomes and a
large number of enzyme and enzyme systems. Among the functions of the
endoplasmic reticulum other than drug metabolism (see sections above and
below) are the synthesis and transport of a number of proteins, including
glycoproteins and lipoproteins, synthesis of cholesterol, steroid hormones,
prostaglandins, phospholipids and triglycerides as well as glycogen
breakdown (Depierre and Dallner, 1975). The endoplasmic reticulum is well
known to respond to phenobarbital, carcinogens and other xenobiotics by
increasing its volume and surface area (about 2 fold in the case of
phenobarbital), (Straubli et al., 1969). Certain regions of the endoplasmic
reticulum bear ribosomes bound to the cytoplasmic surface (rough
endoplasmic reticulum) and are concerned with the synthesis of proteins
secreted from the cell and of proteins destined for incorporation into the
endoplasmic reticulum. Other regions are devoid of ribosomes (smooth
endoplasmic reticulum) and although not capable of synthesising proteins
are involved in the other numerous aspects of this membrane system.
Unlike other organelles, such as mitochondria and lysozymes, the
endoplasmic reticulum is extensively disrupted upon gentle homogenisation
of the liver. This breakage, into the closed vesicles termed microsomes, does
5
not seem to be a purely mechanical process, but to involve an active 'pinching
off process (Depierre and Dallner, 1975). Microsomes have ribosomes on
their outer surface and contain secretory proteins such as albumin (known to
be present in the lumen of the endoplasmic reticulum) in situ. Thus the
outside of the microsome corresponds to the cytoplasmic surface of the
endoplasmic reticulum, while the luminal surface is inside. To date it has
not yet been possible to obtain microsomes with the opposite orientation.
The endoplasmic reticulum has been a rich source in the study of protein
biosynthesis; lipid metabolism; prostaglandin, cholesterol and steroid
biosynthesis; and for the study of drug metabolism. The following sections
will now deal with the major drug metabolising systems found within the
endoplasmic reticulum. Particular emphaisis will be put on the cytochrome
P450 monooxygenase system.
1.2 Drug metabolising systems of the endoplasmic reticulum.
1.2.1. Cytochrome P450.
By far the most studied group of drug metabolising enzymes located on the
endoplasmic reticulum is the cytochrome P450 multisubstrate mixed
function monoxygenase system. The key enzyme components of the
microsomal system are the flavoprotein NADPH cytochrome P450
oxidoreductase (P450red), the cytochrome P450s and cytochrome b5. P450s are
also present in the mitochondria. However, these are quite distinct from their
microsomal counterparts in that they function with a two component system
comprising adrenodoxin and adrenodoxin reductase. The major P450s of the
mitochondria are the cholesterol side chain cleavage enzyme and steroid 17 p
hydroxylase (reviewed by Fevold, 1983). These enzymes are associated with
severe genetic defects in Cortisol biosynthesis (Miller and Levin, 1987). The
microsomal P450s will be dealt with in this section while section 1.2.2 will
discuss P450red with section 1.2.3 dealing with how these enzymes function
together to produce the electron transfer system responsible for the oxidation
of xenobiotics.
A reduced pigment of hepatic microsomes that had an absorption band with
a A,max at 450nm after binding carbon monoxide was first identified by
Klingenberg (1958) and Garfinkel (1958). This pigment was further
characterised as a hemoprotein of the b-type by Omura and Sato (1962).
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Through photochemical action spectra, Cooper et al., (1965) showed that this
hemoprotein was involved in the oxidation of drugs and steroids. The
solubilisation and resolution of the components of this system from
microsomal membranes and the reconstitution of an active complex
containing P450, P450red and phosphatidylcholine permitted the purification
and characterisation of these constitutents (Lu and Coon, 1968; Strobel et al.,
1970).
Animals, plants andmicroorganisms have been found to contain P450s and in
mammals the enzyme system has been found in all tissues examined so far
(Porter and Coon, 1991). P450s have been stated to be the most versatile
catalyst known (Porter and Coon, 1991). Among the compounds metabolised
by P450s are (a) endogenous compounds such as fatty acids, prostaglandins,
steroids and ketones; (b) carcinogens, including polycyclic aromatic
hydrocarbons, nitrosamines, hydrazines and arylamines and (c) a plethora of
clinically important drugs such as the tricyclic antidepressants, antibiotics,
cardiovascular agents, anti-inflammatory compounds and
immunosuppressants (Gonzalez, 1989). Reactions that have been shown to be
mediated by P450s include aromatic and aliphatic hydroxylation, epoxidation,
peroxidation, deamination, desulphuration, dehalogenation and reduction
(Porter and Coon, 1991; Guengerich,1991). The basic and unifying reaction
carried out by P450s is shown below, with RH representing the substrate;
RH + 02 + NADPH + H+ —> ROH + H20 + NADP+ (Equation 1)
To date 221 P450 cDNAs have been isolated which were obtained from 31
eukaryotes, including 11 mammalian species, and 11 prokaryotes (Nelson et
al., 1993). It has been estimated that greater than thirty P450s will be
expressed at any one time in a mammalian species and many of these are
concurrently expressed in a single tissue (Guengerich, 1991).
To aid in the distinction of particular P450 isoforms and to allow isoforms
from different species to be logically related, a nomenclature system for this
supergene family has been devised (Nelson et al., 1993). The basis for this
system is alignments of the amino acid sequences deduced from P450 cDNAs
(Nebert et al., 1991; Nelson et al., 1993). P450 enzymes are denoted by the root
'CYP' and distinguished from other families by an arabic numeral. There is
then a letter describing the subfamily and finally another arabic numeral
denoting the isoform of that subfamily. The mammalian P450 families 1 to 3,
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with the possible inclusion of family 4 are involved in the metabolism of
xenobiotics The individual enzymes of these families are capable of
metabolising a wide range of substrates (Guengerich, 1991). A further six
families are involved in the metabolism of of steroids and bile acids. These, in
comparison to the xenobiotic metabolising forms, have very specific
substrates and reactions.
The diversity of the P450 system has been proposed to have occurred as an
adaptive response to environmental challenge. The drug metabolising P450s
are thought to have appeared at more advanced stages of evolution in order to
protect against toxins in the environment (Nebert, 1979, 1992). This adaptive
response is analagous to the response of the immune system when
challenged by a foreign compound. The number of man-made
'environmental chemicals' has been estimated at greater than 200,000 (Porter
and Coon, 1991). Most of these are thought to be potential substrates for P450
or to act as inhibitors or inducers of the various isoforms.
An area of research that has recieved much attention is the regulation of
P450 expression (reviewed by Gonzalez, 1989; Okey, 1990). Considerable
diversity in the mechanisms of regulation of these enzymes exists. The most
common means of regulation is transcriptional, but post-transcriptional
mechanisms include mRNA stabilisation and post-translational
modifications. Stabilisation or degradation of P450 protein may be mediated
through changes in the phosphorylation state of the enzyme.
Structural studies on mammalian P450s have, until recently, been based on
the three dimensional structure for the soluble prokaryote P450 (CYP101,
P450cam) from Pseudomonas putida (Poulos et al., 1987). More recently the
structure of the P450 portion of the soluble P450/P450 reductase fusion protein
from Bacillus megaterium has been determined (Ravichandrin et al., 1993).
This has been proposed to be a better model for the structure of mammalian
P450s since it shares homology with the P450s of family 4. Mammalian P450s
are believed to have a membrane attachment region at the NH2-terminus of
the protein, while the rest of the protein exists on the cytosolic side of the
endoplasmic reticulum (Nelson and Strobel, 1988).
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1.2.2 NADPH cytochrome P450 oxidoreductase
The first reports concerning what is now known as NADPH cytochrome P450
oxidoreductase (P450red) described the purification of a flavoprotein that was
involved in the reduction of cytochrome c (Haas, 1940; Horecker, 1950). This
early work showed that NADPH was the source of reducing equivalents. The
yeast enzyme was found to contain FMN as a prosthetic group (Haas, 1940)
while the pig liver enzyme had FAD as its cofactor (Horecker, 1950). The
flavin groups were shown to be essential for the reduction of cytochrome c.
Phillips and Langdon (1962) and Williams and Kamin (1962) subsequently
found the enzyme to be located in the endoplasmic reticulum. However, the
physiological substrate for P450red was unknown (since cytochrome c is
found in the mitochondria). Furthermore, the involvement of the flavins in
the electron transport process was not understood and the exact flavin
content of P450red was unknown. More than ten years later the protein was
finally identified as containing one molecule each of FMN and FAD (Iyanagi
and Mason, 1973; Yasukochi and Masters, 1976). Until the recent discovery of
the nitre oxide synthases (Bredt et al., 1991), P450red was a unique
mammalian enzyme in that it contained both of these two flavins as
prosthetic groups.
Indirect support for the role of P450red in microsomal hydroxylation and
demethylation reactions came about when it was found that cytochrome c
reductase activity could be concomitantly induced (Ernster and Orrenius,
1965). Direct evidence for the involvement of P450red in microsomal
hydroxylation reactions came from reconstitution of laurate co-hydroxylase
activity from detergent solubilised preparations of P450, P450red and
phosphatidylcholine (Lu and Coon, 1968). The early difficulties in identifying
a physiological role for the reductase was due to the methods of purification
employed, as these studies used trypsin or lipase treatment (Horecker, 1950
andWilliams and Kamin, 1962). This resulted in a 68 kDa. protein which had
lost approximately 5 kD. from the NH2-terminal region. This region is
responsible for interactions with both P450 and phospholipid (Black and Coon,
1982). The proteolytically cleaved enzyme is unable to reconstitute with P450s
but is still capable of reducing a large number of one and two electron
acceptors including cytochrome c, ferricy anide, 2,6
dichlorophenolindophenol, menadione, nitroblue tetrazolium and 3-
acetylpyridine adenine dinucleotide phosphate (Vermillion and Coon, 1978a).
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The uncleaved form of reductase purified from detergent solubilised
microsomes was found to have a molecular weight of 76-80 kDa. and to
support P450-dependent reactions (Yasukochi and Masters, 1976). In
contrast to the P450 superfamily of enzymes only one form of the P450red has
ever been isolated from mammals. Southern blot analysis suggests that the
reductase is the product of a single copy gene (Porter et al., 1991).
Although the most extensively studied acceptors of electrons from P450red
are the cytochrome P450 superfamily of enzymes, P450red has been shown to
reduce a variety of other endogenous substrates and artificial compounds. As
well as the one and two electron acceptors described above, P450red has been
shown to be involved in nitroreduction (Heimbrook and Sartorelli, 1986) and
in azoreduction of some compounds (Zbaida and Levine, 1990). P450red has
also been shown to reduce mitomycin c (Keyse et al., 1984) and the novel
benzotriazine SR4233 (Walton et al., 1992) which can result in the activation of
biologically active quinones and the production of reactive oxygen radicals
through redox cycling (Kappus, 1986). Thus, levels of P450red may be
important in the response to certain types of cancer chemotherapy. Other
catalytic mechanisms carried out by the reductase involve the reduction of
cytochrome b5 (Enoch and Strittmatter, 1979). A large number of reactions
appear to be catalysed by a cytochrome bs mechanism including fatty acid
elongation (Keyse et al., 1979), phospholipid desaturation (Pugh and Kates,
1977) and stearyl CoA desaturation (Shimekata et al., 1972). P450 reductase
also appears to be involved in supplying electrons to heme oxygenase
(Schahter et al., 1972; Maines, 1988). One product of heme degradation
catalysed by the heme oxygenase system is carbon monoxide. Recent work
showing the colocalisation of P450red and heme oxygenase along with the
rate limiting enzyme in heme biosynthesis (ALS, amino laevulenate
synthetase) and the carbon monoxide sensitive guanylyl cyclase in the brain
has led to speculation that carbon monoxide produced by this system may be
involved in neurotransmission (Verma et al., 1993). This speculation was
based on in situ hybridisation analysis and the similarity between this system
and the nitric oxide system (Bredt et al, 1991).
After the identification of P450red as the electron donor for P450- mediated
reactions, the mechanism of action of this enzyme attracted considerable
attention. Interest in the protein also arose because of its unique property of
containing two different flavins. Since P450red contains the flavins FMN and
FAD as prosthetic groups (Iyanagi and Mason, 1973) it appears yellow in
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colour. A useful characteristic of flavins is that their absorption spectra are
altered by changes in their reduction state. Therefore, the reduction state can
be examined by measuring changes in the visible absorbance range. Each
flavin is capable of carrying up to two electrons, therefore P450red can exist in
a state containing anywhere between zero and four electrons. Hence, there
are nine potential P450red subforms possible. Spectra of all of these subforms
have now been obtained by both experimental means and computer modeling
(reviewed in Backes, 1993). A variety of these spectra will be discussed and
shown in relation to the work presented in Chapter 4 of this thesis.
Many studies in the field of P450red research have come to the conclusion
that FAD is the low potential flavin and accepts reducing equivalents from
NADPH+ while FMN is the high potential flavin, recieving reducing
equivalents from FADH- or FADH2 and transferring them to P450 and
cytochrome c or other electron acceptors (Backes, 1993). The FAD site
appears to be involved in the reduction of ferricyanide but is not the major site
for the reduction of other one electron acceptors (Vermillion and Coon, 1978b).
The transfer of electrons between flavin species has been examined in some
detail by a laser flash photolysis technique (Bhattacharyya et al., 1991). Rapid
intramolecular transfer between flavins was observed. The major function of
P450 reductase is to transfer electrons to cytochrome P450, but, because it has
the potential of nine different subforms (depending on the number of
electrons present) it cannot be treated as a simple electron donor. Each
reductase subform will have its own characteristic ability to donate electrons
to an acceptor such as P450. Work by Backes and Recker-Backes (1988)
suggest that both the 3 and 4 electron containing forms of P450red can rapidly
transfer electrons to the P450s CYP1A2 and CYP2B4, whereas the 2 electron
containing reductase can donate electrons at approximately 10% of the rate
found for the more reduced subforms.
Evidence thus suggests that NADPH cytochrome P450 oxidoreductase has the
ability to bind FMN, FAD, NADPH and to interact with membranes and
proteins such as cytochrome P450. However, in spite of the importance and
complexity of this protein little is understood about the relationship of the
function of P450red to its physical structure.
1 1
1.2.3. Mechanism of cytochrome P450 catalysed reactions.
Stoichiometric studies on the monooxygenation reactions catalysed by P450s
have indicated the consumption of one molecule each of NADPH and
molecular oxygen resulting in the introduction of one oxygen atom into the
substrate molecule (Equation 1). This indicates the supply of two reducing
equivalents from NADPH to one P450 molecule during one cycle of the
reaction (Guengerich, 1991). Titration of purified P450 with sodium dithionite
in the absence of oxygen shows that complete reduction of P450 occurs by one
reducing equivalent per mole of heme (Peterson et al., 1977). Therefore, the
mechanism of P450-catalysed oxygenation must explain the introduction of a
second electron into the P450 in the reaction cycle. P450red has been
identified as the physiological donor of electrons for this system (see 1.2.2).
Cytochrome bs may also be involved in the donation of the second electron,
although the exact role of this cytochrome in the monooxygenation system
has not been fully characterised. It appears that some P450s require
cytochrome b5 for efficeint catalysis in reconstituted systems whereas others
do not (Schenkman, 1976; Pompon and Coon, 1984).
Cytochrome P450 is present in the endoplasmic reticulum in a 10-25 fold
molar excess over P450red (Estabrook et al., 1971; Peterson et al., 1976).
However, the functional interaction between these two enzymes appears to be
at a ratio of 1:1 (Miwa et al., 1979; Miwa and Lu, 1984). Therefore, only a
fraction of the P450 pool can exist in a functional complex with P450red at any
one time. Thus, accessibility to P450red may be rate limiting. This could be of
importance when a P450 is induced by xenobiotics. Although P450red can
also be induced by a variety of xenobiotics it is not usually up-regulated to the
same extent as some P450s (Gonzalez, 1989). Two possible mechanisms for
the interaction between a P450 and P450red have been proposed (Miwa and
Lu, 1984; Wagner et al., 1984). The first proposes that the two enzymes form a
stable and catalytically active complex. The second suggests that transient
complexes are formed as a result of random collisions occuring from lateral
diffusion within the membrane of the endoplasmic reticulum. Although the
exact mechanism of interaction has not yet been elucidated, evidence points to
there being an electrostatic interaction between P450s and P450red (Berhardt
et al., 1984, 1988; Schenkman et al., 1991). However, interactions may differ
between the isoforms of P450. It has been demonstrated that specific lysine
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Figure 1.2. Proposed catalytic cycle for P450-mediated reactions.
(From Porter and Coon, 1991).
electron transfer complex with P450red (Shimizu et al., 1991). Covalent
modifications of lysine residues on this protein was also shown to affect
interactions with P450red in a reconstituted system. With regard to P450red,
Nadler and Strobel (1991) showed in a cross-linking study that a cluster of
acidic amino-acids (100-120) on the reductase was involved in the interaction
with rat CYP1A1.
The scheme for the mechanism of action of cytochrome P450 is shown in
Figure 1.2. The first step in the reaction cycle is substrate binding, which
perturbs the spin state equilibrium of the cytochrome and facilitates the
uptake of the first electron from P450red. This electron is derived from the
two electron donor NADPH and hence the reductase can be thought of as a
transducer. The mechanism by which P450red passes reducing equivalents
from NADPH through firstly FAD and then FMN onto P450 is a highly
complex process which has been studied for over the last twenty years
(reviewed by Backes, 1993). Substrates which undergo reduction by P450,
rather than oxygenation, such as epoxides, N-oxides, nitro and azo
compounds, and lipid hydroperoxides accept two electrons in a step-wise
fashion to give RH(H)2. To initiate the oxidative reactions, O2 is bound to the
ferrous P450. This intermediate can also be described as the resonance form,
Fe3+(C>2-d, with substrate still present. Transfer of the second electron then
occurs with the possible involvement of cytochrome b5 as an additional
electron donor in mammalian systems (Schenkman et al., 1976; Pompon and
Coon, 1986). The next step is less well understood. It involves splitting of the
oxygen-oxygen bond and the uptake of two protons with the generation of an
'activated oxygen' and the release of H2O. Oxygen insertion into the substrate
is believed to involve hydrogen abstraction from the substrate and
recombination of the resulting transient hydroxyl and carbon radicals to give
the product (Porter and Coon, 1991). Dissociation of ROH then restores the
P450 to the starting ferric state. Also shown in Figure 1.2 is the mechanism
by which a peroxy compound may substitute for O2 and reducing equivalents
in what is known as the peroxide shunt.
A schematic representation of P450 redutcase, cytochrome bs and P450 is
shown in Figure 1.3.
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Figure 1.3. Schematic representation of the P450 monooxygenase
system in the endoplasmic reticulum.
1.2.4. UDP-Glucuronosyltransferases.
One of the most important phase II conjugation reactions is that of
glucuronide conjugation. Many functional groups have the potential to be
glucuronidated including those found on unmodified compounds as well as
the products of phase I metabolism. In glucuronidation, the sugar acid D-
glucuronic acid is coupled with compounds through -OH, -SH or NH groups
to form the p-D-glucopyranosiduronic acids or glucuronides. It is the UDP-
glucuronosyl transferases (UDPGTs) that catalyse the transfer of glucuronic
acid to the suitable compound to form the glucuronic conjugate. Similar to
the cytochrome P450 monooxygenase system, many endogenous compounds
serve as substrates for the glucuronidation reaction, including bilirubin,
steroid hormones, thyroxine and triiodothyronine The availability of the co-
substrate UDPGA is a critical determinant of the glucuronidating capacity of
a tissue (Mulder et al., 1990) with the liver usually containing the highest
amounts of UDPGA.
UDP-Glucuronic acid + ROH —> RO-glucuronide + UDP (Equation 3)
Like the P450 superfamily of enzymes it is has become clear through the
advances in cDNA and gene cloning that the UDPGTs form a large family of
isozymes (Burchell et al., 1991). This heterogeneityof UDPGTs had been
observed in earlier studies employing enzyme assays, tissue distribution and
purification studies (Burchell and Coughtrie, 1989).
Similar again to the P450 superfamily, the UDPGTs are inducible by a variety
of xenobiotics including phenobarbital, 3-methylcholanthrene and
peroxisome proliferators (Burchell and Coughtrie, 1989).
Analysis of the topology of these 50-56 kDa. glycoproteins (using antibodies,
protease and computer predictions) suggests that the transferases are
slightly exposed on the cytoplasmic surface. This region is joined by a
membrane spanning region to the majority of the protein, including the
active site, on the luminal side of the endoplasmic reticulum.
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1.2.5. Epoxide hydrolases.
Epoxide hydrolases catalyse the formation of dihydrodiols and other glycols
from biologically reactive epoxides (Oesch and Daly, 1971). It is the
metabolism of compounds by the P450 system that can produce these highly
electrophilic epoxides which are capable of modifying cellular
macromolecules. The epoxide hydrolase converts these intermediates into
the chemically less reactive dihydrodiols. There are several forms of epoxide
hydrolase including both cytosolic and microsomal species. The major form
of microsomal epoxide hydrolase (mEH) hydrates a wide range of substrates
including epoxides of cyclic compounds. The dihydrodiols that are produced
may then be conjugated by a phase II system and ultimately excreted.
However, some polycyclic aromatic diols can serve as substrates for P450s
which can result in the production of highly reactive potentially carcinogenic
diol epoxides. Therfore the epoxide hydrolases play a central role in both the
detoxication of xenobiotics and in the activation of metabolites to more potent
carcinogens. This pathway of detoxication/activation is shown in Figure 1.4.
Purified preparations of microsomal epoxide hydrolase exhibit molecualr
weights of approximately 48-54 kDa. This is in agreement with the deduced
sizes predicted from the cDNAs obtained from a variety of species including
man. Compared to other species, human liver microsomes contain relatively
high levels of epoxide hydrolase activity with substantial variation in the
enzyme activity within the human population (Kapitulnik 1977).
Figure 1.4. Epoxide formation and metabolism. Scheme for the metabolism
of the polycyclic aromatic hydrocarbon, benzo(a)pyrene resulting in the
formation of of epoxides , diols and diol-epoxides.
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1.2.6 Flavin Containing Monooxygenases.
The flavoprotein that catalyses NADPH and oxygen-dependent oxidation of a
wide variety of xenobiotics was previously termed the microsomal mixed
function amine oxidase and is now known as the flavin containing
monooxygenase (. Jakoby and Zeigler 1990). With few exceptions, virtually all
xenobiotics bearing amine, hydrazine, thiol, disulphide, thiocarbamide,
thioamide, thio acid, dithiocarbamide or phosphine groups serve as
substrates. Hence this broad substrate specificity resesmbles that of the P450
monooxygenase system The flavin containing monooxygenase is a polymeric
protein exhibiting a monomeric molecular weight of 65 kDa. and contains one
mole of FAD per mole of protein (Ziegler and Mitchell, 1972; Poulsen and
Ziegler, 1979). The flavin containing monooxygenase is the only mammalian
flavoprotein hydroxylase known although many bacterial examples are
known. Using N, N'-dimethylaniline as a representative substrate, the flavin
containing monooxygenase system catalyses the following reaction (Equation
3).
NADPH+ H+ + 02 + C6H5-N(CH3)2 —> NADP+ + H20 + C6H5-N(CH3)2->0
1.2.7. Carboxylesterases
The mammalian carboxylesterases are a family of non-specific hydrolases
found in abundance in the endoplasmic reticulum of the liver (Hosokawa et
al., 1989). These enzymes catalyse the hydrolysis of many xenobiotics and
therapeutic drugs containing ester and amide bonds (Heymann, 1982).
However, in many cases hydrolysis of these bonds is only a minor
detoxication pathway. The normal chemical mechanism for the hydrolysis of
ester and amide bonds are very similar and shown in Equation 4 below.
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The liver microsomal carboxylesterases have been shown to be involved in the
hydrolysis of ester bonds in narcotics, local anaesthetics and analgesics.
Esterification of drugs to form prodrug esters may result in improved
properties as compared to the parent compound. By esterification with small
aliphatic or aromatic carboxylic acids the polarity of the drug is reduced.
This promotes absorption through the intestinal wall. For example, inactive
esters of the centrally acting drug oxazepam are bioactivated by hepatic
carboxylesterase (Maksey et al., 1977). Prodrugs can also be used to prolong
the action of drugs. Hydrolysis of peptide bonds in prodrugs has been used
successfully to increase the selectivity of anticancer drugs (Carl et al., 1980).
The microsomal carboxylesterases will be discussed in more detail in the
introduction to chapter 5 where the purification and characterisation of a
human microsomal carboxylesterasewill be discussed.
1.3 Summary
This introduction has served to highlight some important aspects of drug
metabolism and to give an overview of some of the enzyme systems involved
in the metabolism of exogenous compounds found in the endoplasmic
reticulum. Particular emphasis was placed on the P450 monooxygenase
system as studies on NADPH cytochrome P450 oxidoreductase are the major
theme of the work presented within this thesis. The use of a bacterial
expression system to study the role of this enzyme in the bioactivation of redox
cycling compounds will be the focus of work in chapter 3. Structural and
functional studies of NADPH cytochrome P450 oxidoreductase are dealt with
in chapter 4, where the use of a bacterial expression system was used to
express and purify a variety of domains of structural importance. Chapter 5
deals with the purification and characteristion of a human hepatic
microsomal carboxylesterase. The role of this enzyme in an immune
mediated adverse drug reaction, halothane hepatitis, will be considered.
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Chapter 2: Materials and Methods.
2.1 Bacterial strains, growth media, antibiotics and transformation
of bacteria.
2.1.1 Bacterial Strains.
E. coli: JM109 (rec Al, sup E44, end Al, hsd R17, gyr
A96, rel Al, thi D (lac-pro AB))
F' [/raD36 proAB+lacI1 lacZ DM15]
NM522 Sup E, thi-1 D (lac-pro AB), D(hsd SMM-
crB)5 (nk-mk)
These strains were used as general hosts for recombinant manipulations
and for heterologous expression.
E. coli: BL21(DE3) hsd S gal (lcl ts 857 ind 1 Sam 7 nin 5 lac
UV5-T7 gene 1) pLysS.
This strain was used for heterologous expression studies when using the
pET15b system. Note, the plasmid pLysS contains a copy of T7 lysozyme
under the control of laq 11 and is selected for using chloramphenicol.
S. typhimurium: The strains TA1538 and LR5000, as described by Ames et
al., (1979), were used as hosts for heterologous expression.
2.1.2 Bacterial culture media.
L.B.-broth/litre: 10 g bactotryptone (Difco), 5 g yeast extract (Difco), 5 g
NaCl.
L.B.-agar/litre: As for L.B.-broth with an additional 15 g/litre of agar
(Difco).
Minimal agar/litre: 200 ml 5x M9 salts (64 g NaHPO4.7H20,15 g KH2PO4,
2.5 g NaCl, 5 g NH4CI, 20 ml 20% glucose (w/v)),
supplemented with maltose to 0.2% (w/v) and
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MgSC>4 to 0.1 mM. This agar was used to ensure
retention of the F' episome in bacterial strains.
2.1.3 Antibiotics.
Ampicillin: Stock of 50 mg/ml prepared in distilled water, used at a
working concentration of 50 gg/ml in both media and
agar plates.
Chloramphenicol: Stock of 34 mg/ml prepared in ethanol, used at a
working concentration of 34 gg/ml in both media and
agar plates.
2.1.4 Bacterial transformation using calcium chloride.
0.5 ml of an overnight culture of E.coli was added to 20 ml of L.B. broth and
allowed to grow with shaking until the culture reached an O.D.600 °f 0.5-0.6.
Cells were pelleted by centrifugation at 6,000 g, 4°C for 5 minutes,
resuspended in 10 ml of 100 mM calcium chloride and kept on ice for 1 hour.
The cells were pelleted again in an identical manner and resuspended in 2
ml of 100 mM calcium chloride. Cells were stored at 4°C and used within 2
days of preparation.
Ligation mix or plasmid DNA (0.01 gg-1 gg) was added to 200 pi of competent
cells and left on ice for 1 hour. The cells were then heat shocked at 42°C for 90
seconds and added to 500 pi of prewarmed L.B.-broth. The cells were pre-
expressed at 37°C for 1 hour to allow for the expression of resistance proteins.
The cells were then pelleted, 6,000 g for 5 mins, resuspended in 200 pi of fresh
L.B. broth and applied to an L.B. agar plate, containing the appropriate
antibiotic(s), inverted and incubated overnight at 37°C .
2.1.5 Transformation of bacteria by electroporation.
Since calcium chloride treatment (2.1.4) does not generate a high level of
transformation competent cells in S.typhimurium, these bacteria were
transformed by electroporation. This was carried out by mixing 0.1 pg of
plasmid DNA with 500 pi of bacteria, O.D.600 = 0.6, and electroporating them
at 40 pF, 0.2 kV using an IBI electroporator. The cells were pre-expressed at
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37°C for 1 hour to allow for the expression of resistance proteins. The cells
were then pelleted, 6,000 g for 5 mins, resuspended in 200 pi of fresh L.B. broth
and applied to an L.B. agar plate, containing the ampicillin at 50 pg/ml,
inverted and incubated overnight at 37°C.
2.2 DNA isolation and analysis.
2.2.1 Plasmids used in this study.
Plasmid Use
pTZ19R (Pharmacia) General cloning
pCITE2a (Novagen) General cloning;has a very large
2.2.2 Plasmid preparations.
2.2.2a DNA isolation from small scale (5 ml) bacterial cultures.
Bacteria from an overnight culture were harvested by centrifugation at 6,000
g for 10 minutes and resuspended in 100 pi of 10 mM Tris.HCl, 0.1 mM EDTA
buffer, pH 8.0. The cells were lysed by the addition of 200 pi of 0.2 M NaOH, 1%
SDS (w/v) and left at room temperature for 5 minutes. To the lysed bacteria 40
pi of 3 M potassium acetate, pH 4.8, was added and left at room temerature for
2 minutes before centrifugation, 13,000 g for 15 minutes, 4°C, to remove
genomic DNA and cell debris. RNA was precipitated from the supernatent
fraction by the addition of 450 pi of 5 M LiCl and storage at -20°C for at least 30
minutes. The precipitated RNA was removed by centrifugation, 13,000 g for
15 minutes, 4°C, before precipitating the plasmid DNA with 1.5 volumes of
isopropanol. After being left at room temperature for at least 5 minutes, the
DNA was pelleted by centrifugation, 13,000 g for 10 minutes, room
temperature, and then washed with 70% ethanol before being dried in a
vacuum oven at 30°C. The resulting plasmid DNA was dissolved in 25-50 pi
10 mM Tris.HCl, 0.1 mM EDTA buffer, pH 8.0. 5 pi of RNAse A (2 mg/ml)
was added to the DNA and incubated at 37°C for 15-30 minutes.
polylinker
pKK223-3 (Pharmacia)






2.2.2b DNA isolation from medium scale (up to 100 ml) and large
scale (above 100 ml) bacterial cultures.
Qiagen DNA affinity columns (Qiagen Inc.) were used in the isolation of
plasmid DNA from medium and large scale bacterial cultures. Steps in the
procedure were scaled up accordingly from the protocol described above
(2.2.2a) up to the addition of 3 M potassium acetate (pH 4.8). At this point the
sample was immediately centrifuged for 30 minutes at 30,000 g. The
supernatent, containing the plasmid DNA, was applied to an appropriately
sized Qiagen column which had been previously equilibrated with buffer QBT
(750 mM NaCl, 50 mM MOPS, 15% (v/v) ethanol, 0.15% (v/v) Triton X-100, pH
7.0) and allowed to enter the resin under gravity. The column was washed
with 3 column volumes of buffer QC (1 M NaCl, 50 mM MOPS, 15% (v/v)
ethanol, pH 7.0) during which the plasmid DNA remains bound to the resin.
The plasmid DNA was eluted from the resin with 1.5 column volumes of high
pH buffer QF (1.25 M NaCl, 50 mM MOPS, 15% (v/v) ethanol, pH 8.2). The
plasmid DNA was precipitated from the eluant by the addition of 0.7 volumes
of isopropanol and collected by centrifugation at 30,000 g for 30 minutes. The
DNA pellet was resuspended in 50 pi of 10 mM Tris.HCl, 0.1 mM EDTA, pH
8.0 per 100 ml of initial culture.
2.2.3 DNA concentration estimation.
Spectrophotometric readings of a known dilution of DNA samples were taken
at 260 nm and 280 nm. An A26O reading of 1 corresponds to approximately 50
pg/ml for double stranded DNA. An estimation of sample purity is provided
by the ratio of the absorbance values at 260 nm and 280 nm, with pure DNA
having a value of 1.8.
2.2.4 Restriction endonuclease analysis of DNA samples.
Restriction endonucleases were obtained from Boehringer Mannheim (BCL),
New England Biolabs, Bethesda Research Laboratories (BRL) or Amersham
International (Amersham). Digestions were carried out using the
manufacturer's recommended buffer and conditions.
21
2.2.5 Agarose gel electrophoresis of DNA.
DNA samples were analysed using horizontal gel electrophoresis tanks
(BRL). Agarose gels were prepared from electrophoresis grade (Ultra Pure,
BRL) agarose for both diagnostic and preparative gels. Agarose was used at a
variable concentration between 1 and 2% (w/v) in TAE buffer (0.04 M Tris-
acetate, 1 mM EDTA, pH 8.0). 0.2 volumes of gel-loading dye (0.25% (w/v)
bromophenolblue, 0.25% (w/v) xylene cyanol FF, 15% (w/v) ficoll, in water) was
added to DNA samples before applying them to the gel. Following
electrophoresis, the DNA samples were stained with ethidium bromide by the
addition of ethidium bromide to a concentration of 0.5 pg/ml in water. The
gel was then washed extensively with distilled water and the DNA visualised
using a short wavelength trans-illuminator.
2.2.6 DNA fragment isolation and preparation for subcloning.
The DNA fragment ("insert DNA") to be subcloned, whether derived from a
plasmid or the polymerase chain reaction (PCR), was separated from other
DNA material on a 1- 2% agarose gel depending on the size of the fragment.
The DNA of interest was dissected from the body of the ethidium bromide
stained gel using a scalpel. The insert DNA was separated from the agarose
using either Geneclean (Bio 101 inc.) glass bead solution or GlassMax (BRL)
glass matrix spin columns according to the manufacturer's instructions. If
the insert DNA required further modification prior to subcloning, e.g. 'end-
filling' or restriction endonuclease digestion, then these manipulations were
performed. Following these modifications the DNA was purified from any of
the contaminating proteins by using the Geneclean or Glassmax systems, as
discusssed above. The DNA was resuspended in a volume of 10-20 pi (10 mM
Tris.HCl, 0.1 mM EDTA, pH 8.0).
2.2.7 Vector preparation for the receipt of DNA inserts.
The vector into which the DNA insert was to be subcloned was digested with
the appropriate restriction endonucleases and subjected to any further
modifications such as "end-filling" or dephosphorylation. Following these
manipulations the vector was purified from any contaminating proteins by
using the Geneclean or Glassmax systems (2.2.6) and resuspended in 10 mM
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Tris.HCl, 0.1 mM EDTA, pH 8.0. The DNA concentration was then estimated
(2.2.3).
2.2.8 "End-filling" recessed 3' terminals of PCR products using the
"Klenow" fragment.
In order to generate DNA molecules with non-recessed 3' termini from PCR
products the recessed terminii can be filled in by the action of the large
fragment of E. coli DNA polymerase I, termed the "Klenow" fragment (BRL).
1-10 pg of DNA was mixed with 50 mM Tris.HCl, pH 7.5 10 mM MgCl2, 0.25
mM each dNTP (Pharmacia) and 1 unit of Klenow fragment in a final
volume of 25 pi and incubated at 37°C for 30 minutes. The DNA was purified
from the enzyme and unincorporated dNTPs using Geneclean (2.2.6) and
resuspended in 20 pi of 10 mM Tris.HCl, 0.1 mM EDTA, pH 8.0.
2.2.9 Dephosphorylation of 5' terminal phosphates.
Vectors linearised using a single restriction endonuclease or with two
restriction endonucleases, one of which may be inefficient in its cutting {e.g.
Nde I) may recircularise on ligation. To reduce this possibility 5' terminal
phosphates were removed from digested vector DNA using calf intestinal
phosphatase (CIP) (Promega). 1-5 pg of DNA was resuspended in 40 pi of 10
mM Tris.HCl ,pH 8.0 and 5 pi of lOx CIP buffer (0.5 mM Tris.HCl, pH 9.0, 10
mM MgCl2, 1 mM ZnCl2, 10 mM spermidine). To this, 0.5 units of CIP was
added and the sample incubated at 37°C for 30 minutes followed by the
addition of a second 0.5 unit aliquot of CIP for a further 30 minutes at 37°C.
The DNA was then purified from any contaminants using Geneclean (2.2.6)
and resuspended in 10-20 pi of 10 mM Tris.HCl, 0.1 mM EDTA, pH 8.0.
2.2.10 Ligation of the prepared insert and vector DNA.
For ligation of DNA fragments and vectors with cohesive terminals, blunt
ends or with both, 100-200 ng of vector DNA and a 3 fold excess of insert DNA
were mixed to a final volume of 7.5 pi. To this was added 1 pi of lOx ligation
buffer (200 mM Tris.HCl, pH 7.6, 50 mM MgCl2, 50 mM dithiothreitol), 1 pi of 5
mM ATP and 1 unit of T4 DNA-ligase (BCL). The reaction was allowed to
proceed for no longer than 16 hours at 12°C.
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2.2.11 Screening of bacterial colonies transformed with
recombinant plasmid constructs.
2.2.11a a-complementation screening of bacterial colonies.
The vector pTZ19R used in this study carries a short segment of DNA that
contains the regulatory sequence and first 146 amino acids of the E.coli lac Z
gene encoding the fl-galactosidase enzyme. On transformation of the parent
plasmid into certain host strains, which produce the C- terminus of the p-
galactosidase enzyme encoded on the F' episome, the two fragments can
interact and produce an active protein (Ullman et al., 1967). This process is
termed a-complementation. Bacteria transformed with the parent vector
form blue colonies in the presence of X-gal (5-bromo-4-chloro-3-indolyl-|3-D-
galactoside) after induction of the lac Z gene fragments by IPTG addition.
However, insertion of a recombinant fragment (the "insert") into the cloning
site of the vector leads to disruption of the lacZ N-terminal fragment
resulting in colonies that appear white in the presence of X-gal or IPTG.
Bacteria transformed with pTZ19R, which allows a-complementation to be
performed, were plated onto L.B. agar/ampicillin plates which were
prespread with 40 pi of X-gal (20mg/ml in dimethylformamide) and 40 pi of
IPTG (20 mg/ml in water).
2.2.11b Screening of bacterial transformants by colony
hybridisation.
A modification of the method of Grunstein and Hogness (1975) was used to
screen for bacterial transformants. Transformed colonies were picked using
sterile toothpicks and duplicate colonies streaked onto gridded nitrocellulose
membranes that were placed on L.B. agar plates containing ampicillin.
Plates were inverted and incubated at 37°C overnight. One of these plates
was stored at 4°C (the 'master" plate). The second filter was removed from
its plate and placed colony side-up on Whatman 3MM paper soaked in 10%
SDS (w/v) for 3 minutes, denatured for 5 minutes (0.5 M NaCl, 1.5 M NaOH)
and neutralised for 5 minutes (0.5 M Tris.HCl, pH 7.5, 1.5 M NaCl). The filter
was air dried at room temperature and baked in a vacuum oven at 80°C for 2
hours. The bacterial debris was removed from the filter by washing in 50 mM
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Tris.HCl, pH 8.0, 1.5 M NaCl, 1 mM EDTA and 1% SDS (w/v) in a shaking
water bath at 42°C for 1 hour. Filters were then prehybridised and hybridised
using a radiolabeled insert as a probe (see 2.2.12 and 2.2.13 below).
Recombinant colonies that hybridised with the probe were picked and grown
from the duplicate colony on the retained master filter.
2.2.12 Random prime labelling of double-strand derived DNA
probes.
Double stranded DNA was labelled by the random priming method of
Feinberg and Vogelstein (1983). The DNA insert was heat denatured in the
presence of a molar excess of random hexanucleotide primers. Radioactive
nucleotides were added into the probe DNA following primer extension by the
large fragment of E.coli DNA polymerase I (Klenow fragment). The above
was carried out as follows; 50 ng of the DNA to be labelled was denatured at
100°C for 3 minutes and mixed with the following components:
OLB (see below) 3pl
BSA (lOmg/ml, Sigma) 2pl
Klenow fragment 2 units
[a-32p] dCTP sp.activity> 3,000 Ci/mmole; lOCi/ml 3pl
ddH20 to lOOpl
OLB comprised of a mixture of the solutions A,B and C in a ratio of 2:5:3
A: 2M Tris.HCl, pH 8.0 625 pi
5M MgC12 25 pi
DDH2O 350 pi
2-mercaptoethanol 10 pi
lOOmM dTTP, dCTP, dGTP, dATP 5 pi of each
in 3mM Tris.HCl, pH8.0, 0.2M EDTA (Pharmacia)
B: 2M Hepes (pH 6.6)
C: Hexadeoxyribonucleotides in 3 mM Tris.HCl (pH 7.0), 0.2 mM EDTA
to a concentration of 90 O.D.units/ml (Pharmacia)
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2.2.13 Establishing the efficiency of radiolabel incorporation into
double strand DNA derived probes.
1 pi of the labelled probe mixture was spotted onto Whatman DE-81 filter
paper. The filter is positively charged and binds oligonucleotides and double
stranded DNA whereas unincorporated nucleotides are bound less strongly.
The nucleotides can be separated from the larger DNA species
chromatographically using 0.3 M ammonium formate (pH 8.0). By exposing
the resultant filter to X-ray film an assessment of the relative levels of
incorporated to unincorporated radiolabeled nucleotides was obtained. An
estimated efficiency of greater than 80% was routinely obtained.
2.2.14 Hybridisation of radiolabeled DNA probes to membrane
bound DNA.
Membrane bound DNA samples were prehybridised for at least 3 hours at
65°C in glass tubes in a rotisserie oven (Techne).




0.1% Sodium pyrophosphate (w/v)
20X SSC, pH 7.0/ litre: 175.3 g NaCl, 88.2 g sodium citrate.
50X Denhardt's solution 10 g each of BSA (Sigma),
polyvinylpyrollidine (Sigma), Ficoll-400
(Sigma) made up in DDH2O.
After prehybridisation the radiolabeled DNA probe was denatured at 100°C
for 3 minutes and added to fresh prehybridisation solution. Hybridisation
took place at 65°C overnight.
After hybridisation the filters were washed with four changes of 2X SSC and
0.1% SDS at room temperature for 5 minutes. The membranes were then
washed in 1XSSC and 0.1% SDS twice for 90 minutes at 65°C. The filters were
air-dried on 3MM paper, covered with clear plastic film (Saran-wrap) and
exposed to X-ray film in a cassette for 30 minutes at room temperature.
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2.2.14 Sequencing of double stranded DNA.
Double stranded (ds) DNA templates were sequenced using a modified
version of the chain termination method (Sanger et al., 1977) using the
Sequenase enzyme (USB), a genetic varient of the T7 DNA polymerase lacking
3'-5' exonuclease activity. DNA templates were prepared using Qiagen
columns (2.2.2b). Template denaturation and primer annealing were carried
out as follows; to 10 pg of dsDNA, in a final volume of 8 pi, 1 pi of primer (10
ng/ml) and lpl of 1M NaOH were added and the mixture heated for 10
minutes at 68°C. The sample was neutralised by the addition of 4 pi of TDMN
(3.2g TES (Sigma), 0.5ml chloroform, 0.368g DTT, 4 ml 1M MgCl, 2 ml 5 M
NaCl, DDH2O to 50 ml, pH 1.6). The sample was left to cool to room
temperature over a period of 10 minutes.
Labelled DNA was generated from the annealed primer in the following
extending reaction for 5 minutes at room temperature.
Annealed template/ primer mix 10 pi
0.1 M dithiothreitol 1 pi
5X Sequenase labelling mix 0.4 pi
[a-35S]dATP sp. activity 1000 Ci/mmol, lOmCi/ml 1 pi
Sequenase (diluted 1:5 with enzyme dilution buffer) 2 pi
5X labelling mix: 7.5 mM each of dCTP, dGTP, dTTP
Sequenase dilution buffer: 10 mM Tris.Cl, pH 7.5, 5 mM dithiothreitol
0.5 mg/ml BSA.
4 pi aliquots of the extension reaction were terminated following the addition
to separate tubes containing 2.5 pi of 8 mM each ddNTP. The termination
reaction was incubated for 10 minutes at 37°C and was stoppped by the
addition of 4 pi of loading buffer (95% formamide, 20 mM EDTA, 0.05%
Bromophenol Blue, 0.05% Xylene Cyanol FF). The samples were heated at
100°C for 2 minutes and resolved on a 6% acrylamide, 7 M urea (Ultrapure),
IX TBE gel. Following electrophoresis the gel was fixed in 10% (v/v) acetic
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acid, 10% (v/v) methanol and dried for 2 hours under vacuum at 80°C prior to
exposure to X-ray film overnight.
2.2.16 The polymerase chain reaction (PCR).
The following reactions were carried out to amplify specific regions of DNA.
Details on regions that were amplified will be given at the appropriate point
in the text.
Template DNA 1 pi (l-10ng)
dNTPs (2.5 mM of each dNTP) 8 pi
Oligonucleotide primers (0.5 pg/ml) 1 pi each
10X reaction buffer 10 pi
Pfu DNA dependent DNA polymerase 1 unit
DDH20 (Stratagene) to 100 pi
10X reaction buffer: lOmM Tris.HCl, pH8.3, 50 mM KC1, 1.5 mM MgCl2,
0.01% (w/v) gelatin.
The mixture was overlaid with 50 pi of white mineral oil (Sigma) to prevent
evaporation before being subjected to the following reactions in a Hybaid
Omnigene thermal cycler.
Mixing, 92°C 5 minutes (1 cycle)
Denaturing, 92°C 30 seconds (30 cycles)
Annealing, 50°C 60 seconds (30 cycles)
Extending, 72°C see below (30 cycles)
The length of the extension step was varied according to the expected length
of the amplified product. An extension time of 1 minute per lkb was
generally used (Innis and Gelfand, 1990).
2.2.17 Computer analysis of DNA and amino acid sequence data.
Sequence data was analysed for restriction endonuclease sites, protease sites
and for homology with other proteins using the 'Map', 'Pepmap' and 'Bestfit'
programs of the GCG package respectively (Devereux et al. 1984). Multiple
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sequence alignments were carried out using the 'Pileup' and 'Prettybox'
programs of the GCG package. Isoelectric point determination was achieved
using the 'Isoelectric' program from the GCG package
2.3 Biochemical Techniques.
2.3.1 Protein concentration determination.
The protein concentration of samples to be analysed was determined by the
method of Lowry et al. (1951). A range of BSA concentrations,O-lSOmg/mljvas
used to generate a standard curve each time the assay was performed. The
sample to be analysed was mixed 1:40 or 1:200 (v/v) in 0.1M NaOH. To this
was added 5 volumes of freshly prepared alkaline carbonate solution (490ml
70 mM Na2C03, 40mM NaOH, 5 ml 40 mM CUSO4 and 5ml 71 mM potassium
tartrate per 500ml). This solution was then incubated for 10 minutes at room
temperature. 0.1 volumes of Folin Ciocalteau reagent was added and the
sample incubated for 1 hour at room temperature. Absorbance values at 600
nm were determined using a Shimadzu U.V. 160 spectrophotometer. The
standard protein concentration values were determined in duplicate and the
sample values in triplicate.
2.3.2 Sodium dodecyl-sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) of protein samples.
Protein samples were prepared for SDS-PAGE at 2X the required
concentration and diluted 1:1 with 2X boiling mix (50 mM Tris.HCl, pH 6.8,
2% (w/v) SDS, 5% (w/v) P-mercaptoethanol, 10% (w/v) glycerol, 0.05% (w/v)
bromophenol blue) and boiled for 5 minutes.
SDS-PAGE was carried out according to the method of Laemmli (1970). For
detection of P450 reductase and carboxylesterase samples were separated on
9% (w/v) polyacrylamide gels (8.7% acrylamide, 0.3% N, AT-methylene-bis-
acrylamide) in 0.375 M Tris.HCl (pH 8.8), 0.15% (w/v) SDS. Ammonium
persulphate (AMPS, 3% (w/v)) and N, N, N', AT-tetra-methyl ethylenediamine
(TEMED) were added to 0.05% (v/v). For detection of lower molecular weight
proteins such as the domains of P450 reductase and cytochrome c, samples
were separated on 12% or 15% (w/v) polyacrylamide gels. A stacking gel was
prepared (4.5% (w/v) acrylamide, 0.125 M Tris.HCl (pH 6.8), 0.125% SDS, 0.05%
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each of TEMED and AMPS) and poured on top of the polymerised separating
gel. The gels were prepared in BioRad Protean 2 or BioRad Mini-Protean
verical electrophoresis equipment. Protein samples were subjected to
electrophoresis using electrode buffer (0.05 M Tris HC1, pH 8.3, 0.05 M glycine,
0.1 % SDS) at 60 mA through the stacking gel and 30 mA through the
separating gel. The. apparatus was water cooled. After electrophoresis the
gels were removed and either stained with coomassie blue (2.3.3) or subjected
to Western blot analysis (2.3.4). Molecular weight standards were obtained
from Sigma. For 9% gels the following standards were used (SDS-6H):
carbonic anhydrase, 29 kDa.; egg albumin, 45 kDa; bovine plasma albumin,
66 kDa; phophorylase b, 97.4 kDa; /3-galactosidase; 116 kDa; myosin, 205 kDa.
For 12% gels the following standards were used (SDS-6): lysozyme, 14.3 kDa;
P-lactoglobulin, 18.4 kDa.; trypsinogen, 24 kDa.; pepsin, 34.7 kDa; egg
albumin, 45 kDa.; bovine plasma albumin, 66 kDa. For 15% gels the following
standards were used (Boehringer Mannheim Biochemica, 1317 474):
Glutamate dehydrogenase, 55 kDa; aldolase, 39.2 kDa; triosephospate
isomerase, 27 kDa., trypsin inhibitor, 20 kDa., lysozyme, 14.3 kDa.
The Pharmacia Phast System was also used for SDS-PAGE and isoelectric
focusing of the carboxylesterase. Precast gels were used and electrophoresis
carried out according to the manufacturer's instructions.
2.3.3 Coomassie blue staining of polyacrlyamide protein gels.
Gels were stained and fixed in 0.25% w/v Coomassie blue R, 10% acetic acid,
40% methanol for up to 2 hours. Destaining was performed in 20% methanol,
7.5 % acetic acid.
2.3.4 Western blot analysis of SDS-PAGE separated protein samples.
Western blot analysis was performed by a modification of the method of
Towbin et al. (1979). SDS-PAGE resolved protein was transferred using a
BioRad Protean II transblot cell onto 0.45 mm nitrocellulose filters ( Schleicher
and Schuell) in transblot buffer (20 mM disodium orthophosphate, 20% (v/v)
methanol) for 15 hours at 250 mA. After protein transfer the filter was
stained with Ponceau S (0.01%) w/v to check for efficiency of transfer. The
filter was washed in TBST (50 mM Tris.HCl, pH7.9, 0.15 M NaCl, 0.05% Tween
20) for 2X 10 minutes. Following this the filter was blocked in 5% (w/v) low fat
30
powdered milk (Marvel, Cadbury's) in TBST for 1 hour. After blocking and
washing the filter for 3X 15 minute periods in TBST, the first antibody, raised
against the protein of interest, was added at a dilution of 1:1000 (in TBST) and
left for 1 hour. The first antibody was removed and the filter washed for 4X 15
minute periods in TBST before addition of the second antibody at a dilution of
1:1000 (in TBST). Since the first antibodies used in this study were raised in
rabbits (2.3.6) the second antisera used was donkey anti-rabbit IgG. After
washing (4X 15 minutes in TBST) the immunoreactive protein antibody
complexes were probed in 0.19 MBq of 125i.conjuga^e(j protein A in 50 ml of
TBST for 45 minutes followed by extensive washing in TBST to remove non-
specifically bound radioactivty. The filters were then exposed to X-ray film.
Some modifications on the above procedure were employed when looking for
autoantibodies in patients' sera. The method employed has been described
previously (Kenna et al, 1987). The basic differences were that instead of
using Marvel to block the nitrocellulose filter 5% w/v casein (Hammerstan
grade, BDH) in TBST was used. The filters were blocked overnight. Also, the
washing procedures employed TBST with 0.5% w/v casien- The human
serum was diluted 1:100 while the secondary antisera employed was a goat
anti-human IgG (diluted 1:1000 in TBST).
2.3.5 Transfer of protein to polyvinyldifluoride membranes
Protein samples for solid-phase sequence analysis (Matsuidara, 1987) were
transferred from standard polyacrylamide gels (2.3.3) after electrophoresis
onto polyvinyldifluoride (PVDF) membranes. Solid phase N-terminal
sequence analysis was kindly carried out by Dr. Darryl Pappin, I.C.R.F.,
London, using a Milligen 6600 solid phase sequencer (Pappin et al., 1990).
SDS-PAGE resolved protein was transferred, using a BioRad Protean II
transblot cell, onto methanol washed PVDF (Immobilon, Millipore) in
transblot buffer (10 mM 3-cyclohexylamino-l-propanoic acid, pH 11, 10% (v/v)
methanol) for 15 hours at 250mA.
2.3.5 Development of rabbit anti-serum.
Polyclonal anti-serum against human P450 reductase and human
carboxylesterase were raised in New Zealand White rabbbits at the I.C.R.F.
Clare Hall laboratories, Potters Bar, Herts, U.K. On day 1 of week 1, 10 ml of
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preimmune serum was obtained before injecting, intra/subcutaneously, the
rabbit with 200 pg of purified protein in Freund's complete adjuvent. At
weeks 4 and 6 the rabbit was boosted with a further 100 pg of pure protein in
Freund's incomplete adjuvent. 10 ml of test serum was obtained at week 7.
The rabbit was given a final boost with 100 pg of protein in Freund's
incomplete adjuvant at week 8. Rabbits were bled 9 days after the last boost
and the serum isolated.
2.3.7 Human Serum Samples.
Sera were kindly provided by Dr. J. Gerry Kenna, St. Mary's Hospital Medical
School. Sera from 20 patients with halothane hepatitis, defined clinically as
otherwise unexplained hepatitis within 28 days of halothane anaesthesia
were studied. They were aged 32-60 (median 53) and 17 were female. All had
had halothane anaesthesia before, on between 1 and 8 occasions (median 2),
and the interval between the current and previous or latest exposure ranged
from 7 days to 10 years (median 6 weeks). 13 patients had liver failure and 12
died. Control sera were obtained from 9 patients who had recieved halothane
several times without liver damage; from 18 healthy blood donors; and from
11 patients with fulminant hepatic failure (6 paracetamol, 2 hepatitis B, 1
hepatitis A, 2 non-A, and non-B hepatitis), 6 with autoimmune chronic active
hepatitis, 4 with alcoholic liver disease, 8 with primary biliary cirrhosis (PBC)
and 4 with jaundice due to flucloxacillin.
2.3.8 Immunohistochemical analysis of human and rat liver.
Tissue for immunohistochemical analysis was cut into small fragments and
placed in formal saline (14% (v/v) formaldehyde in PBS)
PBS/litre: 1.5gNa2HP04, 8 gNaCl, O.lgMgCl2-6H20,1.5 g KH2P04,
0.2 g KC1, 0.132g CaCl2.2H20
The tissue was paraffin embedded and sectioned at 3 |im. Sections were
dewaxed in xylene and rehydrated through graded alcohols. Slides were
washed several times in 100 mM Tris.HCl, pH 7.4, 0.1% Tween 20, 5% (v/v)
normal goat serum, before overnight incubation with rabbit polyclonal
human carboxylesterase antisera (diluted 1: 5,000 in the above buffer). The
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slides were then washed, 3X 10 minutes, and incubated for 30 minutes with
biotinylated goat anti-rabbit IgG (diluted 1:500 in the above buffer). Sections
were exposed to streptavidin-peroxidase conjugate for 30 minutes before being
developed with 3,3' diaminobenzidine and lightly counterstained with
heamatoxylin.. Carboxylesterase localisation was then achieved using false
colour image analysis via a Kontron system. Maximum intensity of antibody
binding was signified by a blue colouration through green/yellow to red,
signifying weak binding.
2.3.9 Isolation of microsomal fractions.
Tissue was added to 3 volumes of KCl-phosphate buffer (10 mM potassium
phosphate, pH 7.4, 1.15% (w/v) KC1, 0.1 mM EDTA) and homogenised in a
Silverson Laboratory mixer homogeniser at 4°C. The homogenate was
centrifuged at ll,000g for 20 minutes to remove cell debris and larger cellular
organelles such as mitochondria, nuclei and peroxisomes. The pellet was
discarded and the supernatent centrifuged at 230,000g for 80 minutes, 4°C, to
separate the microsomal and cytosolic fractions. The microsomal pellet was
washed by resuspension in KCl-phosphate buffer using a Teflon-glass hand
homogeniser and recentrifuged at 230,000g for 60 minutes at 4°C. The
resulting pellet was resuspended by hand homogenisation in 0.25 M sucrose,
10 mM potassium phosphate buffer, pH7.7. Samples were stored at -40°C at a
protein concentration of 15-30 mg/ml.
2.3.10 Enzyme Linked Immunosorbent Assay.
Purified carboxylesterase protein was prepared at a concentration of 2 pg/ml
in 10 mM sodium phosphate buffer, pH 7.0. 50 pi of the protein was added to
the wells of a 96-well polyvinylchloride microtitre plate and incubated at 4°C
overnight. After removing the contents of the well, the plate was washed
twice with PBS before filling the wells with 3% BSA in PBS for 2 hours at
room temperature. The plate was then washed 2X with PBS before adding 50
pi of the appropriate sera at a dilution of 1:100. After incubation at room
temperature for 1 hour the plate was washed twice with PBS before the
addition of 50 pi of horse-radish peroxidase conjugated goat anti-human IgG
at a dilution of 1:1000 in 3% BSA in PBS. After incubation at room
temperature for 1 hour the plate was washed 3X with PBS. Substrate solution
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was prepared as follows; 0.1 mg of o-phenylenediamine dihydrochloride
(OPD) was dissolved in 0.1 ml of DMSO before making up to 10 ml with 0.1 M
sodium acetate (pH 6.0). Hydrogen peroxide was then added to a final
concentration of 0.01%. 50 pi of the substrate solution was added to each well
and incubated for 20 minutes at room temperature. 50 pi of 1 M sulphuric
acid was added to stop the reaction and the optical density at 492 nm
measured.
2.4 Protein Purification Procedures
The major protein purification strategy employed in this study took into
consideration the fact that along with P450 reductase it was hoped that
isozymes of P450 and/or other hepatic drug metabolising enzymes would be
purified. One of the major reasons for this was the value of human
microsomes. This led to the development of a P450 reductase purification that
was essentially similar to the one described by Yasukochi and Masters (1976)
and a P450 purification that was similar to that described by Wolf et al. (1980).
The purification was based around an initial step of ion-exchange
chromatography on DEAE-cellulose so as to produce a pool of (i) partially
purified P450 reductase and (ii) a pool of P450 isozymes for further
purification. P450 reductase could then be purified by affinity
chromatography on 2'5' ADP-sepharose. The pool of P450 isozymes would
then undergo further chromatography on hydroxylapatite. However, on
further purification of the P450 pool, two proteins were obtained in an
electrophoretically homogenous form. At this stage and from the subsequent
identification of one of these as a carboxylesterase it was decided that this
protein should be the focus for further study (Chapter 5).
The solubilisation stage and all chromatography were performed at 4°C.
2.4.1 Solubilisation of hepatic microsomes.
Microsomes were solubilised at a concentration of 10 mg/ml in 10 mM
potassium phosphate buffer, pH 7.7 containing 0.1 mM dithiothreitol and 0.1
mM EDTA, by the slow addition of a 10% (w/v) solution of sodium cholate to
give a final concentration of 1 mg detergent per 1 mg microsomal protein.
After 30 minutes of stirring, glycerol was added to give a final concentration
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of 20% v/v. The solubilised microsomes were then subjected to centrifugation
(100,000 g, 30 minutes) to remove any unsolubilised material/ debris.
2.4.2 Ion exchange chromatography using DEAE-cellulose.
DEAE-cellulose (Whatman DE52) was prepared according to the
manufacturers instructions. A column of DEAE-cellulose was prepared (5 x
90 cm) and equilibrated with 10 mM buffer A (potassium phosphate buffer,
pH 7.7 containing 20% glycerol, 0.1 mM dithiothreitol and 0.1 mM EDTA).
Once the column was equilibrated, the solubilised microsomes were applied
at a flow rate of 120ml/ hour. The column was washed extensively with 10
mM buffer A + 0.2% sodium cholate. By increasing the ionic strength of
buffer A to 30 mM and by the addition of Emulgen 911 to 0.1% (v/v) a pool was
eluted that was rich in cytochrome P450 and carboxylesterase. By applying a
0-500 mM KC1 gradient to the column a pool of P450 reductase was eluted at
around 250 mM. The pool of P450 reductase was identified by cytochrome c
reductase activity (2.5.2).
2.4.3 2'5' ADP-sepharose chromatography.
The affinity resin 2'5' ADP-sepharose interacts strongly with NADP+
dependent dehydrogenases and other enzymes which have affinity for
NADP+. The reductase can be sucessfully eluted from the column by the use
of 2' AMP which has a slightly lower binding constant for the reductase than
NADP+.
The P450 reducatse pool obtained after DEAE-cellulose chromatography was
applied to a 2' 5' ADP- Sepharose column (10 x 1.5 cm) pre-equilibrated with
lOmM buffer A + 0.2% v/v sodium cholate at a flow rate of 25 ml/ hour. The
bound P450 reductase was washed extensively with the equilibration buffer
and eluted by the addition of 2'AMP to a final concentration of 0.7 mM. Any
remaining P450 reductase was eluted by the addition of 0.1% (v/v) Emulgen
911 to the buffer. The pooled P450 reductase was dialysed extensively against
lOmM buffer A and stored in aliquots of approximately 1 mg/ml at -40°C after
concentration using an Amicon concentrator with a PM30 membrane.
Purity of fractions was assessed by SDS-PAGE (2.3.2).
A modified version of this procedure was used when purifying expressed rat
P450 reductase from S. typhimurium (Chapter 3). 10 mis of an overnight
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culture of TA1535, harbouring the rat P450 reductase expression vector
pMP230, was added to 1 litre of fresh L.B. broth containing ampicillin, 50
pg/ml. After 1.5 hours, isopropyl-l-thio-(3-D-thiogalactopyrannoside was
added to a final concentration of 1 mM. After 4 hours expression the cells
were harvested, 5000 g for 10 minutes, and resuspended in 10 mM potassium
phosphate buffer, pH 7.7, 20% glycerol and 0.1 mM DTT (3 ml buffer/ 1 g cells).
Lysozyme was added to a final concentration of 1 mg/ml and left at 4°C for 30
minutes with rotary mixing followed by the addition of Triton X-100 to a final
concentration of 0.1% and mixed for a further 10 minutes. 0.1 volumes of 4%
sodium deoxycholate was subsequently added and the resulting lysed bacteria
centrifuged at 230,000g for 1 hour. The supernatent was removed, applied to
2' 5' ADP-sepharose and chromatography carried out as described above.
The purified recombinant rat P450 reductase was purified in the one-electron
reduced air-stable semi-quinone form, as judged by spectral analysis.
2.4.4 Hydroxylapatite chromatography.
In order to resolve the carboxylesterase and P450 containing pool obtained
from the DEAE-cellulose step, hydroxylapatite chromatography was
employed.
A 2.5 x 20 cm hydroxylapatite (Biorad HT) column was prepared and
equilibrated with 10 mM buffer A. The carboxylesterase/ P450 containing pool
was diluted 5 fold with 10 mM buffer A and applied to the column at a flow
rate of 40 ml/ hour. After extensive washing with 10 mM buffer A, elution of
proteins took place in a stepwise manner by increasing the phosphate
concentration of buffer A in 10 mM steps in the presence of 0.1% (v/v)
Emulgen 911. In this way a variety of microsomal proteins were resolved as
judged by SDS-PAGE analysis. It is important to remember that Emulgen
911 has a very high absorbance at 276nm and hence protein elution cannot be
carried out by monitoring at 280nm.
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2.4.5 Concanavalin A-Sepharose chromatography.
Concanavalin A (con A) binds molecules which contain oc-D-
mannopyranosyl, a-D-glucopyranosyl and sterically related residues. The
binding sugar requires the C-3, C-4 and C-5 hydroxyl groups for reaction with
con A (Goldstein et al., 1965).
Since microsomal carboxylesterases have been shown to be glycosylated
(Harano et al., 1988) it was felt that by using con A-sepharose
chromatography any remaining protein impurities along with Emulgen 911
would be removed. A con-A sepharose (Pharmacia) column (0.5x 5 cm) was
equilibrated with 10 mM buffer A and to it was applied hydroxylapatite
purified carboxylesterase at a flow rate of 20 ml/ hour. After extensive
washing of the bound carboxylesterase with 10 mM buffer A, carboxylesterase
was eluted from the resin by the addition of 0.2 M a-methylmannoside.
Samples were dialysed extensivley against 10 mM buffer A and stored at
-40°C.
2.4.6 Deglycosylation and glycosylation studies.
Deglycosylation was carried out by incubating 10 pg of purified
carboxylesterase with 2 units of N-glycosidase F in 50 mM potassium
phosphate buffer, pH 7.7 containing 10 mM EDTA, 1% (v/v) Triton X-100, 0.1%
(w/v) SDS and 1% (v/v) 2-mercaptoethanol at 37°C overnight. Loss of sugar
residues was visualised by SDS-PAGE on a pre-cast 10-15% acrylamide
gradient gel on a Pharmacia Phast System.
Glycans were identified after transferring purified carboxylesterase resolved
on a 10-15% acrylamide gel onto PVDF membranes, using a glycan
differentiation kit (Boehringer Mannheim) according to the manufacturers
instructions.
2.4.7 Purification of the domains of P450 reductase.
Cloning into the Ndel/Xhol sites of pET15b engineers a 6x His-linker and a
thrombin cleavage site onto the NH2-terminus of the expressed protein.
Protein purification of the His-tagged domains was carried out using nickel-
agarose chromatography. BL21 strains harbouring the domain expression
plasmids were grown at 37°C overnight in L.B. broth containing 50 pg/ml
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ampicillin and 34 pg/ml chloramphenicol. 500 ml of fresh LB broth was
inoculated with 5 ml of the overnight culture and grown at 37°C to an O.D. of
0.5-0.6. Isopropyl-l-thio-p-D-galactopyrannoside was then added to give a
final concentration of 0.5 mM and the culture allowed to grow for a further 2.5
hr before harvesting at 5000 g for 10 min. The bacterial pellet from a 500 ml
culture was resuspended in 20 ml of 'binding buffer' (5 mM imidazole, 500
mM NaCl, 20 mM Tris-HCl, pH 7.9) and frozen at -70°C for 1 hr. Upon
thawing the bacteria were lysed, since the expression strain BL21 contains a
plasmid bearing T7 lysozyme. Sonication, using an MSE soniprobe at full
power (2x 35s with 1 min incubation on ice between steps), was carried out to
shear genomic DNA present in the lysed bacteria. The bacterial extract was
then centrifuged (39,000g for 30 min) to remove cellular debris and insoluble
protein. Bacteria were analysed for domain expression by SDS-PAGE of
soluble and insoluble fractions. The FMN/anchor, FMN, FMN (small) and
FAD/NADPH domains produced soluble protein extracts. However, the FAD,
FAD/NADPH(small) domains were insoluble, as was the FMN/FAD domain
with only a very small percentage present in the soluble fraction. The
supernatant containing the soluble domains was applied onto 2 ml nickel-
agarose columns previously equilibrated with 'binding buffer'. Columns
were washed with 10 volumes of 'binding buffer' and then 10 volumes of
'wash buffer' ('binding buffer' containing 20 mM imidazole). The
FMN(small) domain was found to elute in the 'wash buffer'. The FMN (no
anchor) and the FAD/NADPH domains could be eluted from the nickel-
agarose column by increasing the imidazole concentration to 60 mM, while
the FMN/anchor region was eluted by increasing the imidazole concentration
to 300mM. Insoluble proteins were purified in a manner similar to the
soluble domains but in the presence of 6 M urea. Attempts to renature the
insoluble domains were unsuccessful. The purity of the domains was
determined by SDS-PAGE. The insoluble domains were not used for any
further experiments. Purified soluble domains were extensively dialysed
against 10 mM potassium phosphate buffer, pH 7.7, 20% glycerol and stored at
-40°C
2.4.8. Removal of the 6x- His -Tag by thrombin cleavage.
Thrombin cleavage was performed in 20mM Tris-HCl, pH 8.4, 150mM NaCl
and 2.5 mM CaCl2 with a w/w domain to thrombin ratio of 5000:1. Cleavage
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took place at 4°C and was monitored at various times by SDS-PAGE. 100%
cleavage occurred after 10 min for the FMN (no anchor) domain and after 4
hr for the FAD/NADPH domain. The His-tag could not be removed from the
FMN/anchor domain. PMSF was added to a final concentration of 0.1 mM to
inhibit the thrombin after removal of the His-tag. The cut domains were
separated from the His-tag by passing the sample through a nickel-agarose
column. Cleaved proteins were dialysed against 10 mM potassium phosphate
buffer, pH 7.7, 20 % glycerol and stored at -40°C
2.5. Biochemical Assays.
2.5.1. Spectral Analysis.
Absorption spectra were obtained using a Shimadzu U.V. 2000
spectrophotometer. FMN and FAD content was calculated after releasing the
flavin from the domains by boiling for 3 min in the dark, followed by
centrifugation (39,000g for 10 min) to remove denatured protein. The flavin
concentration was determined at 450nm using extinction coefficients of 12.2
mM~lcm~l for FMN (Whitby, 1953) and 11.3 mM~lcm"l for FAD (Beinhert,
1960).
2.5.2. P450 reductase assays.
A variety of assays were perfromed to study the one-electron reduction ability
of bacterially expressed P450 reductase and the domains of P450 reductase.
These assays were all taken from the work of Vermillion and Coon, (1978a)
and carried out at 37°C in 50 mM potassium phosphate buffer, pH 7.7 using a
Shimadzu U.V. 2000 spectrophotometer. Apart from the reconstitution of the
domains of P450 reductase, cytochrome c reduction was carried out in 300
mM potassium phosphate buffer , pH 7.7. Compounds were obtained from
Sigma. The reduction of horse heart cytochrome c (40 pM) was followed at 550
nm using an extinction coefficient of 21,400 M_1 cm-1. The reduction of
dichlorophenolindophenol (50 pM) was followed at 600 nm using an
extinction coefficient of 21,000 M"1 cm"1, The reduction of potassium
ferricyanide (500 pM) was followed at 420 nm using an extinction coefficient
of 21,400 M_1 cm-1. The reduction of menadione (50 pM) was followed
indirectly by measuring the reduction of NADPH using an extinction
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coefficient of 6,220 M_1 cm-1 at 340 nm. The reduction of 3-acetyl pyridine
adenine dinucleotide phosphate (500 pM) was followed at 363 nm using an
extinction coefficient of 5,600 M"1 cm-1.
2.5.3. Reconstitution of cytochrome P450 monooygenase activity.
Reconstitution of cytochrome P450 monooygenase activity was carried out
using purified rat P450 (CYP1A1) and purified rat P450 reductase or a
mixture of the FMN/anchor and FAD/NADPH domains. CYP1A1 was
obtained previously by the method of Wolf and Oesch (1983) and rat P450
reductase obtained by the method described above (Yasukochi and Masters,
1976). The O-deethylation of 7-ethoxyresorufin was followed by measuring the
rate of resorufin formation (Burke and Mayer, 1974) An excitation
wavelength of 535nm and an emission wavelength of 585nm were used. The
concentration of substrate was 1 pM and the assays performed at 37°C in 10
mM potassium phosphate buffer, pH 7.7. For reconstitution using the
FMN/anchor and FAD/NADPH regions of human P450 reductase, domains
(0.1 nmol) were mixed in 10 mM potassium phosphate buffer, pH 7.7 in a
volume of 20 pi at 4°C. After various times or in varying concentrations of
buffer, the domains were incubated with dilaurylphosphatidylcholine (25 pg)
and CYP1A1 (37.5 pmol in 5 pi) at 37°C for 5 minutes before measuring the
rate of resorufin formation (Burke and Mayer, 1974).
2.5.4 Effect of human P450 reductase domains on monooxygenase
activty.
CYP1A1 (7.5 pmol) and 25 pg of dilaurylphospatidylcholine were incubated
for 5 minutes with varying concentrations of the FMN/anchor, FMN or
FAD/NADPH domains (0.04-1.7 nmol) in a total incubation volume of 47.5 pi at
37°C for 5 minutes. Native P450 reductase (0.05 nmol in 2.5 pi) was then
added and the sample incubated for a further 5 minutes before measuring 7-
ethoxyresorufin O-deethylation. Free FMN was also used in experiments at
the same concentrations to the domains used.
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2.5.5. Carboxylesterase Assay.
Esterase activity was determined by measuring the formation of p-
nitrophenol using p-nitrophenyl acetate (1.6 mM) at 405nm (Krisch, 1966)
Incubations were at 37°C in 50 mM Tris.HCl buffer, pH 8.0. Inhibition
studies were carried out by incubating carboxylesterase in varying
concentrations of phenylmethylsulphonyl fluoride and bis-4-nitrophenyl
phosphate for 30 minutes at 37°C prior to assay.
2.5.6. Superoxide dismutase Assay.
Superoxide dismutase (SOD) assays were performed on soluble extracts
from E. coli. (39,OOOg,supernatant • after 2x 30 second sonication bursts using
an M.S.E. soniprobe. The SOD assay was performed according to the method
of McCord and Fridovich, 1969. The assay was carried out in 50 mM
Tris.HCl, pH 7.4 containing 1 mM MgCl2. The reaction mixture contained 10
pM cytochrome c, 50 pM xanthine and xanthine oxidase to a concentration
(around 5 nM) that produced a rate of reduction of cytochrome c at 550nm of
0.025 A.U. per minute. Under these conditions the amount of superoxide
dismuthase required to inhibit the rate of reduction of cytochrome c by 50%
(i.e. to a rate of 0.0125 A.U. per minute) is defined as one unit of activity.
2.5.7. Catalase Assay.
Catalase assays were performed on soluble extracts from E. coli. (39,OOOg,
supernatant) after 2x 30 second sonication bursts using an M.S.E. soniprobe.
The catalase assay was performed according to the method of Beers and Sizer
(1952). The assay was performed in 50 mM potassium phosphate buffer, pH
7.0 containing 5 mM hydrogen peroxide. Destruction of hydrogen peroxide
was followed at 240 nm.
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Chapter 3: Expression of rat NADPH cytochrome P450
oxidoreductase in S. typhimurium and E. coli for the study of one-
electron reduction reactions.
3.1 Introduction and aims.
One method to assess the role of individual drug metabolising enzymes in the
metabolism of xenobiotics is by the use of heterologous expression systems
(Simula et al., 1993a). The use of yeast and bacterial systems have been
exploited a great deal for this purpose (Bloch et al., 1986; Watanabe et al., 1987;
Black et al., 1989; Simula et al., 1993b; Simula et al., 1993c). The attraction of
these systems stems from the fact that, unlike mammalian cells, there is a
low background of endogenous xenobiotic metabolising enzymes, making
results for a particular enzyme more easily interpretable. Cytotoxic effects on
bacteria or yeast can simply be assessed by plating chemically exposed cells
onto nutrient agar and comparing the survival frequency of enzyme
expressing and non-expressing cells. A major reason for the use of
heterologous expression systems for studying individual enzymes has been
the advent of recombinant DNA technology. Heterologous expression systems
are not only of value for cytotoxicity or mutagenicity studies but for the study
of enzymes which are present in low abundance where their isolation maybe
very difficult (Miles andWolf, 1991).
Advantages of yeast and bacterial systems over mammalian cells for
heterologous expression is their ease of genetic manipulation, where
controlled and stable expression of foreign proteins is more easily achievable.
The simplistic nature of yeast and bacteria has enabled detailed study of their
transcription and translation machinery to be made. This has subsequently
led to the construction of efficient expression vectors with promoters which
are able to express the foreign protein of interest. However, successful
expression of mammalian proteins is not always achieved using yeast and
bacterial systems. Many explanations abound for the failure of these systems
to express foreign proteins. For example, limitations in translation maybe
encountered since there is a marked difference in codon usage between
organisms. Differences can exist in RNA processing, post-translational
modifications and the misreading of cellular targeting signals. The size of
proteins and their hydrophobicity can also present problems as well as
unwanted proteolysis (Goeddel, 1990).
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One criticism of using heterologous expression systems to study the
functional properties of an expressed enzyme is that foreign proteins in the
cell system may have adverse effects on the host cells normal functions.
Therefore, this may alter the cells sensitivity to a chemical toxicity. An
example of this has been in the study of superoxide dismuthase (SOD)
overexpression in E.coli (Bloch et al., 1986). Rather than protect against the
cytostatic effects of the superoxide generating compound paraquat it was
found that SOD expressing bacteria were more sensitive to the cytostatic
effects of paraquat than non-expressing bacteria. This paradox was
explained by Liochev and Fridovich (1991) who showed that SOD expression
interfered with the induction of the protective sox RS system. This reduced
the ability of the SOD expressing bacteria to adapt to the presence of paraquat
compared to non-expressing bacteria.
Earlier studies from this laboratory have shown that P450 reductase has the
ability to enhance the cytotoxic properties of the redox cycling anticancer
agents mitomycin C and doxorubicin (Bligh et al., 1991 and Bartoszek and
Wolf, 1992). These studies were performed by exogenously treating the cells
with the drug, P450 reductase and NADPH. The study on the capacity of P450
reductase to bioactivate mitomycin C also used an S.typhimurium strain
(LR5000) expressing rat P450 reductase. In cytotoxicity assays it was shown
that the P450 reductase expressing strain was more sensitive to mitomycin C
than the non-expressing strain. This implicated P450 reductase in the
bioactivation of mitomycin C in vivo. Other work has looked at the
overexpression of GSTs in Ames Test strains to increase or decrease the
mutagenicity of a variety of compounds (Simula et al., 1993b, Simula et al.,
1993c). Therefore, previous work has shown the usefulness of heterologous
expression sytems for the study of drug metabolising enzymes.
The aims of this chapter were to study the effects of P450 reductase
overexpression in S. typhimurium on the cytotoxic actions of the redox
cycling compounds paraquat, menadione and the anticancer agent
doxorubicin. Low levels of P450 reductase expression were obtained in the
previous work of Bligh et al. (1991) when using the S. typhimurium strain
LR5000. To overcome this the use of two, more efficient, bacterial expression
systems were decided upon. This chapter will discuss the expression of rat
P450 reductase in S.typhimurium and E.coli using the modified pKK233-2
(pGLWll) and pOR263 expression vectors. The effects of the expression of
P450 reductase on the cytotoxicity S. typhimurium by the aforementioned
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compounds will be discussed. While this work was being carried out
extensive analysis of the sox RS and oxyR regulons in E.coli became available
(Demple and Amabile-Cuevas, 1991; Storz et al., 1990). The ability of P450
reductase expression in E.coli to modulate these regulons when exposed to
the redox cycling compounds was also investigated. These latter experiments
were carried out in E.coli since these regulons have been more fully
characterised in this bacteria.
3.2-3.4 Results and discussion.
3.2.1 Heterologous expression of rat NADPH cytochrome P450
oxidoreductase in E.coli and S.typhimurium.
To express a eukaryotic protein in a bacterial system modifications have to be
made to the eukaryotic transcript before it will be translated in the
prokaryote. Bacterial transcripts contain a conserved sequence just 5' of the
initiation methionine codon termed the Shine-Dalgarno (S.D.) or ribsomal
binding sequence (RBS) (Shine and Dalgarno, 1974). This sequence shows a
variable degree of complementarity to a region of the ribosomal 16S RNA
(Atkins, 1979) In general the RBS has four nucleotides from the sequence
AGGAGG placed at a distance of between 5 and 9 base pairs from the
initiation codon, ATG. Therefore, eukaryotic messages need to be modified by
the addition of an appropriately spaced S.D. sequence upstream of the
initiating codon. Other modifications that have been included to enhance the
expression of a mammalian protein in a prokaryote include altering the
codon bias to that of the prokaryote and replacing structural sequence after
the initiation codon with unstructured sequence (Barnes et al., 1991). The
expression vectors used in this study were a modified version of pKK223-3
(Pharmacia) termed pGLWll and pOR263 (Shen et al., 1989). The former
vector contains a promoter derived from the fusion of the bacterial trp gene
promoter, a partial Pribnow box, a Shine-Dalgarno sequence and a lac-
operator sequence from the lac UV5 gene. Collectively this is called the tac II
promoter. If the host strain harbouring the plasmid produces the repressor
protein encoded by the lac I gene the promoter is transcriptionally inactive.
However, addition of isopropyl-l-thio-(l-D-thiogalactopyrannoside (IPTG)
leads to the dissociation of the bound repressor from the operator sequence
allowing transcription to procede. pGLWll also contains a copy of the lac Iq
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gene which results in the over-production of the lac I repressor. This
basically means that pGLWll does not require a lac Iq host strain. The
modification of the vector pKK223-2 was carried out by Dr I. Hunter,
University of Glasgow. The expression plasmid pOR263 utilises the trp
promoter and encodes the first 12 amino-acids of the outer membrane protein
A (ompA) signal peptide. By cloning in frame with the ompA leader
sequence the resulting expressed protein is exported to the periplasm of the
bacteria. This expression vector containing the rat P450 reductase cDNA was
generously provided by Dr. Charles. B. Kasper, University ofWisconsin (Shen
et al. 1989). Construction of the P450 reductase expression plasmid, pMP230,
was performed by cloning the rat cDNA into the expression vector pGLWll
(described above). This cloning was performed in this laboratory in
collaboration with Pauline van der Drift. A Bam HI fragment containing the
rat P450 reductase cDNA was isolated from the plasmid pJLAl (Bligh et al.,
1991), blunt ended using nuclease SI and ligated into the Klenow filled Eco RI
site of pGLWll. Clones were obtained with the cDNA in the correct and
incorrect orientation, the latter being used for control experiments. Figure
3.1 shows SDS-PAGE analysis of both insoluble (39,000g pellet) and soluble
extracts (39,000g supernatent) from E.coli (NM522) and S. typhimurium
(TA1535) expressing and non-expressing bacteria. What can clearly be seen
from these gels is that the majority of the expressed protein after both 4 and
22 hours is found in the insoluble fraction of the bacteria. Higher levels of
expressed rat P450 reductase can be seen to be produced from the pOR263
expression plasmid. Interestingly, higher levels of expression can be seen in
the S. typhimurium strain than in the E. coli. Of particular note from this
gel is that the protein produced by the pMP230 expression vector is smaller
than that expected for P450 reductase (compare 65 kDa. with 78 kDa.).
Analysis of cytochrome c reductase activity found in both the soluble and
insoluble extracts ofE.coli (NM522) and S. typhimurium (TA1535) is shown in
Figure 3.2. Samples were analysed at both 4 and 22 hours. Similar to the
levels of expressed protein observed by SDS-PAGE, the S. typhimurium strain
and the pOR263 derived P450 reductase had the greater capacity to reduce
cytochrome c. Interestingly, Simula et al. (1993a) found that the heterologous
expression of human GST isozymes was elevated in S.typhimurium by at
least 2-3 fold over that found in E. coli strains. Expression of a mouse
cytochrome P450 (Cyp2El) was also found to be elevated when expressed in S.
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Figure 3.1. SDS-PAGE (9%) analysis of expressed rat P450 reductase
in E.coli (NM522) and S.typhimurium (TA1535). (A) soluble fraction
(39,000g supernatent). (B) insoluble fraction (39,000g pellet). Expression
vectors used are shown, as are times of harvest after IPTG induction. Rat red,
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Figure 3.2. Cytochrome c reductase activity of expressed rat P450
reductase in (A) E. coli (NM522) and (B) S. typhimurium (TA1535).
Assays were performed after 4 and 22 hours of IPTG induction. Results are
the mean of two seperate experiments performed in triplicate. Sup, 39,000g
supernatent; pel, 39,000g pellet.
observations for the GST isozymes and Cyp2El do indeed appear true for the
rat P450 reductase expressed here. The mechanisms for this higher level of
expression in S. typhimurium over E. coli are not clear and maybe due to
either a more efficient initiation of transcription and/or translation or a
reduced level of protein turnover.
3.2.2. Purification and characterisation of the 65 kDa. form of
recombinant rat P450 reductase.
Expression of the rat P450 reductase cDNA in both E.coli and S. typhimurium
utilising the expression vector pGLWll resulted in the production of a 65 kDa
protein which appeared highly active in the one-electron reduction of
cytochrome c. In order to further characterise this protein it was purified
from the soluble fraction of S.typhimurium using a one step affinity
purification with the matrix 2'5' ADP-Sepharose (Figure 3.3). This one step
procedure resulted in a 95% purified protein which was highly active in the
reduction of cytochrome c, 48,000 nmol cytochrome c reduced / minute/ mg
protein. Spectral analysis revealed the protein to contain both flavins and to
have been purified from the bacteria in the one-electron reduced air-stable
semiquinone form.
These results suggested that the protein was degraded from the NH2-
terminus. Sequence alignments of P450 reductase with spinach ferredoxin
NADP+ reductase (whose crystal structure is known) suggest that the last
three residues of P450 reductase are critical for FAD binding (Karplus et al.,
1991) along with other residues in the C-terminal portion that are important
for NADPH binding and therefore catalysis and interaction with the affinity
resin. It can be postulated that degradation was occuring from the NH2-
terminus of the protein. To confirm this the purified 65 kDa. P450 reductase
was transferred onto a PVDF membrane and the amino-acid sequence of the
NH2-terminus obtained by solid phase sequencing. The sequencing was
kindly performed by Dr. Darryl Pappin, I.C.R.F., London. The sequence that
was obtained revealed that the first 69 amino-acids of the protein were not
present. This results in the loss of a predicted 7.8 kDa. of the protein. This
region of P450 reductase encodes the membrane anchoring region and the
proposed bridge between the anchor and the predicted FMN domain (Porter
and Kasper, 1990). Therefore, it would appear that the bacteria are efficiently




Figure 3.3. SDS-PAGE analysis (9% gel) of the 2'5' ADP-sepharose
affinity purification of the 65 kDa. form of rat P450 reductase
expressed in S. typhimurum (TA1535). Stds, prestained molecular weight
standards ; rat red., native rat P450 reductase (2pg); sol., soluble fraction
loaded onto 2'5' ADP-sepharose; F.T., flow through; 2'AMP, fraction eluted
with 0.7 mM 2'AMP.
A peptide map of the protein, produced by the computer program 'Pepmap'
from the GCG package reveals that a chymotrypsin site is present at this part
of the rat P450 reductase protein. It can be suggested that a chymotrypsin
like enzyme present in E.coli is causing this cleavage. The rat reductase
expressed from the plasmid pOR263 was found not to be degraded. This is
because at the NH2-terminus of the protein there is the signal peptide
sequence for the ompA protein of E.coli. This leader sequence will transport
the protein to the periplasm where it will be protected from degradation (Shen
et al., 1989). Despite the degradation of the protein expressed from the
pGLWll vector, the 65 kDa form of rat P450 reductase was still highly
efficient in cytochrome c reduction and appeared to bind both its flavins. A
large scale purification of this degraded protein has enabled crystallisation
trials to be set up in collaboration with Dr. Huub Driessen, Birkbeck College,
London. Since hydrophobic proteins are inherently more difficult to
crystallise, the removal of the anchor region of P450 reductase may prove of
value in attempts at crystallisation.
3.3 Effects of redox cycling agents on the viability and growth of rat
P450 reductase expressing and non-expressing S. typhimurium
strains.
3.3.1. Overview of redox cycling.
A summary diagram of redox cycling showing the production of reactive
oxygen species is shown in Figure 3.4. It is both the active oxygen products
produced and the one-electron reduced compound that can result in cellular
damage whether at the level of DNA, lipid or protein. In general, the
compound is reduced in a one electron step to a reactive intermediate which
is able to transfer one electron to molecular oxygen resulting in the formation
of the superoxide anion radical. Only if the reductase involved is not inhibited
by dioxygen can redox cycling occur. The enzymes involved in catalysing
redox cycling of foreign compounds are flavoproteins with relatively low
substrate selectivity (Kappus, 1986). Therefore, the number of enzyme
systems being able to catalyse such a reduction step is limited. As shown in
Figure 3.4, with quinonoid compounds, semiquinone radicals are formed
which can go on to reduce dioxygen. (Paraquat, methyl violgen, a dipyridyl is






Figure 3.4. Overview of redox cycling of quinone containing
compounds. (Modified from Kappus (1986)).
that is formed can then undergo a variety of reactions. O2" will oxidise thiols,
ascorbate, tocopherol and catecholamines . Proteins containing FeS4
clusters are highly sensitive to attack by O2" (Gardner and Fridovich, 1991).
Probably the most important reaction of O2" is its dismutation to hydrogen
peroxide and its ability to reduce transition metals and metal complexes. The
relevant transition metals in vivo are Fe3+ and Cu2+. The reduction of metal
ions leads to the so-called metal catalysed Haber-Weiss cycle. The reduction
of cupric and ferric ions by O2" can occur even when the metals exist in a
complexed form. For example, cytochrome c (Fe3 + ) can be reduced to
cytochrome c (Fe2+) by O2" (McCord and Fridovich, 1969). Hydrogen peroxide
produced can be removed either by catalase or by glutathione peroxidase.
Hydrogen peroxide produced is most likely responsible for hydroxyl radical
formation which occurs in the presence of reduced metals like ferrous ions.
The hydroxyl radical is the most reactive oxygen metabolite and is suggested
to be responsible for some of the serious damage occurring during redox
cycling processes e.g. peroxidation of membrane lipids, protein, DNA damage
(Kappus, 1986). Lipid peroxidation changes cellular integrity and releases
toxic reaction products (Kappus, 1985). Protein damage by oxygen radicals
leads to amino-acid oxidations resulting in conformational changes and
enzyme inactivation (Mason, 1982). While DNA damage by hydroxyl radicals
can lead to cytotoxicity, mutagenicity and carcinogenicity.
In an attempt to assess the role of the flavoprotein NADPH cytochrome P450
oxidoreductase in reducing a quinone (menadione), an anthracycline
(doxorubicin) and the dipyridal compound paraquat in vivo the S.
typhimurium strains described above (3.2.1, 3.2.2) were used.
3.3.2 Cytotoxic and growth inhibitory effects of paraquat on P450
reductase expressing and non-expressing S. typhimurium.
Paraquat (l,l-dimethyl-4,4'-bipyridilium; methyl viologen) is a non-selective
contact herbicide (Figure 3.5). The paraquat dication is known to undergo
cyclic oxidation-reduction (Bus et al., 1974). Enzymatic one-electron reduction
of the paraquat dication results in formation of the paraquat cation free
radical. In the presence of oxygen the paraquat cation radical is immediately
reoxidised and the superoxide radical immediately generated (see Figure 3.4).
The cytotoxic effects of varying concentrations of paraquat on the
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Figure 3.6. Survival of S. typhimurium (TA1535) transformed with
pMP231 (control) and the rat reductase expression vectors pMP230
and pOR263 following exposure to paraquat. All measurements are in




























Figure 3.7. Effect of paraquat on the growth of S.typhimurium
(TA1535). (A,C) pMP231 (control) and the rat reductase expression vector
pMP230. (B,D) pMP231 and the rat reductase expression vector pOR263.
Paraquat (pq) concentrations are shown.
shown in Figure 3.6. It can be clearly seen that the P450 reductase
expressing bacteria are more susceptible to the cytotoxic effects of paraquat in
comparison to the non-expressing strain. This appears to be dose-dependent
and also more enhanced in the bacteria expressing the greater levels of P450
reductase (pOR263 compared with pMP230). The ability of P450 reductase to
affect the growth of TA1535 in liquid culture is shown in Figure 3.7. Again
the pOR263 harbouring strain appears most sensitive to the effects of
paraquat with almost complete inhibition of growth seen in this strain at a
concentration of lOmM paraquat. These results clearly establish that P450
reductase has an enhanced effect on the cytotoxic and growth inhibitory
effects of paraquat in S. typhimurium.
3.3.2 Cytotoxic and growth inhibitory effects of menadione on P450
reductase expressing and non-expressing S. typhimurium.
Menadione is an electrophilic quinone compound (Figure 3.5) which is easily
reduced to the semiquinone form which in turn readily reduces O2 to O2".
Menadione is able to be reduced by P450 reductase in vitro (Vermillion and
Coon, 1978a). Figure 3.8 shows that expression of P450 reductase in S.
typhimurium (using both pOR263, pMP230) enhances the cytotoxic effect of
the quinone containing compound menadione when compared to the non-
expressing strain (pMP231). In this case there appeared to be little difference
between the greater P450 reductase expressing (pOR263) and the lower
expressing P450 reductase (pMP230) strains. However, when looking at the
ability of menadione to inhibit the growth of S.typhimurium in liquid culture
(Figure 3.9) the effects of P450 reductase expression were dramatic in the
pOR263 harbouring strain. Expression of P450 reductase from the pMP230
vector appeared to have little effect compared to the control. Strains were
checked for their ability to reduce cytochrome c and the pMP230 harbouring
strain appeared to still have cytochrome c reductase activity. One reason for
the difference in effect seen between the two P450 reductase expressing
bacteria maybe the localisation of the P450 reductase in the bacteria. The
pOR263 vector directs the expressed P450 reductase to the periplasm through
the incorporation of the ompA signal peptide sequence to the amino-terminus
of the protein. Therefore, the dramatic effect seen for the pOR263 harbouring
strain maybe due to the membrane localisation of P450 reductase.
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Figure 3.8. Survival of S. typhimurium (TA1535) transformed with
pMP231 (control) and the rat reductase expression vectors pMP230
and pOR263 following exposure to menadione. All measurements are
in triplicate with S.D.s shown.
Figure 3.9. Effect of menadione on the growth of S.typhimurium
(TA1535). (A,C) pMP231 (control) and the rat reductase expression vector
pMP230. (B,D) pMP231 and the rat reductase expression vector pOR263.
Menadione (men.) concentrations are shown.
3.3.2 Cytotoxic and growth inhibitory effects of doxorubicin on
P450 reductase expressing and non-expressing S. typhimurium.
Doxorubicin is an anthracyclin anti-cancer drug (Figure 3.5) and one of the
most valuable of this class of drugs in present clinical use. A single
explanation for its anti-tumour activity (if indeed one exists) has proved
elusive despite over 20 years of research. However, four mechanisms which
could produce tumour cell cytotoxicity have emerged. These are a) DNA
intercalation and stabilisation of the topoisomerase II and DNA cleavage
complex (Liu et al., 1989); b) perturbation of the biochemistry of the cell
membrane (Tritton and Yee, 1982); c) covalent binding to DNA (Moore, 1977
and Sinha and Gregory, 1981) and d) enzyme catalysed and iron-mediated
free radical formation (Handa and Sato , 1975 and Powis, 1987). At present,
the literature favours the first of these mechanisms. However, the final
mechanism is obviously of relevance to the work described here. Handa and
Sato (1975) first showed in vitro that doxorubicin could be converted to a
semiquinone free radical by an NADPH dependent one electron reduction.
This or a similar process was also believed to occur in intact Ehrlich ascites
cells. No specific enzyme has been discovered which acts as a doxorubicin
quinone reductase. However, several enzymes accept the drug as a substrate
for one electron reduction in vitro including P450 reductase, NADH
dehydrogenase, xanthine oxidase and an unknown component of the nuclei
(Cummings et al., 1991). The cytotoxic effects of various concentrations of
doxorubicin towards the P450 reductase expressing and non-expressing
S.typhimurium are shown in Figure 3.10. It can be seen that there is no
significant difference between the P450 reductase expressing and non-
expressing bacteria. The data shown in Figure 3.10 suggests that P450
reductase has no effect on the cytotoxic effects of doxorubicin on
S.typhimurium. This suggests that free radical formation may not play a
role in the cytotoxicity observed in this system.
The effects of doxorubicin on the growth of S. typhimurium in liquid culture
are shown in Figures 3.11. Apart from Figure 3.11D, it appears that
doxorubicin has little effect on growth inhibition of either expressing or non-
expressing S.typhimurium. One problem in the experiments described here
is that it is unknown how much of the doxorubicin is being taken up by these
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Figure 3.10. Survival of S. typhimurium (TA1535) transformed with
pMP231 (control) and the rat reductase expression vectors pMP230
and pOR263 following exposure to doxorubicin. All measurements are











































































Figure 3.11. Effect of doxorubicin on the growth of S.typhimurium
(TA1535). (A,C) pMP231 (control) and the rat reductase expression vector
pMP230. (B,D) pMP231 and the rat reductase expression vector pOR263.
Doxorubicin (dox.) concentrations are shown.
medium (nutrient broth) whereas the cytotoxicity experiment was carried out
by treating cells with drug in phosphate buffered saline.
For free radical formation by doxorubicin to have any clinical relevence then
a variety of criteria would have to be fulfilled such as; a) identification of
hydroxyl radicals being produced in a site specific manner; b) detection of
damage consistent with free radical formation and c) antagonism of
cytotoxicity by free radical scavengers and detoxification enzymes
(Cummings et al., 1991). Evidence for the above is not very convincing. For
example, OH" radicals have been detected by electron spin resonance,
however, these were observed after treatment ofMCF7 cells with a doxrubicin
concentration two orders of magnitude higher than clinically achievable
concentrations and the majority of these radicals were detected outside the
cells (Sinha et al., 1987). Another study failed to detect OH" in MCF7 cells and
showed O2' to be produced in the extracellular space after diffusion of the
doxorubicin semiquinone from inside the cells (Alegria et al., 1989). Non¬
protein associated DNA breaks, consistent with free radical damage have
only been observed at concentrations well in excess of the IC50 (Potmisil et al.,
1983). In certain cell lines (MCF7 and Ehrlich ascites) free radical
scavangers antagonise cytotoxicity while in other cell systems (A2780) they do
not (Keizer, 1990).
3.4 Effect of redox cycling agents on enzyme levels controlled by the
sox RS and OxyR regulons in E.coli.
Oxidative stress exerted by superoxide generating agents such as paraquat
triggers the sox RS regulon of E.coli. (Demple and Amabile-Cuevos, 1991). In
this system, sox R protein is the redox sensitive activator of the sox S gene.
The sox S protein activates around 10 promoters of this regulon. Proteins
induced by this system include Mn and Fe superoxide dismuthases, glucose-
6-phosphate dehydrogenase (G6PDH), endonuclease IV and NADH
dehydrogenase These proteins can be thought of as being induced to play a
defensive role against the adverse effects of oxygen free radicals.
The oxyR protein is the transcriptional activator of an H2O2 inducible regulon
(Stortz et al., 1991). The oxyR protein is only transcriptionally active when
oxidised and turns on the expression of catalase, glutathione reductase and






pMP231 0 29.8 (100%) 28.9 (100%)
2 233.9 (785%) 79.5 (275%)
10 249.8 (838%) 88.9 (307%)
pOR263 0 41.6 (100%) 30.8 (100%)
2 313.3 (753%) 130.1 (422%)
10 287.3 (690%) 151.0 (490%)
pMP230 0 35.1 (100%) 33.3 (100%)
2 300.0 (855%) 69.5 (209%)
10 255.1 (727%) 70.2 (211%)
Table 3.1. Effect of paraquat on enzyme levels controlled by the soxRS






pMP231 0 27.5 (100%) 25.4 (100%)
0.5 81.9 (298%) 115.4 (454%)
10 72.8 (265%) 102.3 (402%)
pOR263 0 26.6 (100%) 33.3 (100%)
0.5 69.4 (261%) 88.2 (265%)
10 71.2 (268%) 87.5 (263%)
pMP230 0 27.3 (100%) 33.8 (100%)
0.5 56.0 (205%) 107.7 (319%)
10 53.1 (195%) 67.7 (200%)
Table 3.2. Effect of menadione on enzyme levels controlled by the






pMP231 0 34.4 (100%) 27.8 (100%)
1 26.0 (75%) 17.0 (61%)
100 17.0 (49%) 18.6 (67%)
pOR263 0 33.6 (100%) 23.8 (100%)
1 29.8 (89%) 19.6 (82%)
100 29.3 (87%) 17.9 (75%)
pMP230 0 21.7 (100%) 22.1 (100%)
1 27.7 (78.3%) 15.3 (69%)
100 20.2 (93%) 18.9 (86%)
Table 3.3. Effect of doxorubicin on enzyme levels controlled by
soxRS and oxyR regulons in E.coli.
the
been more fully characterised in E.coli than in S.typhimurium (Farr and
Kogoma, 1991).
The effect of P450 reductase expression on these regulons was investigated in
the presence and absence of a redox cycling compound. E.coli were grown in
the presence of the chemical and after 4 hours extracts were prepared and
assays performed on the soluble fraction for superoxide dismuthase and
catalase activities. Effects of paraquat, menadione and doxorubicin on these
enzyme levels are shown in Tables 3.1, 3.2 and 3.3 respectively. What can be
seen from this data is that P450 reductase expressing bacteria had a variety of
different effects on the enzyme levels compared to non-expressing E.coli. An
important observation is that the regulons appeared not to be induced by P450
reductase expressing bacteria in the absence of a redox cycling compound.
This suggests that if any free radicals are being produced by the expresed
reductase they are not in sufficient concentration to ellicit a response. That
doxorubicin did not induce any of the protective enzymes suggests that if
redox cycling of this drug was occurring in this system then it was not at a
level high enough to induce a response.
3.5 Summary.
The data in this chapter has served to highlight the use of P450 reductase S.
typhimurium strains in the study of in vivo activation of redox cycling
compounds. Two well known redox cycling compounds, paraquat and
menadione had dramatic effects on the bacteria expressing P450 reductase.
However, doxorubicin had no clear effect over wild type. This system may be
of value in the study of the bioactivation of proposed redox cycling compounds.
However, further studies using other compounds will need to be looked at.
The work on the Sox RS and Oxy R regulons in E. coli showed that when
P450 reductase expressing bacteria were subjected to the compound of
interest there was little effect over wild type levels of enzymes regulated by
these systems. However, of importance from this work is the fact that P450
reductase expressing bacteria, in the absence of any redox cycling compound
did not induce a stress response via these regulons. Since heterologous
expression of mammalian proteins is becoming ever important for the
pharmaceutical/ biotechnology industries, it is important to know the
stresses imposed on host cells by the foreign protein.
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Chapter 4. Expression, purification and biochemical
characterisation of domains of NADPH-Cytochrome P450
oxidoreductase.
4.1 Introduction and Aims.
From the original sequence alignments of the deduced amino-acid sequence
from the rat P450red cDNA (Porter and Kasper, 1985; Porter and Kasper, 1986;
Porter et al., 1990) it was evident that P450 reductase contained two separate
and distinct flavin binding domains. The two flavin binding domains found
in P450 reductase were proposed to have been the result of a fusion of two
ancestral flavoproteins rather than the outcome of a gene duplication event of
a single flavin binding domain (Porter and Kasper, 1985). Porter and Kasper
(1986) went on to propose that the fusion was of two ancient proteins that lay
in tandem on a primordial operon.
These workers found that the N-terminal portion of the protein shows strong
homology with the bacterial flavodoxin from Desulfovibrio vulgaris. The C-
terminal portion of the protein shows homology with spinach ferredoxin
NADP+ reductase (FNR). Figures 4.1A,B,C show the results of multiple
sequence alignments carried out using the programs 'Pileup' and Prettybox'
from the GCG computer package. These Figures highlight the regions of
importance in flavin binding and NADPH binding as deduced previously
from the known crystal structures of flavodoxin, from Desulfovibrio vulgaris,
and ferredoxin NADP+ reductase, from spinach (Porter and Kasper, 1985,
Porter and Kasper, 1986, Porter et al., 1990, Karplus et al., 1991, Shen and
Kasper, 1993). In Figure 4.IB, regions involved in binding the FMN
phosphate group and the FMN isoalloxazine ring are shown. In Figure 4.1C
regions involved in binding the FAD pyrophosphate group and isoalloxazine
ring are shown along with a region at the C-termini shown to interact with
the dimethylbenzene ring of FAD. Two regions proposed to be involved in
NADPH binding are illustrated in Figure 4.1C. NADPH 1 shows the
dinucleotide binding site while NADPH 2 is a region proposed to be involved
in binding the 2' phosphate of NADPH. The amino-acid sequences of P450red
from Saccharomyces cerivisiae and Bacillus megaterium along with human
brain nitric oxide synthase (NOS) and sulphite reductase from Salmonella
typhimurium are included to show the striking homology across members of
the FMN/FAD containing family of flavoproteins. Regions of P450red
53












FERREDOXIN NADP + REDUCTASE: 24% (48%)
SULPHITE REDUCTASE: 30% (55%)
NITRIC OXIDE SYNTHASE (C-terminus): 33% (54%)
Figure 4.1A Summary diagram of amino-acid sequence alignments of P450
reductase with desulfovibrio vulgaris flavodoxin; spinach ferredoxin NADP+
reductase; salmonella typhimurium sulfite reductase; human brain nitric
oxide synthase (C-terminal half). Percentage identities are shown with
homologies in brackets. Regions involved in FMN and FAD/NADPH binding
are shown, as deduced from the crystal structures of flavodoxin and
ferredoxin NADP+ reductase respectively. Alignments were performed
using the 'Bestfit' program.
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Figure 4.1B Multiple amino acid sequence alignment of; P450 reductases
from human, bacillus megaterium and sacharomyces cerivisiae\ Salmonella
typhimurium sulphite reductase; human brain nitric oxide synthase and
desulfovibrio vulgaris flavodoxin. The alignment was performed using
'Pileup' and 'Prettybox' from the GCG package. Residues in bold are
identical while those shaded are conserved. Regions shown are discussed in
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Figure 4.1C Multiple amino acid sequence alignment of; P450 reductases
from human, bacillus megaterium and sacharomyces cerivisiae; Salmonella
typhimurium sulphite reductase; human brain nitric oxide synthase and
spinach NADP+ ferredoxin reductase. This alignment was performed using
'Pileup' and 'Prettybox' from the GCG package. Residues in bold are
identical while those shaded are conserved. Regions shown are discussed in
the text, iso, isoalloxazine. Amino-acid numbers are shown..
proposed to be involved in P450 (SRS) and cytochrome c (SRS 2) interactions
are also shown in Figure 4.IB (Nadler and Strobel, 1992, Nisimoto, 1986).
Work on the structural analysis of P450 reductase has so far focused on the
use of site-directed-mutagenesis and chemical modification to alter proposed
residues of structural importance (Shen et al., 1989; Shen and Kasper, 1990;
Sem and Kasper, 1993; Nisimoto and Shibata, 1982; Lazar et al, 1977, Vogel
and Lumper, 1986; Haniu et al., 1984, 1989, Nisimoto, 1986). The residues for
the site-directed mutagenesis analysis were deduced from the alignments
with the aforementioned bacterial and plant proteins for which the crystal
structures are known. For example, site-directed mutagenesis of the rat
protein has demonstrated the roles of Tyr 140 and Tyr 178 in FMN binding
and catalysis (Shen et al., 1989). While Arg 597 of the rat reductase has been
shown to be of importance in discriminating between NADH and NADPH
(Sem and Kasper, 1993). Site-directed mutagensis of acidic residues in the
region 200-220 of the rat protein has provided some evidence for their
interaction with cytochrome c and P450 (Shen and Kasper, 1990). Cross
linking studies have also shown the importance of this region in cytochrome
c binding (Nisimoto, 1986)
However, no work has so far looked at dissecting P450 reductase or
structurally similar proteins into the distinct functional domains that are
suggested from the sequence alignments. One reason for believing that
splitting the protein up into distinct flavin binding units could be successful
is that the proposed contact points for FMN and FAD binding are in different
regions of the protein as suggested from the proposed evolution of the protein.
An argument against the ability to dissect the protein is that co-operativity
between the flavin binding domains may be of importance for their correct
folding and hence incorporation of their respective flavins (Vermillion and
Coon, 1978b, 1981; Iyanagi et al., 1981; Kurzban and Strobel, 1986, Kurzban et
al., 1990). That proteins can be split into functional domains is exemplified by
the steroid hormone binding receptors (Kumar et al., 1986, 1987, Green and
Chambon, 1987) and tissue plasminogen activator (Patthy, 1985). The latter
protein being the first example of what is termed a 'mosaic' protein. These
'mosaic' proteins have a modular structure in a manner similar to that
proposed for P450 reductase. These proteins are totally dissimilar but the
modular structure of the proteins serves a point, i.e. one region serves one
function while another quite separate region of the protein serves another.
Using the steroid hormone binding receptors as an example, one region of the
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protein acts as the hormonal receptor while the other binds DNA (Kumer et
al., 1986, 1987; Green and Chambon, 1987). P450 reductase binds three
different prosthetic groups, namely NADPH, FMN, FAD, and has the ability
to interact with both membranes and with cytochromes P450. This would
suggest the existence of distinct functional domains in this protein.
In order to attempt the dissection of P450 reductase into distinct functional
domains a variety of regions of the protein were proposed for expression in
E.coli (Figure 4.2). Bacterial expression of these proposed domains would not
only allow insights into the basic structure, function and evolution of the
protein but provide an abundant source of material for future structural
analysis, such as NMR and X-ray crystallography. Analysis of the rat P450
reductase gene by Porter et al., (1990) revealed that distinct groups of exons
coded for the proposed functional domains of the protein as shown in Figure
4.2. The regions of the human P450 reductase to be used for bacterial
expression were decided upon using the organisation of the rat gene as a
model. The rat gene was used as a model since the human gene for P450
reductase has not yet been cloned. The rat and human reductases show 97%
similarity and 92% identity at the amino acid level so it was felt that the rat
gene would be a representative model to define the functional units of the
human protein using exon/intron boundaries (Figure 4.2). Indeed,
intron/exon boundaries have been shown to be identical for a variety of
human and rat genes including the human and rat UDPGT genes
(Monaghaun, 1994) the cytochrome P450 genes in family 2 (Hawkins, 1988)
and the aldolase genes (Rottman et al., 1987).
The extensive analysis of gene structure carried out by Traut (1988) showed
that, for the genes he analysed, there was a greater than 50% correlation
between exons and structural/functional domains of the protein. Some
examples where exons have been shown to correlate with
structural/functional domains include glyceraldehyde phosphate
dehydrogenase (Shih et al., 1988), triosephosphate dehydrogenase (Straus and
Gilbert, 1985), immunoglobulin G heavy chain (Sakano et al., 1979) and
lysozyme (Jong et al., 1980). Some examples where exons have been shown
not to correlate with structural/functional units of the protein include
carboxypeptidase (Quinto et al., 1982), lactate dehydrogenase (Li et al., 1982)
calmodulin (Simmen et al., 1985) and actin (Weber and Kabsch, 1994). As can
be imagined, from the above analysis of protein structure with exon/intron
organisation, there has been much debate in the literature on whether
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proteins have evolved through the assembly of exons that define distinct
structural/functional units or not. This debate ensued after the observation
that eukaryotic genes are generally built from short exons separated by long
introns (reviewed by Witkowski, 1988). The opposing viewpoints are based on
the models termed 'intron early' and 'intron late'. In the intron early model,
genes were assembled in early evolution from exons encoding functional
domains, folding regions or structural elements via intron mediated
recombinations thus allowing for the production of proteins with a variety of
functions (Gilbert, 1988). This model assumes a complete loss of introns in
prokaryotes while in eukaryotes introns are thought of as primitive relics
which were in part lost and part retained (Gilbert, 1978; Cornish-Bowden,
1985). In contrast, the intron late model assumes that introns were gained
only by early eukaryotic genomes and during their later evolution i.e. introns
invaded the otherwise uninterupted coding regions of genes (Cavallier-Smith,
1985). However, an important aspect of both models is that they allow for exon
shuffling later in eukaryotic evolution. Which model P450 reductase supports
is unclear since both have their merits. Specific exons of the rat reductase
gene code for the proposed prosthetic group binding sites while other
important binding sites are split between exons (Porter et al., 1990). P450
reductase can be thought of as an ancient protein since it exists as a fusion
with a P450 in the bacteria Bacillus megaterium (ATCC 14481) (Nahri and
Fulco, 1986). The ancestral reductase protein may have lost introns during
the evolution of B. megaterium or may have gained introns during the
evolution of the eukaryotic reductases.
To define the regions of P450 reductase to be expressed on the intron/exon
organistion of the gene may be futile since the original structural boundaries,
that may or may not have existed, in the ancestral reductase will most
probably have been lost through the further evolution of the protein in the
modern forms of the reductase. P450 reductase has evolved to serve a
completely different function from that of its proposed ancestors, the
flavodoxin and ferredoxin NADP+ reductase. However, using the
intron/exon boundaries will, at the least, be useful for initial studies in
defining the limits of the proposed functional domains not only in P450
reductase but in other structurally related proteins such as the nitric oxide
synthases and sulfite reductases.
The initial aims of this work were to produce functional domains of human
P450 reductase, as proposed by Porter and Kasper (1986), using a bacterial
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expression system. The domains for expression were, as discussed above,
defined by the intron/exon boundary of the rat gene (Porter et al., 1990) and
shown in Figure 4.2. Why these domains were chosen will be discussed in
the next section.
4.2 /4.3 Results and discussion.
4.2 Expression, purification and characterisation of the proposed
functional domains of human NADPH cytochrome P450
oxidoreductase.
4.2.1. Proposed functional domains of human NADPH cytochrome
P450 oxidoreductase used for bacterial expression.
A variety of domains of P450 reductase were chosen for expression (Figure
4.2) using the bacterial pET (plasmid for expression by T7 RNA polymerase)
system (Figure 4.4). Exons encoding the domains for the proposed 'minimal'
FMN and FAD/NADPH (termed FMN(small) and FAD/NADPH(small)) were
selected for expression along with groups of exons that encoded regions
outwith the minimally defined regions. Exons 4,5,6 contain all the contact
points for FMN binding as defined by sequence alignment with the flavodoxin
from Desulfovibrio vulgaris whose crystal structure is known (Porter and
Kasper, 1986; Watenpaugh, 1973). This region was named FMN (small) while
the other FMN regions contained exons 2-8 or exons 3-8 and are called the
FMN/anchor and FMN domains respectively. Exons 12-16 were chosen for
expression of the FAD/NADPH(small) domain and contained all the
proposed contact points required for FAD and NADPH binding as defined by
sequence alignment with spinach ferredoxin NADP+ reductase whose
crystal structure is known (Porter and Kasper, 1986; Karplus, 1991). Exons 8-
16 were chosen for expression of a larger FAD/NADPH domain. The larger
domains were chosen for expression since it was felt that regions outwith the
so-called 'minimal' domains would be important in the overall folding of the
domain to produce a functional unit. Although the most significant regions
of alignment with the Desulfovibrio vulgaris flavodoxin and spinach FNR are
within the 'minimal' domains, it must be remembered that P450 reductase
has evolved to serve a different function than these two functionally
dissimilar flavoproteins and hence P450 reductase may contain important
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77 2.14 FMN (small)
FMN/Anchor 274
242 FAD/NADPH (large) 677
61 FMN 274
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414 FAD/NADPH (small) 677
FMN/FAD 602
242 FAD 602
Figure 4.2. Structure of P450 reductase and it putative domains. (A)
Organisation of the P450 reductase domains. Regions of structural
importance are shown. Anc., membrane anchor region; S, substrate
recognition site. (B) Exon organisation of the rat P450 reductase gene. (C)
Domains made for expression in this study. Amino acids flanking the domains
are shown. 5' oligonucleotides were derived from the start of the exons
shown and incorporated an Nde I restriction site. 3' oligonucleotides were
derived from the sequence at the ends of the exons and incorporated a stop
codon followed by an Xho I restriction site.
regions for prosthetic group binding or protein folding outwith the 'minimal'
regions described here. The FMN/FAD domain shown in Figure 4.2
contained all the proposed residues for FMN binding and the majority of
residues important for FAD binding. However, this protein did not contain
Tyr 677 and Glu 674 which, from alignment with spinach FNR, are proposed
to be invloved in covering the face of the flavin and interacting with the
dimethylbenzene ring of the flavin respectively (Karplus et al., 1991). Also,
this construct did not contain a significant portion of the NADPH binding
region of the reductase (exons 15,16). The FAD domain (Figure 4.2) was
similar to the large FAD/NADPH domain but did not contain the last two
exons of the reductase, as described for the FMN/FAD domain.
The expression plasmid pET15b (Figure 4.4) utilises the immensly powerful
bacteriophage T7 promoter along with T7 RNA polymerase. The pET system
relies on there being a copy of T7 RNA polymerase incorporated into the
genome ofE.coli. (Studier and Moffat, 1986; Rosenberg et al. 1987). A copy of
the polymerase has been established, under control of the lacUV5 promoter,
in the E.coli strain BL21(pLysS). On induction of BL21(pLysS) with IPTG the
T7 RNA polymerase is produced. (N.B. Any leaked expression of T7 RNA
polymerase before IPTG induction is inhibited by bacterial lysozyme which is
present in the BL21 strain encoded by the plasmid pLysS). T7 RNA
polymerase is highly specific for the T7 promoter found within pET15b and
after its expression is induced it can lead to the majority of transcription
within the E.coli being driven from the T7 promoter (Studier and Moffat,
1986; Rosenberg et al.; 1987). The ferocious nature of this system can however
lead to the production of insoluble, unfolded protein termed 'inclusion bodies'
(Williams et al., 1982).
One major reason for chosing this plasmid was that by cloning into the
unique Nde I and Xho I sites a 6x Histidine tag followed by a thrombin
cleavage site would be engineered onto the NH2-terminus of the expressed
proteins (Figure 4.4). This would allow a single step purification using the
affinity matrix nickel-agarose. Nickel-agarose chromatography also allows
proteins that are insoluble to be purified under denaturing conditions.
58
4.2.2. Cloning of the human NADPH cytochrome P450
oxidoreductase cDNA.
The cDNA for the human reductase was cloned by PCR from human skin
fibroblast cDNA using oligonucleotides for the 5' and 3' ends of the cDNA
derived from the sequence of the human reductase (Shepherd et al., 1990) as
shown in Figure 4.3. The oligonucleotide for the 5' end had an Eco RI
restriction site incorporated into it. After amplification (Figure 4.3),
treatment with Klenow and digestion with Eco RI, the PCR products from
two reactions were cloned into the EcoRI/ Sma I site of the phagemid
pTZ19R. After sequence analysis it was found that the cDNA was identical to
that of the human P450 reductase sequence present in the EMBL data-base
(Shepherd et al., 1992).
This cDNA was then used as the template for the amplification of the cDNAs
encoding the domains of P450 reductase shown in Figure 4.2. The 5'
oligonucleotides derived from the sequence at the start of the exons shown in
Figure 4.2 incorporated an Nde I restriction site, while the 3' oligonucleotides
derived from the sequence at the ends of the exons shown in Figure 4.2
incorporated a stop codon followed by an Xho I restriction site. After
amplification the cDNAs were digested with Nde I and Xho I followed by
ligation into the appropriate sites of the expression vector pET15b (Figure 4.4).
4.2.3. Expression of the proposed functional domains of human
P450 oxidoreductase in E.coli.
Figures 4.5-4.11 show the expression and purification of the domains of P450
reductase that are illustrated in Figure 4.2 using the expression plasmid
pET15b (Figure. 4.4). By cloning into the Nde I/ Xhol sites of pET15b a 6xHis-
linker and thrombin cleavage site are engineered onto the NH2-terminus of
the expressed protein (Figure 4.4). The generation of a 6xHis linker on the
NH2-terminus of the expressed protein allows purification to be carried out
employing nickel-agarose chromatography.
From the initial expression studies it became evident that the level of
expression of soluble protein varied from one domain to the next. One
problem of bacterial expression is the formation of inclusion bodies (Williams
et al., 1982). Inclusion bodies can be formed from the clumping together of








Digestion with Eco R1.
Subclone into Eco R1/Sma 1 site of pTZ19R
Figure 4.3. Cloning of the human P450 reductase cDNA. (A) The human
cDNA was amplified by PCR (lanes 2,3) from skin fibroblast cDNA using the
oligonucleotides shown. Lane 2; kb ladder. (B) The amplified 2.1 kb fragment
was subcloned into the phagemid pTZ19R (lanes 2, 3) and the sequence
confirmed. Lane 1; kb ladder.
NdeI XhoI
Figure 4.4. The expression vector pET15b. The cDNAs encoding the
domains shown in Figure 4.2 were cloned into the uniqueNdel /Xhol
sites, thus engineering a 6X His-tag and thrombin cleavage site onto
the N-terminus of the expressed proteins.
the bacteria. A major reason for the production of inclusion bodies can be due
to the strength of the promoter used. The rampant nature of the T7 promoter,
found in pET15b, can lead to high production levels of protein resulting in the
saturation of the protein folding mechanisms in E.coli. This leads to large
amounts of unfolded protein within the bacteria which results in the
production of inclusion bodies. In Figures 4.5-4.11 it can be observed that for
all the proteins expressed some if not all of the protein expressed was
insoluble. Indeed, no soluble protein could be produced for the
FAD/NADPH(small) or FAD domains (Figure 4.8,4.9). These domains could
only be purified under denaturing conditions. In stark contrast, the FMN
domain produced large amounts of soluble protein, up to 35 mgs of pure
protein from a 1 litre culture (Figure 4.6). The expression and
characterisation of the domains shown in Figure 4.2 will be discussed
individually in the following sections.
4.2.4. Expression, purification and characterisation of the
FMN(small) domain of human P450 oxidoreductase.
Figure 4.5 shows the expression and purification of the FMN(small) domain
of human P450 reductase. When this 'minimal domain' was expressed the
majority of the protein was found to be insoluble. However, some protein was
purified from the soluble fraction of the lysed bacteria eluting from the nickel-
agarose column at an imidazole concentration of 20 mM. Around 1 mg of
FMN(small) protein could be purified from a 1 liter culture of E.coli induced
with 0.5 mM IPTG for 2 hours. What was evident from looking at the purified
protein was that no flavin had been incorporated. There was no evidence for
FMN incorporation as judged by the absorption spectrum of the oxidised
purified protein. This region of the reductase extends from amino-acids 77-
214 and incorporates all the residues proposed to be involved in the binding of
FMN as judged from the alignment of this region of P450 reductase with the
flavodoxin from Desulfovibrio vulgaris (Porter and Kasper, 1986). This result
suggests that regions of the reductase outside amino-acids 77-214 are
important for binding the FMN moiety and/or correctly folding the functional
FMN binding domain of the protein. The predicted molecular weight of the
FMN(small) domain is 15.3 kDa. The molecular weight predicted from SDS-
PAGE using a 15% gel was 15 kDa.
60
Figure 4.5. Expression and purification of the FMN (small) domain
of P450 reductase. SDS-PAGE (15%) analysis of the expressed and purified
FMN (small) domain. Lanes: Stds, molecular weight standards. Insol.,
insoluble fraction (10gg); Sol, soluble fraction (lOgg); F.T., flow through
(lOgg). 1-3 Protein eluted with binding buffer + 20mM imidazole.
4.2.5. Expression, purification and characterisation of the FMN
domain of human P450 oxidoreductase.
Figure 4.6A shows the expression and purification of the FMN domain of
P450 reductase. Around 40% of the expressed protein was found to be in the
soluble fraction of the lysed bacteria. This domain was found to elute from
the nickel-agarose column with an imidazole concentration of 60 mM. From
a 1 litre culture of E.coli, induced for 2 hours with 0.5mM IPTG, 35 mg of
purified FMN domain could be obtained.
Some interesting observations were made when purifying this domain. On
preparing the soluble bacterial extract, before loading onto nickel-agarose, it
was found to be a very dark grey colour. On addition of the extract onto the
nickel-agarose column, the protein that bound to the top of the column
appeared very dark blue, almost black in colour. However, on washing the
column the colour of the bound protein changed from dark blue to green and
then eventually to yellow. When eluted from the column the purified protein
appeared yellow. What can initially be inferred from these observations is
that incorporation of flavin into the FMN domain had taken place. As
regards the colour changes on the column, it can be speculated that the FMN
domain was initially isolated from the bacteria in a reduced form. The one
electron reduced forms of FMN containing proteins, such as flavodoxins, are
known to be air-stable and have high absorbance in the red region of the
visible spectrum. This results in the proteins appearing blue when in a one
electron reduced state. The absorption spectrum of the oxidised FMN domain
is shown in Figure. 4.12A while that of an air-stable reduced form is shown
Figure 4.12B. The oxidised spectrum contains absorption maxima at 370nm,
453nm and a broad absorption band between 570nm and 630nm (most
probably due to some reduced FMN being present in the sample). This
spectrum is virtually identical to that obtained by Kurzban et al. (1990) for
FAD-depleted P450 reductase and similar to that predicted from a computer
model by Oprian and Coon (1982). The spectrum also shows strong
similarities to the flavodoxin from Peptostreptococcus elsdenii (Iyanagi et al.,
1974). In an attempt to chemically reduce the FMN domain an experiment
was carried out which involved adding a 10 molar excess of sodium dithionite
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Figure 4.6. Expression, purification and thrombin cleavage of the
FMN domain of P450 reductase. (A) SDS-PAGE (12%) analysis of the
expressed and purified FMN domain. Lanes: Stds, molecular weight
standards. Sol, soluble fraction (15gg); F.T., flow through (15gg). 1-4 Protein
eluted with binding buffer + 60mM imidazole. (B) SDS-PAGE (12%) analysis
of the FMN domain after thrombin cleavage. Stds, molecular weight
standards. Times of incubation with thrombin are shown.
remain in a one electron reduced state for a long period (up to 48 hours)
(Iyanagi and Mason, 1973) it was presumed that a similar state may be
achieved for the FMN domain. The two electron reduced FMN in native P450
reductase is unstable and passes an electron onto oxygen (Backes, 1993). This
results in the semiquinone form of FMN in P450 reductase being produced.
What was anticipated in the experiment described here was that the excess of
reducing equivalents would be passed onto molecular oxygen leaving only the
one-electron reduced FMN. The result of adding an excess of sodium
dithionite to the FMN domain is shown in Figure 4.12B. This spectrum was
achieved two hours after the reductant was added and did not change for up
to 4 hours. This rate of oxidation, compared to the native reductase, has been
observed previously for the FAD-depleted reductase (Kurzban et al., 1990).
Compared to the oxidised spectrum (Figure 4.12A vs 4.12B) the air stable
reduced spectrum had an increase in absorbance at 585nm with a prominant
shoulder at 630nm, while there is a decrease in absorbance at 453nm. An
absorbance maximum at 345nm is also observed with a decrease at 370nm.
This spectrum is identical to that of the air-stable FAD-depleted reductase
produced by photoreduction (Kurzban et al, 1990) and similar to that predicted
by a computer model (Oprian and Coon, 1982). The spectrum shown in
Figure. 4.12B is also similar to the air-stable, one elecron reduced form of the
flavodoxin from Peptostreptococcus elsdenii (Mayhew and Massey, 1969;
Iyanagi and Mason, 1973).
Determination of flavin content revealed that FMN was incorporated in the
protein at a ratio of 0.63 mol per mol of protein. This is below the predicted 1:1
ratio and may reflect a loss of flavin during purification. FMN is known to be
less tightly bound to the native protein than FAD (Vermillion and Coon 1978b,
Kurzban et al., 1990). Another reason may be that for the correct
incorporation of FMN into the protein FAD and/or the FAD domain is
required. In support of the former argument, it is found that FMN is more
easily removed from FAD-depleted reductase (Kurzban and Strobel, 1986,
Kurzban et al., 1990).
Since this protein bound FMN it was decided that for further studies the Non¬
terminal 6xHis-tag would be removed by thrombin cleavage (Figure 4.6B).
The His-tag was easily be removed from this domain in 10 minutes using a
ratio of thrombin to domain of 1:5,000. The shift in mobility as judged by SDS-
PAGE is clearly shown in Figure 4.6B, giving an estimated size of the FMN
domain of 28 kDa. in comparison to the predicted size of 24.2 kDa.
62
4.2.6. Expression, purification and characterisation of the
FMN/Anchor domain of human P450 oxidoreductase.
Figure 4.7B shows the expression and purification of the FMN/anchor
domain of P450 reductase. The majority of this protein was found to be in the
insoluble fraction of the lysed bacteria. This insolubility problem is most
probably due to the hydrophobic nature of the NH2-terminus of P450
reductase that is present in exon 2 (amino-acids 1-60). This region contains a
long hydrophobic stretch extending from residues 20-44 followed by a cluster
of basic residues (amino-acids 45-48), which is characteristic of a simple
eukaryotic transmembrane segment (von keijne, 1985). Hydrophobic proteins
are known to be problematic when expressed in E.coli. (Williams et al., 1982).
Despite this, up to 5 mg of the protein from a 1 liter culture could be purified.
This domain was eluted from the nickel agarose column by an imidazole
concentration of 300 mM.
The yellow appearance of the purified sample suggested flavin incorporation
had taken place. The flavin content of the protein was estimated to be 0.67 mol
flavin/ mol protein. The oxidised absorption spectrum of the FMN/anchor is
shown in Figure 4.13. The most apparent aspect of this spectrum, in
comparison to the FMN domain (Figure 4.12A), is the central peak at 420 nm.
Apart from this peak the spectrum appears identical to that for the oxidised
FMN domain (Figure 4.12A). One explanation for the peak at 420nm may be
that there is a heme-contamination from the nickel-agarose purification
since free heme would produce a peak in this region of the absorption
spectrum. However, after purifying the other soluble FMN domains and
FAD/NADPH domain there was no evidence for a similar contamination as
judged by the absorption spectrum of the purified proteins (Figures 4.12A and
4.14A). Also, when a control purification was carried out using the soluble
extract from non-expressing BL21, no heme was observed to be purified. This
peak at 420nm was also unable to be removed by dialysis. Another
explanation may be that the contaminant comes from the co-purification of a
heme containing protein from the BL21. The gel of the FMN/anchor
purification reveals no obvious presence of a contaminating band. However,
some minor contaminating bands can be seen in Figure 4.7B when attempts
were made on removing the His-tag from the NH2-terminus of the protein. If
the contaminant is a cytochrome then it most likely has an extinction
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Figure 4.7. Expression, purification and thrombin cleavage of the
FMN/anchor domain of P450 reductase. (A) SDS-PAGE (12%) analysis of
the expressed and purified FMN/anchor domain. Lanes: Stds, molecular
weight standards. Sol, soluble fraction (15gg); F.T., flow through (15gg). 1-4
binding buffer + 60mM Imidazole; Lane 5, Binding buffer + 300mM imidazole.
(B) SDS-PAGE (12%) analysis of the FMN/anchor domain after thrombin
cleavage. Stds, molecular weight standards. Times of incubation with
thrombin are shown.
coefficient that is ten times that seen for flavins in this range of the visible
spectrum. Hence, a cytochrome may represent a contaminant of up 10% in
the FMN/anchor preparations. The only difference between this domain and
the FMN domain is the first 60 amino-acids, which are predominatly
hydrophobic. This region of the reductase has been implicated in membrane
binding and P450 interactions (Black et al., 1979). It may be speculated that
this region of the reductase is interacting with a bacterial cytochrome. If an
interaction with a bacterial cytochrome is taking place then it is probably
hydrophobic in nature since the purification was carried out in high salt
concentration (500 mM NaCl). It is interesting to note that studies on the
bacterial expression of cytochrome P450 CYP17A (Barnes et al., 1991) found
that P450 monooxygenase activity could be reconstituted from bacterial
membranes without the exogenous addition or co-expression of P450
reductase. Recent, unpublished, work from the laboratory ofWaterman has
found that the heterologously expressed cytochrome P450 CYP17A was
interacting with the E.coli flavodoxin (Waterman, personal communication).
Since this domain was able to bind flavin, it was decided to be used for further
studies despite the presence of a contaminant. The removal of the 6xHis-tag
was attempted using thrombin. Unfortunately, as shown in Figure. 4.7B, the
removal of this linker from the N-terminus of the protein was unsuccessful,
even at a ratio of thrombin:protein of 1:1000. This is in contrast to the FMN
domain (Figure 4.6B). Accessibility to the thrombin cleavage site by the
protease is most probably the determining factor in this instance.
Determination of flavin content revealed that FMN was incorporated in the
protein at a ratio of 0.67 mol per mol protein.
4.2.7. Expression, purification and characterisation of the FAD
domain of human P450 oxidoreductase.
Expression of the FAD domain of P450 reductase (Figure 4.8) resulted in the
production of only insoluble protein. No soluble protein could be purified from
the soluble fraction of the E.coli (Figure 4.8A). This protein was purified from
inclusion bodies under denaturing conditions (Figure 4.8B). The protein was
found to elute from the nickel-agarose at an imidazole concentration of 20
mM in the presence of 6 M urea. Initial attempts at refolding this domain
were unsuccessful. Further refolding experiments of this protein to a soluble
















Figure 4.8. Expression and purification of the FAD domain of P450
reductase. (A) SDS-PAGE (12%) analysis of the expressed and purified FAD
domain under non-denaturing conditions. Lanes: Stds, molecular weight
standards, sol., Soluble fraction loaded onto nickel-agarose; F.T. flow
through; insol., insoluble fraction; wash, wash with binding buffer; 1-3
protein eluted with binding buffer +60mM imidazole; 4-5 protein eluted with
binding buffer + 1M imidazole. (B) SDS-PAGE (12%) analysis of the
expressed and purified FAD domain under denaturing conditions.Insol. on,
insoluble fraction loaded onto Nickel-agarose; F.T., flow through; 1,2 Protein
eluted with binding buffer + 20mM imidazole + 6M urea; 3, protein eluted
with Binding buffer + 300mM imidazole + 6M urea.
domain had an apparent molecular weight of 42 kDa., as judged by SDS-
PAGE and a predicted molecular weight of 41.0 kDa.
This domain contains the majority of the residues proposed to be involved in
the binding of FAD as judged by the sequence alignment with spinach FNR
whose crystal structure is known (Karplus et al., 1991). However, at the C-
terminus of FNR, amino acids Tyr 314 and Glu 312 are involved in shielding
the face of the flavin and making some contact with the dimethylbenzyl ring
respectively. These amino-acids align with Trp 676 and Glu 674 of the human
reductase and hence will not be present in the construct described here. Also,
this construct did not contain a significant portion of the NADPH binding
domain as judged from the alignment with spinach FNR. When describing
the structure of spinach FNR, the authors stated that due to the large contact
area between the FAD and NADPH domains it would not be possible to
functionally separate these two domains (Karplus et al., 1991). The work
presented here on the bacterial expression of this region of P450 reductase
suggests that the FAD/NADPH binding region of P450 reductase cannot be
separated into distinct functional units.
4.2.8. Expression, purification and characterisation of the
FAD/NADPH(small) domain of human P450 oxidoreductase.
Figure 4.9 shows the expression and purification of the FAD/NADPH(small)
domain of P450 reductase. This 'minimal' FAD/NADPH domain contains all
the critical amino-acid residues for FAD and NADPH binding. These critical
residues were derived from alignment of P450 reductase with spinach FNR
(Karplus et al., 1991). However, this protein could not be obtained in a soluble
form and was purified under denaturing conditions (Figure 4.9A, 4.9B). The
protein eluted from the nickel-agarose column with 20 mM imidazole in the
presence of 6 M urea. However, a large proportion of the protein passed
through the column without binding. The molecular weight as judged by
SDS-PAGE on a 12% gel was 31 kDa in comparison to the predicted weight of
30.2 kDa. Similar to the FAD domain, initial attempts at refolding this
protein proved fruitless and no further trials at renaturation were carried
out. Potential reasons for the inability to obtain this protein in a soluble and
functional form will be discussed at the end of the next section (4.2.9) which









Figure 4.9. Expression and purification of the FAD/NADPH (small)
domain of P450 reductase. (A) SDS-PAGE (12%) analysis of the expressed
and purified FAD/NADPH domain under non-denaturing conditions. Lanes:
Stds, molecular weight standards, sol., Soluble fraction loaded onto nickel-
agarose; F.T. flow through; wash, wash with binding buffer; 1-3 protein
eluted with binding buffer +60mM imidazole; 4-5 protein eluted with binding
buffer + 1M imidazole. (B) SDS-PAGE (12%) analysis of the expressed and
purified FAD/NADPH (small) domain under denaturing conditions. Insol. on,
insoluble fraction loaded onto Nickel-agarose; F.T., flow through; 1,2,3
Protein eluted with binding buffer + 20mM imidazole + 6M urea; 4,5,6 protein
eluted with Binding buffer + 300mM imidazole + 6M urea.
4.2.9. Expression, purification and characterisation of the
FAD/NADPH domain of human P450 oxidoreductase.
Figure 4.10A shows the expression and purfication of the FAD/NADPH
domain of human P450 reductase. As can be seen from this Figure, the
majority of the protein expressed ended up in the insoluble fraction of the
bacteria. However, up to 3.5 mg of the FAD/NADPH domain could be purified
from the soluble bacterial fraction obtained from a 1 litre culture of E.coli
induced with 0.5 mM IPTG for 2 hours. This protein eluted from the nickel-
agarose column with an imidazole concentration of 60 mM. The estimated
molecular weight of the protein as judged by SDS-PAGE, after thrombin
cleavage, was 50 kDa in comparison to the predicted size of 49.7 kDa.
Similar to the FMN and FMN/anchor domains, the purified protein appeared
yellow suggesting the incorporation of flavin into this domain. The
absorption spectrum of the FAD/NADPH domain is shown in Figure 4.14A.
This spectrum shows absorption maxima at 382nm and 454nm. The
spectrum is virtually identical to that produced by FMN-depleted native P450
reductase (Vermillion and Coon, 1978b; Iyanagi et al., 1981; Vermillion and
Coon; 1981; Kurzban and Strobel; 1986). However, the FAD/NADPH domain
spectrum shows considerably more definition to the spectrum of the FMN
depleted reductase produced by site-directed mutagenesis (Shen et al., 1989).
Mutagenesis may not only perturb the local environment of the protein but
may also have a global effect on the structure of the whole protein. In the
case of P450 reductase, mutagenising tyrosine residues involved in the
binding of FMN (Shen et al., 1989) may have perturbed the overall structure of
the protein and affected the incorporation of FAD into the mutated protein
and/or affected the orientation of the FAD in its binding site. These maybe the
reasons for the poorly defined spectrum obtained by Shen et al., (1989) and
also for the reduced incorporation of FAD found in their mutated protein.
Similar to the FMN and FMN/anchor domains the FAD/NADPH domain
contained less than the predicted amount of flavin. The ratio of FAD:protein
was calculated as 0.70:1. This reduced flavin content may reflect a loss of
flavin during purification and/or a requirement for the FMN domain of the
protein for correct incorporation/stabilisation of the FAD moiety. In the early
work that was performed on removing the more labile FMN moiety from











Figure 4.10. Expression, purification and thrombin cleavage of the
FAD/NADPH domain of P450 reductase. (A) SDS-PAGE (12%) analysis of
the expressed and purified FAD/NADPH domain. Lanes: Stds; Molecular
weight standards; Insol, insoluble fraction (15gg); sol, soluble fraction loaded
onto the Nickel-agarose column (15pg); F.T. Flow through (15pg); 1-4,
Fractions eluted with binding buffer + 60mM imidazole. (B) SDS-PAGE
(12%) analysis of thrombin cleaved FAD/NADPH domain. Stds., molecular
weight standards; Times of incubation with thrombin are shown.
the FMN-depleted reductase (Vermillion and Coon, 1978b; Iyanagi et al., 1981;
Vermillion and Coon; 1981; Kurzban and Strobel; 1986). These workers have
suggested that some cooperativity exists between the flavins and that both
require one another for stabilisation. Bonants et al. (1990) found alterations
in the FAD P31 NMR resonance upon removal of FMN suggesting altered
binding of FAD in the FMN-depleted reductase. However, what is clear from
the results shown in this study is that incorporation of each flavin into its
respective domain is not entirely dependent on the other flavin and/or
domain.
Functional analysis of electron transfer reactions within P450 reductase have
concluded that electrons flow from NADPH through the low potential flavin
(FAD) to the high potential flavin (FMN) and then onto the cytochromes P450
(reviewed by Backes, 1993). Reduction of the FAD/NADPH domain with a 10
fold molar excess ofNADPH, under aerobic conditions, resulted in alterations
in the oxidised absorption spectrum (Figure 4.14A) as shown in Figure 4.14B.
A decrease in the absorbance maximum at 454nm can be observed with the
production of an absorbance peak at 592nm after 10 minutes. This is
indicative of the production of an FAD semiquinone moiety (Vermillion and
Coon, 1978b; Vermillion et al., 1982)). Unlike the FMN semiquinone, which
was stable in air for several hours (Figure 4.12B) this species was not stable
and after 25 minutes under aerobic conditions the spectrum had reverted
back to that of the oxidised FAD/NADPH domain (Figure 4.14B). This data is
consistent with results obtained for the FMN-depleted reductase (Vermillion
and Coon, 1978b; Iyanagi et al., 1981; Vermillion and Coon; 1981; Kurzban and
Strobel; 1986). These workers observed that when the FMN-depleted
reductase was reduced with NADPH, in air, the reduced FAD quickly
reoxidised.
Since this 'functional' domain was to be used for further studies attempts
were made at the removal of this 6xHis-tag from the N-terminus of the
recombinant protein. Figure 4.10B shows that the tag could be efficiently
removed from the NH2-terminus of the protein using a ratio of
thrombin:domain of 1:5000. 100% cleavage was found to occur after 4 hours.
The shift in mobility as judged by SDS-PAGE using a 12% gel can be seen.
The ability of this domain to reduce a variety of one electron acceptors, and
cytochrome P450, is shown in Table 4.1. The data is expressed as mmol of
substrate reduced per/ minute/ mg of protein. This data indicates that the
FAD/NADPH domain is catalytically active towards a variety of substrates.
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Table 4.1: Specific Activity of P450 reductase and domains.
Activity*
Substrate P450 red. FAD/NADPH FAD/NADPH FMN
+FMN
Ferricyanide 33.1 17.9 (54.1%) 16.1 (48.6%) N.D.
DCPIP 11.2 0.456 (4.1%) 0.705 (6.3%) N.D.
Menadione 7.67 0.145 (1.9%) 0.134 (1.7%) N.D.
3-AcPy-ADP 1.14 0.228 (20%) 0.207 (18%) N.D.
CYP1A1 6.34 0.001 (0.016%) 0.121 (1.9%) N.D.
Cytochrome c 23.5 0.025 (0.11%) 0.410 (1.7%) N.D.
Specific activities are expressed as pmols substrate
reduced/minute/mg protein except for menadione where the
oxidation of NADPH was followed. CYP1A1 activity was
determined by measuring the oxidative O-deethylation of
ethoxyresorufin and is expressed as nmol resorufin
produced/min/ nmol P450. All assays were carried out in
triplicate with SEM< 5%. N.D., not detectable
However, the ability to reduce these compounds is diminished by varying
degrees compared to native P450 reductase. Of particular note is the poor
activity that the FAD/NADPH domain exhibits towards CYP1A1 and
cytochrome c. The data here is found to be very similar to that obtained for
the FMN-depleted reductase (Vermillion and Coon, 1978b) except for the
reduction of cytochrome P450 and cytochrome c. This is most probably due to
the removal of the FMN domain in the construct described here. Regions
within the FMN domain have been shown to interact directly with rat
CYP2B1 (Nelson and Strobel, 1991) and cytochrome c (Nisimoto, 1986). In
FMN depleted reductase not all the FMN is able to be removed and so some
functional protein is still present as well as the substrate interaction site(s).
In comparison, the FAD/NADPH domain described here does not contain the
FMN binding region thus removing the P450 and cytochrome c interaction
site along with the FMN prosthetic group.
In comparison to the FAD/NADPH(small) domain (4.2.8), the protein
described in this section had an additional 172 amino acids at the NH2-
terminus (Exons 8-11). Since no functional protein could be obtained for the
FAD/NADPH(small) domain it can be concluded that exons 8-11 or regions
within this part of the protein are important for the overall folding of the
protein and/or for the incorporation of FAD. In the early alignments of the
rat P450 reductase protein with a variety of flavoproteins (Porter and Kasper,
1986) it was found that amino-acids 266-325 (amino- acids 267-326 of the
human reductase) showed weak homology with the amino terminus of
spinach FNR and cytochrome b5 reductase (homology over this region can be
seen in Figure 4.1C). Porter and Kasper (1986) suggested that these amino-
acids might be important for interaction with the pyrophosphoryl region of
the FAD. However, after the structure of spinach FNR became available
(Karplus et al., 1991) it became evident that this region of FNR was not
important for interaction with the pyrophosphoryl group. This may not
preclude amino-acids within this region of P450 reductase from interacting
with FAD. Removal of this region from the FAD/NADPH domain, producing
the FAD/NADPH(small) domain, appears to prevent formation of a protein
able to bind FAD. Interestingly, following this stretch of weak homology with
cytochrome b5 reductase and FNR (amino-acids 266-325) there is a region of
the protein termed 'the insertion' (Porter and Kasper) which appears not to
align with any other proteins apart from members of the FMN/FAD
containing family i.e. P450 reductase, sulfite reductase and nitric oxide
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synthase. Porter and Kasper (1986) proposed that this insertion is necessary
for the proper positioning of the FMN and FAD moieties and for efficient
transfer. This insertion would not be required in FMN only and FAD only
containing flavoproteins. Therefore, this region may be required for helping
to maintain the FAD in its binding site. It does not appear to be of major
importance in FMN binding or orientation as shown in Figure 4.12A,B but
may be another factor for the less than stoichiometric amounts of FMN found
in the FMN and FMN/anchor domain.
4.2.10. Expression, purification and characterisation of the
FMN/FAD domain of human P450 oxidoreductase.
The results of the expression and purification of the FMN/FAD domain are
shown in Figures 4.11A,B. A very small percentage of this protein was found
to be soluble. However, on purification this protein was extremely susceptible
to proteolysis despite the presence of a cocktail of protease inhibitors in the
purification (Figure 4.11A). The purification shown in Figure 4.1 IB was
carried out under denaturing conditions. The estimated molecular weight of
this protein was 69 kDa. as judged by SDS-PAGE using a 12% gel, in
comparison to the predicted molecular weight of 61.3 kDa.
Similar to the FAD domain described in section 4.2.7, this region of P450
reductase did not contain the last 75 amino acids, i.e. exons 15 and 16.
Therefore, as described in section 4.2.7, it does not fully qualify as the FAD
domain. The protein produced will probably contain both structured and
unstructured regions from the FMN binding region and the partial FAD
binding region respectively. This will most probably lead to the production of
an unstable protein which may be the reason for its susceptibility to
proteolysis. It appeared form the colour of the degraded sample that some



















Figure 4.11. Expression and purification of the FMN/FAD domain.
(A) SDS-PAGE (12%) analysis of the FMN/FAD domain purified from the
soluble bacterial extract. Lanes: Stds, Molecular weight standards; sol.,
soluble fraction (lOgg) loaded onto Nickel-agarose; F.T. Flow through; 1,2
fractions obtained from elution with binding buffer + 60mM imidazole. (B)
SDS-PAGE analysis of the FMN/FAD domain purified under denaturing
conditions. Lanes: Stds, molecular weight standards; Insol, insoluble fraction
loaded onto Nickel-agarose; F.T. flow through; 1-3, fractions eluted with
binding buffer + 20mM imidazole + 6M urea.
4.3 Reconstitution studies using the bacterially expressed
'functional' domains of human NADPH cytochrome P450
oxidoreductase.
4.3.1 Reconstitution of human NADPH cytochrome P450
oxidoreductase spectra using the FMN and FAD/NADPH domains.
The spectra shown in Figure 4.12 and Figure 4.14 showed that the purified
FMN and FAD/NADPH domains could bind their respective flavins
independently. In order to investigate whether the FAD/NADPH domain
could transfer electrons from NADPH via FAD to the FMN domain, in a
manner similar to native P450 reductase, the two domains were mixed
together (Figures 4.15A,B). In both native and trypsin treated P450 reductase
electrons are transferred from NADPH through FAD and onto FMN
(Vermillion and Coon, 1978b; Iyanagi et al., 1981; Vermillion et al., 1982;
Kurzban and Strobel, 1986, reviewed in Backes, 1993). When the reductase is
reduced under aerobic conditions with an excess of NADPH, an air stable
semiquinone species is produced slowly. This semiquinone species has been
identified as the one-electron reduced FMN reductase. (Iyanagi and Mason,
1973; Iyanagi et al., 1974; Iyanagi et al., 1978; Vermillion and Coon, 1978a;
Yasukochi et al., 1979). A U.V.-visible spectrum characteristic air-stable
semiquinone species for human P450 reductase is shown in Figure 4.15A.
An increase in absorbance at 585nm with a shoulder at 630nm and a
decrease in absorbance at 455nm can be observed. This species is stable for
between 24 and 48 hours when left open to air (Horecker, 1950; Masters and
Kamin, 1965; Iyanagi and Mason, 1973; Iyanagi et al., 1974; Iyanagi et al.,
1978; Vermillion and Coon, 1978a; Yasukochi et al., 1979). If electrons could
be transferred from NADPH via the independent FAD/NADPH domain onto
the FMN domain then a spectrum similar to Figure 4.15A should be
produced indicating FMN semiquinone formation. This semiquinone would
be predicted to be air stable. Fig. 4.15B shows the ability of equimolar amounts
of the FMN and FAD/NADPH domains to produce a spectrum similar to that
of native P450 reductase. When reduced by NADPH the two independent
domains do indeed produce a spectrum indicative of an air-stable semiquione
species. A decrease in absorbance at 455nm can be observed with a
concomitant increase in absorbance at 585nm and a shoulder at 630nm. This
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Figure 4.12 Absorption spectra of the FMN domain of P450 reductase.
(A) The oxidised FMN domain, 55|J.M. (B) The air-stable reduced form of the
FMN domain (30|iM), 2 hours after reduction with an excess of sodium
dithionite.
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Figure 4.14 Absorption spectra of the FAD/NADPH domain of P450
reductase. (A) Oxidised FAD/NADPH domain (50gM). (B) FAD/NADPH
domain (20|iM) after reduction with 200pM NADPH under aerobic conditions.




Figure 4.15. Absorption spectra of native P450 reductase and the
mixed FMN and FAD/NADPH domains. (A) Absorption spectra of
oxidised native P450 reductase (lOpM) and the air stable semiquinone form, 18
hours after reduction with 200pM NADPH. (B) Absorption spectra obtained
on mixing the FMN (7.5pM) and FAD/NADPH (7.5pM) domains and after
reduction with NADPH (200gM). Times after reduction with NADPH are
shown on the spectrum.
human liver microsomes (Fig. 4.15A). The reconstituted domains slowly
reoxidised after a period of 4 hours in comparison to the purified reductase
which maintained its air-stable species for up to 24 hours before reoxidising.
This faster reoxidation of the semiquinone species seen for the two mixed
domains compared to native P450 reductase maybe due to stability of the FMN
semiquinone that the intact protein can provide. Indeed, the air-stable
semiquinone of the FMN domain (Figure 4.12B) was stable for a similar time
to the air-stable form produced by the mixed domains before slowly re-
oxidising.
4.3.2 Interaction between the FMN and FAD/NADPH domains.
In view of the observation that electrons could be transferred from NADPH
via the FAD/NADPH domain onto FMN it was decided to further examine the
interaction between the two domains. The His-tagged FMN domain was
mixed with nickel-agarose and a His-tagged-FMN domain nickel-agarose
column produced. To this column the FAD/NADPH domain (without the
His-tag) was applied. This was carried out in low ionic strength buffer
(lOmM potassium phosphate, pH7.7) as shown in Figure 4.16. The
FAD/NADPH domain only bound to the His-tagged-FMN domain column and
not the nickel-agarose alone. The FAD/NADPH domain could be
dissociated/eluted from the column by increasing the ionic strength of the
buffer (Figure 4.16). This result indicates that ionic interactions are
important for the domain interaction to occur.
4.3.3. Interaction of cytochrome c with the FMN domain of human
NADPH cytochrome P450 oxidoreductase.
The ability of cytochrome c, a well characterised one electron acceptor of P450
reductase, to interact with either the FMN or FAD/NADPH domain was
looked at using His-tagged domains bound to nickel agarose columns. This
experiment was carried out in a manner similar to that described in 4.3.2.
When cytochrome c was applied to the column containing the immobilised
FMN domain, in low ionic strength (ImM potassium phosphate, pH 7.7), the
protein was retained on the column (Figure 4.17). The cytochrome c could be
eluted by increasing the ionic strength of the buffer. In a similar experiment
with the His-tagged FAD/NADPH protein immobilised on a nickel agarose
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Figure 4.16. Interaction of the FMN and FAD/NADPH domains. 2 mg
of His-tagged FMN domain was bound to a 1ml nickel-agarose column and the
FAD/NADPH domain (O.lmg/ml) applied in lOmM potassium phosphate
buffer, pH 7.7. This resulted in the binding of the latter domain. The ionic
strength of the buffer passed through the column was increased in a step¬
wise fashion and the resulting eluates analysed by SDS-PAGE followed by
Western blotting using an antibody to full length reductase.
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Figure 4.17 Interaction of the FMN domain with cytochrome c. 2mg
of His-tagged FMN-domain was bound to a 1ml nickel-agarose column and
cytochrome c (0.5 mg/ml) applied in ImM potassium phosphate buffer, pH7.7.
This resulted in the cytochrome c binding. The ionic strength of the buffer
was then increased in a stepwise manner and eluted fractions analysed by
SDS-PAGE (15% gel). F.T., flow through.
column it was found that cytchrome c did not bind. The direct involvement of
the FMN domain with cytochrome c binding is in agreement with the
previous study of Nisimoto (1986) who was able to cross-link P450 reductase
with cytochrome c in low ionic strength buffer. His work indicated that some
of the amino-acids in the region 200-220 of the rat P450 reductase are involved
in the interaction with cytochrome c. These residues are located in the FMN
domain. Ionic strength effects on cytochrome c reductase activity were
observed in the early studies of the purified reductase (Williams and Kamin,
1965). These studies showed that by increasing the ionic strength the rate of
cytochrome c reduction increased. The standard assay for cytochrome c
reduction is carried out in 300mM potassium phosphate buffer, pH7.7. The
data in Figure 4.17 and that published previously (Nisimoto, 1986) shows that
in low ionic strength buffer the FMN domain reductase can bind with
cytochrome c. However, in low ionic strength buffer cytochrome c reductase
activity is low. These observations warrent further investigation.
4.3.5. Reconstitution of cytochrome c and cytochrome P450
reductase activity using the domains of human NADPH cytochrome
P450 oxidoreductase.
The data so far presented in this chapter shows that the recombinant FMN,
FMN/anchor and FAD/NADPH domains folded correctly and that an
interaction could take place between the FMN and FAD/NADPH domains. It
was also observed that the FMN domain could form a complex with
cytochrome c. A variety of experiments were carried out to establish whether
the domains could couple to form a catalytically competent unit.
Cytochrome c reductase activity could be reconstituted when a combination of
the FMN and FAD/NADPH domains was used (Figure 4.18A). The ability to
form an active complex was time dependent and had an estimated tl/2 of 3
hours. The final activity of the reconstituted domains was found to be around
2% of the native enzyme. It is important to note that the assays were carried
out in 50mM potassium phosphate buffer, i.e. in a buffer concentration that
allowed the interaction between the domains but did not allow direct binding
of cytochrome c with the FMN domain (Figures 4.16, 4.17). In order to test for
the reconstitution of cytochrome P450 monooxygenase activity the rat
cytochrome P450 CYP1A1 was incorporated into incubations containing the



















Figure 4.18 Reconstitution of cytochrome c and cytochrome P450
reductase activity. (A) Reconstitution of cytochrome c reductase activity
using the FMN and FAD/NADPH domains. (0.1 nmol) of each domain were
mixed in lOmM potassium phosphate buffer, pH7.7 in a volume of 20gl at
4°C, before assaying at various time points. (B) Reconstitution of cytochrome
P450 reductase activity using the FMN/anchor and FAD/NADPH domains. (0.1
nmol) of each domain were mixed in lOmM potassium phosphate buffer,
pH7.7 in a volume of 20pl at 4°C. After various times, the domains were
incubated with dilaurylphosphatidylcholine (25pg) and CYP1A1 (37.5 pmol in
5pl) at 37°C for 5 minutes, before assaying for EROD activity by measuring
the rate of resorufln formation.
measuring the rate of ethoxyresorufin O-deethylation (EROD) (Figure 4.18B).
Using these two domains a functional monooxygenase system could be
reconstituted that was time dependent and had a similar tl/2 to the
reconstitution of cytochrome c reduction, (tl/2 estimations were kindly
performed by Dr. David Tew, London). The FAD/NADPH domain alone had
virtually no ability to reconstitute CYP1A1 monooxygenase activity (Table 1).
These observations on the time dependence of reconstitution are intriguing.
From the FMN and FAD/NADPH column binding experiment it was
observed that the binding interaction was instantaneous and not time
dependent. The time dependence observed in the reconstitution of activity
may be due to establishing the correct orientation and/or stabilisation of the
FAD and FMN for efficient electron transfer.
The reconstitution of P450 reductase activity using the FMN/anchor and
FAD/ NADPH domains was also found to be ionic strength dependent (Figure
4.19). This result is in keeping with the observation that the FMN and
FAD/NADPH complex was disrupted by increasing ionic strength.
The reconstitution of activities observed by the domains in this study, albeit
extremely fascinating, may not optimal. As can be seen in Figure 4.2, the
FMN and FMN/anchor domain share an exon 8 overlap with the
FAD/NADPH domain. This may provide the two domains with some form of
steric hindrance, resulting in the domains not interacting correctly with one
another. Also, the FMN and FAD contents of the domains are below that
found in native P450 reductase resulting in smaller specific activities than
would be observed with domains containing the correct amount of flavin.
Another important point for the FMN/anchor domain is the presence of a
contaminating protein. Although this can be speculated to be a 10%
contaminant it may have an effect on the reconstitution of cytochrome P450
reductase activity. One other factor that may be the cause of these
interactions is the relative 'stickiness' of P450 reductase. This protein has 97
Asp and Glu residues and 74 Arg and Lys residues out of a total of 677 amino-
acids. Therefore the specificity of the domain interactions that have been
observed must be noted with caution.
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Figure 4.19 Effect of ionic strength on the reconstitution of
cytochrome P450 reductase activity. The FMN/anchor and FAD/NADPH
domains (0.1 nmol of each) were incubated for 2 hours in different
concentrations of potassium phosphate buffer, pH 7.7 at 4°C.
Dilaurylphosphatidylcholine (25gg) and CYP1A1 (37.5 pmol in 5gl) were then
added. The samples were incubated for 5 minutes at 37°C before measuring
EROD activity.
4.3.6. Effect of FMN, FMN/Anchor and FAD/NADPH domains on a
reconstituted rat CYP1A1/ rat P450 reductase monooxygenase
system.
The ability of the functional reductase domains to perturb a reconstituted
monooxygenase system was looked at (Figure 4.20A, 4.20B). Perturbation of
ethoxyresorufuin O-deethylation (EROD) activity produced by a reconstituted
rat CYP1A1/ rat P450 reductase system was used. This assay is rapid,
sensitive and highly specific for CYP1A1 (of which a large supply of purified
enzyme was available in this laboratory).
Figure 4.20A shows the effect of the FMN/anchor domain and the
FAD/NADPH domain on the reconstitution of EROD activity. By
preincubating CYP1A1 with the FMN/anchor domain (for 5 minutes) almost
complete inhibition of EROD activity was observed. Fifty percent inhibition
was observed at a ratio of domain to native rat reductase of approximately 4:1.
This inhibitory result could be explained by the domain preventing the
association of the P450 to P450 reductase. This result is in keeping with a
previous study where the purfied hydrophobic 6kDa. NH2-terminal tryptic
fragment from rabbit P450 reductase was found to be a potent inhibitor of
reconstituted monooxygenase activity (Black et al., 1979). However, the His-
tag and thrombin cleavage site could not be removed for the FMN/anchor
domain. It can not be ruled out that the His-tag may affect the association of
the domain with the bilayer and that the inhibitory effect that is being
observed may be occuring outside the bilayer. The FAD/NADPH domain had
little effect on EROD activity, although a reproducible slight decrease in
activity was seen at the lowest domain concentration tested (Figure 4.20A).
Most interestingly, the FMN domain was found to activate EROD activity by
up to 3 fold (Fig. 4.20B). This appears to be specific for this domain as free
FMN did not cause this effect. This activation effect could be explained if the
FMN domain can accept electrons from the FAD of native P450 reductase and
supply electrons directly to P450. Taken together with the results for the
FMN/anchor domain (Fig. 4.20A) it can be suggested that the hydrophbic
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Figure 4.20 Effects of the FMN/anchor, FMN, FAD/NADPH domains
and free FMN on the reconstitution ofmonooxygenase activity.
CYP1A1 (7.5pmol) and 25pg of dilaurylphosphatidylcholine were incubated
for 5 minutes with varying concentrations of (A) the FMN/anchor or
FAD/NADPH domain (0.04-1.7 nmol) or (B) the FMN domain or free FMN
(0.04-1.7 nmol) in a total incubation volume of 47.5(il at 37°C for 5 minutes.
Native rat P450 reductase (0.05 nmol in 2.5 ml) was then added and the
sample incubated for a further 5 minutes at 37°C before measuring EROD
activity.
4.3 Summary and future work.
This chapter has described the dissection of human NADPH cytochrome P450
oxidoreductase into structurally and functionally independent domains. This
work provides strong experimental evidence to substantiate the hypothesis
that this protein has evolved from two distinct ancestral genes (Porter and
Kasper, 1986). Indeed, many of the properties of the ancestral proteins appear
to have been retained and there is no need for direct interaction between the
two domains for FMN and FAD binding. However, for stabilisation of the
incorporated flavin in the protein (i.e. to maintain a ratio of 1 molecule FMN
or FAD to one molecule of protein) and for efficient electron transfer,
interactions may be needed between the domains and/or flavins. It can be
speculated that as two independent flavoproteins the ancestors of P450
reductase functioned as a dehydrogenase/ electron transferase in a primitive
organism. By fusion of the genes encoding these ancient flavoproteins a more
catalytically efficient electron transfer system was produced.
The FAD/NADPH domain could catalyse the reduction of potassium
ferricyanide, dichlorophenolindophenol and menadione and showed
transhydrogenase activity. These reaction rates were decreased by a variety
of different levels compared to native P450 reductase but provides evidence
that the FAD/NADPH domain is the site, at least in part responsible for the
one-electron reduction of substrates.
The FAD/NADPH domain was able to be reduced by NADPH to a semiquione
state which was not stable in air. This result was the same as that observed
for FMN-depleted reductase (Vermillion and Coon, 1978b, Iyanagi et al., 1981).
The FAD/NADPH domain was able to pass electrons from NADPH onto the
FMN domain producing an air-stable semiquinone form similar to that seen
for native reductase. When reduced by an excess of sodium dithionite the
FMN domain produced an air-stable species that was identical to the one-
electron reduced form of the FAD-depleted reductase (Kurzban et al., 1990).
The FAD/NADPH and FMN domains could be reconstituted to form a
complex that was active in the reduction of cytochrome c and in donating
electrons for cytochrome P450 dependent monooxygenase activity. Although
not optimal this result demonstrated that electron transfer between the
domains and onto an electron acceptor could be achieved. The FMN domains
and FAD/NADPH domain, however, had a 33 amino-acid overlap (exon 8).
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This may have caused problems in the reconstitution of cytochrome c and
P450 reductase activity by sterically hindering the correct interaction of the
domains. Future work should focus at further minimilisation of the
functional domains. Optimisation of domain size will also be of importance
for future studies into the reconstitution of reductase activity. These should
identify some of the structural and functional requirements needed for
efficient transfer between the peptides. Removal of the contaminating factor
from the FMN/anchor domain may also result in improved reconstitution.
The results presented here have shown that it is not enough simply to
express the exons that contain all the proposed amino-acids involved in
binding FMN or FAD. Comparisons of the FMN binding region of P450
reductase with the flavodoxin from Desulfovibrio vulgaris show that highest
homology lies within exons 4,5,6 (Porter et al., 1990). This region, when
expressed in E. coli did not bind flavin. However the larger FMN/anchor and
FMN domains did bind flavin. Similarly, sequence alignments based on the
crystal structure of spinach ferredoxin NADP+ reductase reveal that the
minimal FAD/NADPH binding region of the protein should be contained
within exons 12-16 (Karplus et al., 1991). However, expression of this small
domain yielded an insoluble protein which, from its white appearance, did
not bind FAD. In other cases, even when insoluble products were formed, the
colour of the protein suggested flavin had been incorporated. It was a much
larger FAD/NADPH domain, spanning exons 8-16 that was found to be
functional.
Determination of the flavin content in the domains was found to be less than
the predicted ratio of 1:1 mol protein: mol flavin. For the stabilisation of the
flavin moieties in their respective domains, interactions maybe needed
between the two domains. However, the reduced flavin content may be due to
some incorrectly folded protein being produced by the bacteria or in the flavin
being lost during the purification. Separation of the flavin and non-flavin
containing domains may be possible since it is possible to purify out FAD
depleted reductase from the holo-reductase (Kurzban et al., 1990). To this
end, some recent work in collaboration with Prof. Gordon Roberts, University
of Leicester, has shown that the FMN containing domain can be separated
from the non FMN containing protein by high resolution anion exchange
chromatography. This should also be possible for the FAD/NADPH domain.
In conclusion; the data presented in this chapter support the hypothesis that
P450 reductase has evolved as a fusion of two ancestral proteins (Porter and
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Kasper, 1986, Porter et al., 1990). Indeed, it can be speculated that as two
independent proteins the ancestors of of P450 reductase functioned as a
dehydrogenase/ electron transferase in a primative organism. By fusion of
the genes a more catalytically efficient electron transfer system was
produced. The ability to dissociate P450 reductase into domains will be of
significant value for X-ray and NMR studies as well as in understanding
about how the domains interact with each other. Future work may also look
at the ability of the domains to interact with cytochromes P450 and
cytochrome b5 to form a functional electron transfer unit. Such studies will
not only provide new insights into the structure and function of P450
reductase but into other structurally related proteins such as nitric oxide
synthase and sulfite reductase.
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Chapter 5: Purification and characterisation of a 59kDa.
carboxylesterase from human liver microsomes and its role in the
pathogenesis of halothane hepatitis.
5.1 Introduction.
The human microsomal carboxylesterases have been studied less in
comparison to their rat counterparts. This is most probably due to the
availability of tissue(s) for purification studies as is the case for other drug
metabolising enzymes. Human liver microsomal carboxylesterases have
been purified in the past using a variety of techniques and with varying
degrees of success, (Jung et al., 1974; Jung and Heymann, 1979; Tsujita and
Okuda, 1984 and Ketterman et al., 1989). Most of this previous work focused
on the substrate specificity of the enzymes, molecular weight and isoelectric
point. The early studies on the purified forms of the carboxylesterase either
did not attempt to sequence the amino-terminus or found it to be blocked
(Jung et al., 1974; Tsujita and Okuda, 1984 and Ketterman et al., 1989). Except
for one human carboxylesterase, the 'low pi' form (Ketterman et al., 1989), no
amino-terminal sequence information has been elucidated from the purified
enzymes. It was not until the cloning of a partial cDNA (Long et al., 1989)
and the recent full length cDNAs (Kroetz et al., 1993) for human liver
carboxylesterases that any sequence information for the human proteins has
become available. Interestingly, the sequences obtained for the full length
human carboxylesterases are 99.7% identical to that for a serine protease
cloned from human liver macrophages (Munger et al., 1991).
Interest in the microsomal carboxylesterases has risen in recent years as
investigators have proposed a variety of roles for these enzymes other than
their classical drug/xenobiotic metabolising role. Work by Mentlein et al.,
(1988) has led to the suggestion that the hydrolytic activities of the
carboxylesterases may facilitate the transfer of fatty acids across the
endoplasmic reticulum or prevent the accumulation of potentially membrane
lysing natural detergents. One of the rat liver microsomal carboxylesterases
appears to be identical to egasyn, which functions to retain (3-glucuronidase
in the microsomal membrane (Medda, 1987). The major component of rat
liver microsomal carboxylesterases, carboxylesterase El/ hydrolase pi 6.0,
has been shown to be involved in the non-oxidative metabolism of ethanol,
fatty acid ethyl ester (FAEE) synthesis (Tsujita and Okuda, 1992). The role of
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carboxylesterase in FAEE synthesis has been shown in a variety of tissues,
especially adipose, lung and testis (Tsujita and Okuda, 1992). These workers
purified an enzyme from rat adipose tissue with FAEE synthase activity and
went on to show that the enzyme they had purified was the rat liver
carboxylesterase pi 6.0 (Robbi et al., 1990) also termed El (Harano et al. 1988).
The identification of the carboxylesterase as FAEE synthase was based on
enzyme activities, substrate specificities, inhibition studies and NH2-terminal
sequence.
As mentioned above, a serine esterase released by human alveolar
macrophages was purified and cloned (Munger et al., 1991) and shown to be
identical to a partial human liver carboxylesterase cDNA (Long et al., 1989).
By aligning the alveolar serine protease with the recently cloned full length
cDNAs, Kroetz et al (1993) showed that they are 99.7% identical and therefore
most probably the product of the same gene. Munger et al, (1991), found their
60 kDa. serine protease to be the major esterase in the alveolar epithelial
lining and that the protein was contained within and secreted by alveolar
macrophages. In the alveolar lining layer there are numerous serine
proteases capable of initiating or modulating the inflammatory process. For
example, urokinase and the coagulation factor, factor VII are present and
active in this layer (Chapman et al., 1985 and Bowen et al., 1985). Whether the
carboxylesterase is involved in the modulation of the inflammatory process is
unresolved. Another suggestion is that the enzyme acts as a detoxifier to air¬
borne environmental compounds (Munger et al., 1991).
A proposed role for carboxylesterases has come from a study which showed
that the elevation of cellular cysteine was mediated by hydrolysis of esters of
cysteine (Butterworth et al. 1993). This is an important observation because of
the potential of cysteine esters to increase cellular cysteine in order to protect
against the toxicity ofvarious chemicals (Lailey et al., 1991, Butterworth et al.,
1993). An example being the ability of cysteine iso-propylester to protect
against paracetamol hepatotoxicity.
The role of a microsomal carboxylesterase in the pathogenesis of the adverse
drug reaction halothane hepatitis was put forward by Satoh et al., (1989).
Previous studies had found that patients with halothane hepatitis had
antibodies in their sera that reacted with up to eight microsomal proteins of
varying molecular weight (Kenna et al., 1987a and Kenna et al., 1988). By
treating rats with halothane and then purifying halothane-modified proteins
from the rat livers, Satoh et al. (1989) obtained a 59kDa protein. They then
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went on to show that this protein was a previously characterised
carboxylesterase. A variety of reasons why the carboxylesterase and other
proteins are involved in the pathogenesis of this disease have been put
forward. These include the ability of halothane to be modified to the reactive
trifluoroacetylhalide metabolite, the relative abundance of the
trifluoroacetylated proteins in the endoplasmic reticulum and the
presentation of the modified proteins to the immune system. The studies
using the rat carboxylesterase also showed that for patients' antibodies to
react with the rat protein it had to be trifluoroacetylated. Reasons for the role
of a carboxylesterase in halothane hepatitis will be discussed in more detail
in section 5.3.1.
Therefore, previous work suggests that the microsomal carboxylesterase(s)
are involved in a variety of biologically important reactions as well as being
involved in the pathogenesis of an often fatal adverse drug reaction.
Tha aims of the work presented in this chapter were to characterise a 59kDa.
carboxylesterase purified from human liver microsomes. The purification of
this carboxylesterase will be presented along with the biochemical
characterisation of the enzyme. The relationship of this carboxylesterase
with the other forms of carboxylesterase that have been purified/ cloned in the
past will be discussed. The role of the human microsomal carboxylesterase
in the pathogenesis of the adverse drug reaction halothane hepatitis will also
be considered. Using the sequences of the recently cloned human
microsomal carboxylesterases (Kroetz et al., 1993), computer generated
predictions of some biochemical aspects of the protein will be outlined.
5.2 Results and Discussion.
5.2.1. Purification of a 59kDa. hepatic microsomal carboxylesterase.
A variety of methods have been employed in the purification of hepatic
microsomal carboxylesterases. Solubilisation of microsomes has been
overcome utilising the glycoside detergent saponin (Mentlein et al., 1980 and
Ketterman et al., 1989), ionic detergents (Harano et al., 1988) and non-ionic
detergents, (Ozols, 1988). Early purification studies took into account the
differences in isoelectric points of the proteins as a means of separation
(Mentlein et al., 1980, Mentlein et al., 1987, Ketterman et al., 1987). Indeed,
some of the nomenclature for the carboxylesterases isolated to date have used
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the pi values of the purified proteins (Mentlein et al., 1980, Mentlein et al.,
1987). With regards to human carboxylesterase purification, Ketterman et
al., (1989) used a mixture of ion exchange chromatography,
chromatofocussing and gel filtration to isolate their mid pi and low pi forms
of carboxylesterase from saponin solubilised human liver microsomes. After
the observation that carboxylesterases were glycosylated (Robbi and Beaufay,
1983), Harano et al., (1988) employed concanavalin-A affinity chromatography
into their protocol.
Since the purification described here was initially undertaken to obtain
human NADPH cytochrome P450 oxidoreductase (for the production of rabbit
polyclonal antisera) an initial step of ion exchange chromatography using
DE52 was carried out (Yasukochi and Masters, 1976). This step was
performed after the initial solubilisation of the microsomes with sodium
cholate (Figure 5.1A). A pool containing a prominant 59 kDa. and 45 kDa.
band, rich in cytochrome P450 as judged by spectral analysis, was obtained
(Figure 5.1A, lane 3). This pool eluted in low (30 mM) potassium phosphate
buffer, pH7.7 and then after dilution to 10 mM potassium phosphate, applied
to a hydroxylapatite column and washed extensively. By stepwise elution the
45 kDa. band and the 59 kDa. band were separated at potassium phosphate
concentrations of 20 mM and 60 mM respectively (Figure. 5. IB). The elution
of cytochrome P450 pools followed at 100 mM potassium phosphate. (It should
be noted that when purifying rabbit carboxylesterases Ozols, (1988) found that
the protein co-purified with cytochromes P450 and epoxide hydrolase). At this
stage in the purification described here the pure 45 kDa and 59 kDa. protein
were unknown. It was not until NH2-terminal sequence analysis was
performed (Figure 5.3) that the 59 kDa. protein was identified as a
carboxylesterase. The identification of the 45 kDa protein as epoxide
hydrolase has been determined by Dr. J. G. Kenna, St. Mary's Hospital and
Medical School, U.K. However, this is not the focus of any further work to be
described in this thesis. Unfortunately protein elution profiles at 280nm
could not be obtained because the non-ionic detergent emulgen 911, used
throughout the purification, has an extremely high absorbance at 276 nm. A
profile of carboxylesterase activity was not obtained since the protein was not
identified as a carboxylesterase until late in the purification procedure.
However, pools of the fractions obtained at various stages of the purification
were kept and the activity towards the model carboxylesterase substrate p-
nitrophenylacetate measured (Table 5.1). Previous work on the purification of
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Figure 5.1A.. Purification of a 59kDa. human hepatic microsomal
carboxylesterase. SDS-PAGE (9%) analysis of protein fractions obtained at
different stages of the purification procedure. Lanes: 1, human hepatic
microsomes (20gg); 2, solubilised human hepatic microsomes (20gg); 3,
DEAE-cellulose carboxylesterase pool (lOgg); 4, hydroxylapatite
carboxylesterase pool (lgg)
Figure 5.IB. Purification of a 59kDa. human hepatic microsomal
carboxylesterase. SDS-PAGE (9%) analysis of fractions eluted from the
hydroxylapatite stage.
Human hepatic microsomes
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Figure 5.2. Summary diagram of the human carboxylesterase
purification.
Step Protein (mq) Total activity S.A Yield f%l
Microsomes 9250 1 0452 1.13 1 00
Sol. Micros. 9250 8972 0.97 86
DE52 2292 5517 2.25 53
Hydroxylapatite 32 678 21.2 6.5
ConA-sepharose n.d. n.d. 24.6 n.d.
Specific actvity (S.A.) was determined by measuring the rate of p-nitrophenyl acetate
hydrolysis and is given as pmol product/min/mg protein.
n.d. not determined.
Table 5.1 Summary table of the human microsomal carboxylesterase
purification
rat carboxylesterase (Harano et al., 1988) had employed a concanavalin A
sepharose step since the protein had been shown to be glycosylated (Robbi and
Beaufay, 1983, Harano et al., 1988 and Ozols, 1989). With this knowledge,
concanavalin A chromatography was carried out on a fraction of the
hydroxylapatite pool of carboxylesterase in order to remove the detergent
Emulgen 911 and any other impurities (Table 5.1).
A summary of the purification is shown in Figure 5.2. The molecular weight
of the carboxylesterase was determined as being 59 kDa. This is in keeping
with the rat forms El/ form pi 6.0 of the carboxylesterase (Robbi and Beaufay,
1983, Harano et al., 1988; Hosokawa et al., 1990) the baculovirus expressed
human carboxylesterases (Kroetz et al., 1993) and with the predicted size of
the protein determined from its amino-acid sequence (Kroetz et al., 1993).
The native human 'mid pi' form of carboxylesterase has been shown to have
a molecular weight of 173 kDa. (Ketterman et al., 1989) This suggests the
protein may exist as a trimer.
5.2.2. NH2-terminal sequence analysis of the human microsomal
carboxylesterase and alignment of other mammalian
carboxylesterases.
After blotting the 59 kDa. protein onto a PVDF membrane, solid phase
sequence analysis of the electroblotted protein (Matsuidara, 1987, Pappin et
al., 1990) was kindly carried out by Dr. Darryl Pappin, I.C.R.F., London.
Difficulties were encountered in sequencing the NH2-terminus of the protein,
with a very low yield being obtained, suggesting blockage. However, some
sequence was obtained as is shown in Figure 5.3. After a search of the OWL
protein database, this was found to be highly similar to microsomal
carboxylesterases purified from a variety of species (Figure 5.3). It was noted
previously by Ketterman et al. (1989) that their human carboxylesterase 'mid-
pi' form had a blocked NH2-terminus, but the 'low pi' form was not. The
sequence obtained here showed no similarity with the human 'low pi' form of
carboxylesterase. However, no blockage of rat (Harano et al., 1988; Hosokawa
et al., 1989; Satoh et al., 1989; ), rabbit (Ozols and Frankie, 1988; Ozols, 1989),
hamster (Hosokawa et al., 1990) or monkey (Hosokawa et al., 1990)
carboxylesterases has been reported. Alignments of the NH2-termini
obtained from a variety of mammalian microsomal carboxylesterases are
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Residue Number
1 2 3 4 5 6 7 8 9 10 11 12
Purified human protein Gly Pro Ser Ser Pro Pro Val Val Asp Thr
Human cDNA (Kroetz et al., 1993) His Pro Ser Ser Pro Pro Val Val Asp Thr Val His
Rat protein (Satoh et al., 1989) Tyr Pro Ser Ser Pro Pro Val Val Asn Thr Val Lys
Monkey (Hosokawa et al.,1989) Gly Pro Ser Ser Pro Pro Val Val Asp Asp Val Lys
Rabbit (Ozols, 1987) His Pro Ser Ala Pro Pro Val Val Asp Thr Val Lys
Rat cDNA (Takagi et al., 1988) His Pro Ser Ser Pro Pro Val Val Asp Thr Thr Lys
Figure 5.3. NH2-terminal amino-acid sequence of the human
carboxylesterase. The top sequence is that of the data obtained in this
study. References for the other enzymes are shown.
shown in Figure 5.3. The most striking observation from this is the high
similarity between species.
5.2.3 The human liver microsomal carbxylesterase is glycosylated.
As is shown in Table 5.1, concanavalin A sepharose was used as an affinity
step in the purification. Concanavalin A binds glycoproteins containing
mannose and/or glucose hence it was assumed that these were the moieties
bound to the human carboxylesterase described here. To further identify the
carbohydrates bound to the carboxylesterase a glycan differentiation kit was
employed (Figure 5.4). The results from this showed that the lectin
Galanthus nivalis agglutinin (GNI) bound to the carboxylesterase. This
lectin has been shown to bind to high mannose N-glycan chains on
glycoproteins (Shibuya et al., 1988).
To identify the quantity of carbohydrate groups bound to the carboxylesterase,
the enzyme was treated with N-glycosidase F. This enzyme cleaves all types
of asparagine bound N-glycans provided that the amino group as well as the
carboxyl-group are present in a peptide linkage (Torentino et al., 1985). On
treatment with N-glycosidase F it can be observed that there is an increase in
the mobility of the protein (Figure 5.5). A shift of around 2-3 kDa can be
observed with some smearing being visible above the main band (Figure 5.5).
The smearing most probably represents a mixture of partially deglycosylated
forms of the carboxylesterase. Ozols (1989) observed a shift in the mobility of
his rabbit carboxylesterases, forms 1 and 2, when he treated them with N-
glycosidase F. The rat carboxylesterase El had a shift in electrophoretic
mobility when digested with endoglycosidase H or a-mannosidase (Harano et
al., 1988). However, Ketterman et al., (1989) showed that on treatment of their
'mid pi' and 'low pi' forms of human carboxylesterase with the glycosidases
a-mannosidase and neuraminidase there was no effect on the banding
pattern of the enzymes as judged by isoelectric focusing. Mannose residues
have no overall charge, hence removal of them will not have any effect on the
pi of the protein. Therefore, if mannose residues had been removed by the
glycosidase treatment the banding pattern observed by iso-electric focussing
would be no different from that seen with the native protein.
From the above data it can be concluded that the human microsomal
carboxylesterase described here is a high mannose type glycoprotein
containing up to an estimated 3 kDa. of sugar residues. Utilising a
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Figure 5.4. Glycosylation status of the purified human
carboxylesterase. Purified carboxylesterase (2.5pg) was subjected to
electrophoresis on a preparative 10-15% gradient SDS-polyacrylamide gel
using the Pharmacia Phast System. The protein was then transferred onto a
PVDF membrane which was subsequently cut into strips. Using a glycan
dfferentiation kit, the carbohydrate residues on the carboxylesterase were
identified as being mannose as judged by the binding of the lectin Galanthus
nivalis agglutinin (GNI) to the carboxylesterase. Other lectins used were;
SNA, sambucuc nigra agglutinin; MAA, Maackia amurenis agglutinin; PNA,









Figure 5.5. Deglycosylation of the human carboxylesterase. Pure
carboxylesterase was digested with N-glycosidase F and the resulting
products separated by SDS-PAGE (10-15% gradient gel, Pharmacia Phast
System). Lanes: 1, Pure carboxylesterase (l|ig); 2, N-glycosidase F treated
carboxylesterase (lpg); Stds, molecular weight standards.
baculovirus mediated expression system, Kroetz et al, (1993) carried out
experiments to look at the effects of glycosylation on the activity of the
expressed carboxylesterase cDNAs. By inhibiting the glycosylation of their
expressed protein they were able to show that glycosylation was important for
the activity of the carboxylesterase towards a variety of substrates. Since N-
linked glycosylation of proteins only takes place at the specific motif Asn-X-
Thr/Ser (Hubbard and Ivatt, 1989) it is easy to predict potential sites of
glycosylation on a protein if its sequence is known. The glycosylation site of
the human carboxylesterases described by Kroetz et al., (1993) is predicted to
be at asparagine 62.
5.2.4 Isoelectric focussing of the human liver microsomal
carboxylesterase.
Chromatofocussing and isoelectric focussing have played an important role
in the purification and characterisation of carboxylesterases (Mentlein et al,
1980, Mentlein et al., 1987, Ketterman et al., 1989). For further
characterisation of the carboxylesterase discussed here the determination of
its pi was calculated both experimentally, using gel electrophoresis (Figure
5.6A), and by computation (Figure 5.6B) using the amino acid sequence
predicted from the human liver microsomal cDNA of Kroetz et al., (1993).
Figure 5.6A reveals the carboxylesterase to have a pi value of approximately
5.8. The carboxylesterase bands are shown by the arrows. Samples were
loaded from both the anode and cathode ends of the gel and shown to migrate
to a similar point. The mark in lane 2 was an artifact from damaging the gel
on loading the sample. The pi value obtained from the IEF gel is similar to
that of the human 'mid pi' carboxylesterase determined by Ketterman et al.,
(1989) as being 5.2-5.8. It is also similar to that of the purified rat
carboxylestrase El/ form pi 6.0 (Mentlein et al., 1980, Harano et al., 1988).
Using the predicted amino-acid sequence from the cDNA of the human
carboxylesterase (Kroetz et al, 1993) it was possible to predict the pi value of
the protein using the computer program 'Isoelectric' from the GCG package.
A plot of the result from the program is shown in Figure 5.6B. The total
positive and negative charges and the net charge of the carboxylesterase are
shown as a function of pH. The predicted pi value of the carboxylesterase
was 6.46. This is higher than the experimental value of 5.8. This may be
explained by the fact that the program assumes there are no electrostatic
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Figure 5.6. Isoelectric point determination of the human
carboxylesterase. (A) Isoelectric focusing of the human carboxylesterase
using a precast IEF gel from Pharmacia and performed on the Pharmacia
Phast system. The arrow indicates the resolved carboxylesterase after two
samples were loaded from either end of the gel. The lower dark band in lane
2 was obtained from damaging the gel on loading. (B) Computer prediction
of the carboxylesterase isoelectric point using the program 'Isoelectric' from
the GCG package.
interactions occuring within the protein that would perturb its overall
ionisation. Of course the protein purified here may not be the form cloned by
Kroetz et al., (1993), however relative molecular weight, specific activities to
the substrates shown in Table 5.2, glycosylation status and relative
abundance leads me to believe that they are the same.
5.2.5 Activity of the human liver microsomal carboxylesterase.
The activity of the carboxylesterase towards a variety of substrates is shown
in Table 5.2. The classic substrate p-nitrophenyl acetate was metabolised at a
rate slower but in keeping with that observed by Ketterman et al., (1989) for
the 'mid pi' form of carboxylesterase, compare 21.2 pmol/minute/mg protein
with 67.3 pmol/min/mg protein. The Km obtained was also similar to that
reported previously, compare 0.18 mM with 0.13mM reported by Ketterman et
al. (1989). The malathione data was also similar, compare specific activities
of 0.42 with 2.79 pmols/ min/ mg protein. Since amidase activity of a purified
human carboxylesterase has been reported previously (Junge and Heymann,
1979) the activity of the enzyme towards the arylamide substrates acetanilide
and 4-nitroacetanalide was also looked at. However, the enzyme purified here
was unable to hydrolyse these compounds. Amidase activity was not observed
by Ketterman et al, (1989) for either the 'mid pi' or 'low pi' forms of human
liver microsomal carboxylesterase. On studying the rat carboxylesterases it
was found that amidase activity could only be observed for the low pi forms and
not the mid pi forms (Mentlein et al., 1987).
5.2.6. Inhibition of human liver microsomal carboxylesterase
activity.
The ability of the serine protease inhibitor phenylmethylsulphonylfluoride
(PMSF) (Gold, 1963) and the specific carboxylesterase inhibitor bis-4-
nitrophenylphosphate (BNPP) to inhibit p-nitrophenylacetate hydrolysis by
the human carboxylesterase was studied (Figure 5.7). p-Nitrophenylacetate
hydrolysis was seen to be extremely sensitive to inhibtion by both PMSF and
BNPP with IC50 values of 2 x 10~8 M and 2 x 10"6 M respectively. Curve fitting
of this data was kindly performed by Dr. David Tew, London. PMSF acts by

















Table 5.2. Specific activities of the human microsomal
carboxylesterase. The a-napthyl acetate, Malathione and lambda
cyhalothron assays were kindly performed by Dr. Colin Walker, University
of Reading.
1e-010 1 e-008 1 e-006 0.0001 0.01
Inhibitor concentration (M)
Figure 5.7. Inhibition of carboxylesterase activity. Inhibition of p-
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Figure 5.8. Sequence alignment of a variety of esterases around the
proposed active site residues. This lineup was achieved using the
programs 'Pileup' and'Prettybox' from the GCG package. The active site
serine and histidine are marked with an arrow. Buty, human
butyrylcholinesterase; Ache, human acetylcholinesterase; ratcarl, rat
carboxylesterase El (major form); mousecar 1, mouse carboxylestersase form
1; humancar, human carboxylesterase; rabbitcarl, rabbit carboxylesterase
form 1; ratcar2, rat carboxylesterase 2 (minor form); pigcar, domestic pig
carboxylesterase; rabbitcar2, rabbit carboxylesterase form 2; mousecar2,
mouse carboxylesterase form 2 and Chole, human cholesterol esterase.
which is resistant to spontaneous hydrolysis under neutral conditions (Gold,
1978). BNPP acts by irreversible phosphorylation of the active site serine
(Brendt et al., 1987). The active site serine and histidine for the rabbit form 1
carboxylesterase has been identified (Ozols, 1987). This has also been
achieved for the related esterase enzyme, acetylcholinesterase (Schumacher
et al., 1987). Using the computer programs 'Pileup' and 'Prettybox', a
multiple sequence alignment of a variety of esterases (obtained from the
EMBL genebank) was produced (Figure 5.8) around these defined active site
residues. Strong homology between liver microsomal carboxylesterases and
other serine esterases can be seen to exist around the proposed active site
serine and histidine residues.
5.2.7 Development of antisera to human microsomal
carboxylesterase.
Polyclonal antiserum to the human carboxylesterase was raised in New
Zealand white rabbits. (Figure 5.9) The antisera prepared allowed for Western
blotting studies (Figures 5.10, 5.11, 5.12) and immunohistochemistry (Figure
5.16) to take place. The specificity and titre of the antibody for use in Western
blotting studies is shown in Figure 5.9, using human liver microsomes and
the purified human liver microsomal carboxylesterase. The antisera
appeared to recognise a major band at 59 kDa. in human liver microsomes
and a lower minor band when used at low dilutions (Figure 5.9).
5.2.8. Expression of the carboxylesterase in a human liver
microsome panel.
Using the rabbit polyclonal antisera described in section 5.2.7. and sera from
a patient with halothane hepatitis (see Figure 5.12, sera 2) the level of
expression of the carboxylesterase was looked at using a previously
characterised panel of human liver microsomes (Forrester et al., 1992). It
can be seen from Figure 5.10 that the level of expression across this panel is
relatively constant and similar when contrasting the rabbit and human
antisera. Densitometric scanning of the autoradiographs revealed the
variation across the microsome panel to be 2.5 fold. This variation in the level
of expression is virtually identical when comparing the rabbit anti-sera and
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Pure carboxylesterase Human Liver Microsomes
Figure 5.9. Western blot analysis using rabbit polyclonal antisera
raised to the purified human carbxylesterase. The left hand panel
shows a variety of dilutions used to probe purified carboxylesterase (200ng
per lane) while human liver microsomes were used on the right hand panel
(5pg per lane).
the level of carboxylesterase expression is in contrast to other drug
metabolising enzymes that have been looked at using this panel (Forrester et
al., 1992). For example, some members of the P450 superfamily of drug
metabolising enzymes were seen to vary by up to 60 fold (CYP4A1). By
knowing the amount of protein loaded in the microsomal samples (7.5 pg)
and that of the purified carboxylesterase (200ng) it was estimated from the
densitometric scanning that the carboxylesterase makes up approximately
2% of total microsomal protein. The rat carboxylesterase El/ form pi 6.0 has
also been shown to be expressed at a high level in liver microsomes (Harano
et al., 1988). This study estimated that the rat carboxylesterase makes up to
around 1.5% of the total rat endoplasmic reticulum protein. This high level of
expression is most probably due to an endoplasmic reticulum retention
signal KDEL found at the C-terminus of the protein (Pelham, 1991).
5.2.9 Expression of the carboxylesterase in other species.
Western blot analysis, using the rabbit polyclonal antisera, against a variety
of microsomes from different species is shown in Figure 5.11A. This blot
reveals that an immuno-reactive protein of similar molecular weight to the
human carboxylesterase is present in rat, rabbit, dog, guinea pig and
woodchuck liver microsomes, but not in mouse hepatic microsomes or in
microsomes prepared form xenopus oocytes or yeast. A weak band does
appear to be present in the lane containing the mouse microsomes, however
this is very faint in comparison to the other mammalian species.
5.2.10 Expression of the human carboxylesterase in different human
tissues.
Figure 5.1 IB shows the expression of the carboxylesterase in a variety of
tissues by Western blotting using the polyclonal antisera described in section
5.2.7. Unfortunately only a small number of microsome samples could be
obtained for this study. Figure 5.1 IB shows that this form of human
microsomal carboxylesterase is only expressed at a detectable level in the
liver microsome sample. It would have been interesting to look for
expression of the carboxylesterase in adipose tissue since it has been shown
that the major form of the rat microsomal carboxylesterase is expressed at a
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Figure 5.10. Expression of the carboxylesterase in a human liver
microsome panel. Western blot analysis was performed using the rabbit
antisera and serum from a patient (HH2, Figure 5.13) with halothane
hepatitis. Lanes IV-wl, 7.5gg of microsomal protein, std, 200ng purified
carboxylesterase.
(a) Std. 123 4 56 789 Std.
(b) Std. 1 2 3 4 5 6 Std.
Figure 5.11. Expression of a 59 kDa. carboxylesterase in (A) other
species and (B) in human tissues. (A) Lanes 1-7 (liver microsomes): 1,
human (1 gg); 2, rat (10 gg); 3, rabbit (10 gg); 4, mouse (10 gg); 5, dog (10
gg); 6, guinea pig (10 gg); 7, woodchuck (10 gg) and microsomes from; 8,
xenopus (75 gg) and 9, yeast (75 gg). Std, 200ng pure human
carboxylesterase. (B) Lanes 1-5 human microsomes from 1, liver (1 gg); 2,
kidney (50 gg); 3, colon (50 gg); 4, bladder (50 gg); 5, ovaries (50 gg); 6, testis
(50 gg); std, 200ng pure human carboxylesterase.
high level in this tissue and is involved in fatty acid ethyl ester synthesis
(Tsujita and Okuda, 1992)
.5.3 The role of human liver microsomal carboxylesterase in the
pathogenesis of halothane hepatitis.
5.3.1. Introduction to halothane hepatitis.
Halothane has been widely used as an inhalation anaesthetic agent since its
introduction in 1956 (Johnstone, 1956). Halothane can cause two types of
hepatotoxicity. The milder form is characterised by minor elevations in
serum transaminases, develops in around 20% of patients and has been
attributed to cytotoxic effects of halothane metabolites (Ray and Drummond,
1991; Kenna et al., 1993). The more severe form of hepatotoxicity, termed
'halothane hepatitis', is much rarer, affecting 1 in 10,000, and results in
severe hepatic damage (Ray and Drummond, 1991). Halothane hepatitis is
characterised by extremely large elevations in serum transaminase levels,
jaundice and massive hepatic necrosis with a significant fraction of patients
developing liver failure which is most often fatal (Zimmerman, 1978; Ray and
Drummond, 1991). Halothane hepatitis is an idiosyncratic and dose
independent adverse drug reaction. However, patients who develope this
disease are frequently female, obese and of late middle age (Zimmerman,
1978; Ray and Drummond, 1991). From the clinical and laboratory features of
the hepatitis it has been implied that it is of an immunological basis. For
example, all patients have been exposed to halothane on multiple occasions
with a substantial proportion having developed an adverse reaction, such as
fever or jaundice, after a previous exposure (Zimmerman, 1978; Walton et al.,
1978; Neuberger and Kenna, 1987; Ray and Drummond, 1991). Another
important observation has been that the inter-operative interval can be
prolonged, ranging from 7 days to 10 years (Neuberger and Kenna, 1987).
Compared to direct hepatotoxins, such as paracetamol, the interval from the
anaesthesia to the onset of liver dysfunction is delayed by up to 25 days in
some cases (median 7 days), (Kenna et al., 1987b). These observations were
the basis for the hypothesis that halothane hepatitis is mediated through an
immune response. Other observations suggesting that an immune reaction
is the cause of the disease include pyrexia, eosinophilia and elevated
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circulating immune complexes (Zimmerman, 1978; Walton et al., 1976;
Neuberger and Kenna, 1987). Importantly, it has been discovered that there
are circulating antibodies in the sera of halothane hepatitis patients that are
directed against halothane modified liver antigens (trifluoroacetylated (TFA)
proteins), (Kenna et al., 1987a; Kenna et al, 1988; Kenna et al, 1993). This
latter point has led to the hypothesis that metabolites of halothane react with
proteins within the cell to produce proteins that are recognised as non-self by
the immune system in susceptible individuals (Pohl et al, 1989; Kenna et al.,
1993). Under oxidative conditions halothane is metabolised to a trifluoracetyl
radical which can interact with lysine residues of proteins, resulting in
trifluoroacetylated (TFA)-proteins. (Harris et al., 1991). These TFA-proteins
have been proposed to go on to elicit an immune response which can cause
immune mediated hepatic necrosis in susceptible individuals (Pohl et al.,
1989; Kenna et al., 1993). In recent years, much research has gone into
identifying what these halothane modified proteins are. Western blot
analysis reveals that up to eight different proteins in the microsomal fraction
of livers from rats treated with halothane are recognised by antibodies
present in the sera from halothane hepatitis patients (Kenna et al., 1987;
Kenna et al., 1988). These proteins have varying molecular weights of 100, 80,
63, 59, 58, 57 and 54 kDa. Recent work in identifying these proteins has
focussed around purifying the TFA-proteins from the liver microsomes of
halothane treated rats. The first protein to be identified was the 59 kDa TFA-
protein (Satoh et al.; 1989). This protein was found to be a previously
characterised hepatic microsomal carboxyesterase, form El/ pi 6.0 (Harano
et al., 1988). Since this initial identification, the other TFA-proteins that have
been isolated and identified are the lOOkDa. protein; GRP94/ ERp99/
endoplasmin (Thomassen et al., 1990), the 80kDa. protein; ERp72 (Pumford et
al., submitted), the 63kDa. protein; calreticulin (Butler, 1992) and the 57kDa.
protein; protein disulphide isomerase (Kenna et al., 1990)
From the NH2-terminal sequence of the human carboxylesterase (Figure 5.3),
molecular weight (Figure 5.1A,B), the isoelectric point (Figure 5.6) and the
specific activity towards carboxylesterase substrates (Table 5.2) it is clear that
the human carboxylesterase purified here is or is highly similar to the
enzyme purified form halothane treated rat livers (Satoh et al., 1989). Satoh et
al., (1989) proposed that a human form of the carboxylesterase would be a
target for the antibodies found in halothane hepatits patients' sera. In order
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to test this hypothesis out a variety of experiments were carried out which are
described in the following sections.
5.3.2. Detection of antibodies to human microsomal
carboxylesterase in halothane hepatitis patients' sera by Western
blotting.
The aim of the experiment shown in Figure 5.12 was to see if any patients
had antibodies in their sera directed against purified human
carboxylesterase that could be detectable by Western blotting. It is important
to note that the carboxylesterase purified here was from a pool of liver
microsomes obtained from organ transplant donors who had had no previous
exposure to halothane. Therefore, it could be assumed that the
carboxylesterase was not trifluoroacetylated.
Previous studies using sera from patients with halothane hepatitis have used
the method of Western blotting to identify proteins that are the targets for
antibodies found in the sera (Kenna et al., 1987a, Kenna et al., 1988, Satoh et
al.,1989; Kenna et al., 1993). These studies have relied on using hepatic
microsomes from halothane treated rats or rabbits in order to identify TFA-
proteins recognised by the antibodies in the patients' sera. Sera from 20
patients with halothane hepatitis, kindly provided by Dr. J. Gerry Kenna, St.
Mary's Medical School, London, were studied. These patients were defined
clinically as having otherwise unexplained hepatitis within 25 days of
halothane anaesthesia. Four control samples from patients who had
recieved multiple exposures of halothane but with no adverse reaction to the
drug were also used. Figure 5.12 shows that only one patient (HH 2) had
detectable amounts of antibody in their sera directed against the purified
carboxylesterase when using a serum dilution of 1:100 with the secondary
antibody at a dilution of 1:1000. All other patients' sera appeared not to
contain antibodies directed against the carboxylesterase that could be
identified by this form of immunodetection. However, this result is the first
strong evidence of autoantibodies against the carboxylesterase in a patient
with halothane hepatitis, i.e. the antibodies present in patient HH2's sera are
true autoantibodies and not antibodies against the trifluoracetylated form of
the carboxylesterase. When using native rat carboxylesterase in comparison
to rat TFA-carboxylesterase Satoh et al. (1989) found that for patients' sera to
react with the carboxylesterase it had to be modified by halothane. In another
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Figure 5.12. Detection of antibodies to human microsomal
carboxylesterase in halothane hepatitis patients' sera by Western
blotting. After tranferring purified carboxylesterase from a 9% preparative
poly-acrylamide gel to nitrocellulose, the membrane was cut into strips (~
200ng protein/ strip) and Western blot analysis was carried out. Lanes 1-20,
halothane hepatitis patients' sera. Lanes 21-25, control sera (patients
exposed to halothane but with no adverse reaction).
study (Kenna et al, 1988) the general rule found was that patients' antibodies
did not recognise proteins in liver microsomes from untreated rats.
Therefore previous studies have concluded that the antibodies present in
patients' sera were directed against TFA-proteins, not wild-type proteins.
This appears not to be the case for patient HH2 (Figure 5.12). This may be due
to the fact that this is the first time a human protein has been used for this
sort of study. Previous work has only ever utilised rat or rabbit protein
samples. At the amino acid level the rat carboxylesterase form El/ pi 6.0 is
only 77% identical to the human carboxylesterase as predicted from the
computer algorithm 'Bestfit'. This lack of sequence homology suggests that
epitopes found on the native human carboxylesterase, by antibodies in the
patient's serum, may not be present on the native rat or rabbit protein.
5.3.3 Detection of antibodies to human microsomal
carboxylesterase in halothane hepatitis patients' sera by dot-
blotting and ELISA.
Since Western blotting is carried out under denaturing conditions then
conformational epitopes on proteins may be destroyed by the harsh conditions
used in this method. In order to study whether the patients' sera contain
antibodies to epitopes not detectable by Western blotting the non-denaturing
methods of dot-blotting and ELISA were carried out. Figure 5.13 shows the
result obtained for the detection of antibodies in patients' sera using a dot-blot.
In this experiment 20 patients diagnosed as having halothane hepatitis were
used alongside 6 control sera from patients who had recieved halothane on
multiple toccasions without an adverse reaction and 10 control sera from
healthy blood donors. This blot clearly demonstrates that 7/20 halothane
hepatitis patients have antibodies in their serum directed against the native
carboxylesterase (patients HH2, HH6, HH7, HH8, HH16, HH17, HH20). Low
levels of antibodies were detected in patients HH9, HH10 and in the controls
HC 1, HC2 and BD3, BD4, BD7, BD8. The significance of these control results
are unclear and may be due to non-specific binding of antibodies and/or
protein A to the filter. To obtain a more quantitative analysis of antibodies
present in patients sera an ELISA was set up (Figure 5.14). Due to the ease of
this assay a larger range of control samples could be analysed. This control
pool comprised of 9 sera from patients who had recieved multiple exposures
of halothane but with no adverse effects, 18 healthy blood donors, 11 patients
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Figure 5.13. Detection of antibodies to human microsomal
carboxylesterase in halothane hepatitis patients' sera by dot-
blotting. lOOng of protein per dot was probed with patients' sera. Dots 1-20
(HH1-20), halothane hepatitis patients' sera; Dots 21-26, halothane control
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Figure 5.14. Detection of antibodies to the purified human
carboxylesterase in patients' sera by ELISA. Dotted line shows upper
limit of the normal control range. O.D., optical density.
with fulminant hepatic failure (6 paracetamol, 2 hepatitis B, 1 hepatitis A, 2
non-A and nonB hepatitis), 6 with autoimmune chronic active hepatitis, 4
with alcohol liver disease, 8 with primary biliary cirrhosis and 4 with
jaundice due to flucloxacillin. Figure 5.14 shows the result of the ELISA
assay using sera at a dilution of 1:100 and screened using HRP-conjugated
goat anti human IgG antisera at a dilution of 1:1000. Sera were regarded as
antibody positive when the optical density (O.D.) values at 492nm were greater
than 2 standard deviations above the mean value for the healthy blood donors
(O.D. > 0.211). Antibodies to human liver carboxylesterase were detected in the
sera of 17/20 patients with halothane hepatitis but not in the 9 halothane
exposed controls or 31 of the 33 'other hepatitis' control patients.
Interestingly, low levels of antibodies to the carboxylesterase were detected in
2 of the 8 patients with primary biliary cirrhosis (PBC). This may be
explained by the fact that in PBC an autoimmune response is mediated
against a very wide range of proteins. The carboxylesterase may have been
one of these in the patients looked at here. Alternatively, a similar epitope
may have been recognised and hence the nature of this result may be one of
non-specificity. An interesting observation is that sera HH2, which
recognised the carboxylesterase by Western blotting (Figure 5.12), did not have
the highest titre (sera HH8 had the highest titre in this study). This can be
explained by the fact that ELISA allows the detection of conformational
epitopes which may be lost through the harsh conditions ofWestern blotting.
The ELISA data (Figure 5.14) reveals the presence of autoantibodies against
human microsomal carboxylesterase in 85% of patients tested with halothane
hepatitis. This provides the first clear evidence that autoantibodies against a
human microsomal protein are present in the sera from patients with
halothane hepatitis. Previously, it has always been assumed that the
antibodies found in the patients' sera are against neo-antigens, i.e.
trifluoroacetylated regions of the protein or novel haptens produced on the
protein via the chemical modification but distinct from sites of
trifluoroacetylation. (Kenna et al., 1988; Satoh et al., 1989)
5.3.4 Immunohistochemical localisation of microsomal
carboxylesterase in human and rat liver sections.
An early observation on the pattern of hepatic damage caused by halothane
hepatitis was that it was predominantly centrilobular in nature (Peters et al.,
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Figure 5.16. Immunohistochemical localisation of microsomal
carboxylesterase in (A) a human liver section and (B) a rat liver
section. Blue signifies highest antibody binding with red representing
weaker regions of binding.
1969; Benjamin et al., 1985). Using the rabbit polyclonal antisera raised
against the human carboxylesterase (Figure 5.9) the localisation of the
carboxylesterase was looked at in both human and rat liver sections. This
work was carried out in collaboration with Dr. David J. Harrison, Pathology
Dept., University of Edinburgh. False colour enhanced
immunohistochemistry was performed with blue representing the region of
highest antibody binding with green through to red indicating weaker
regions of binding. Figure 5.15A reveals that the human carboxylesterase
and its rat counterpart (Figure 5.15B) are localised predominantly in the
centrilobular region (zone 3) of the liver around the terminal hepatic venule.
Localisation of the carboxylesterase can be seen to be more defined in the rat
liver section. Centrilobular localisation is a well documented phenomena of
drug metabolising enzymes such as the cytochrome P450 system,
glutathione-S-transferases and the UDP-glucoronyl S-transferases (Hall et
al., 1989). Previous work has also shown that there is a more defined division
of labour within the rat liver in comparison to the human liver (Hall et al.,
1989). This division is clearly seen within the rat liver section (Figure 5.15B)
in comparison to the human liver section (Figure 5.15A).
Taking this data together with the results from the ELISA it can be proposed
that an immune response to human carboxylesterase may have an important
role in the development and/or perpetuation of halothane hepatitis. Of course
the carboxylesterase is only one of up to eight microsomal proteins that
become the targets for antibodies in patients' sera and how much of a role the
carboxylesterase plays in the pathology of this disease will not be known
untill the other human proteins that become trifluoroacetylated are isolated.
5.3.5. Trifluoracetylation of human microsomal carboxylesterase.
One important question is what are the factors that cause a protein to become
trifluoracetylated and hence lead to an immune response? Using the
carboxylesterase as a model protein a few suggestions will be described below.
An obvious factor would be that the protein would have to be close to the site of
halothane metabolism. Halothane is metabolised under oxidative conditions
to a trifluoracetyl radical (Harris et al., 1991). Since the oxidative metabolism
of halothane has been found to take place in the microsomal fraction by a
P450 mediated reaction (Karashims, 1977), then for a protein to be
trifluoracetylated it should be associated with the endoplasmic reticulum of
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the cell. The carboxylesterase purified here was from the microsomal
fraction of human livers and was found to be localised in the centrilobular
region of human and rat liver (Figure 5.15A,B), which is the region where
P450s are predominantly found (Hall et al., 1989). Another factor, which has
been described above (Section 5.2.8; Figure 5.10), is the relative abundance of
the protein. It would seem feasible that the more abundant the protein the
greater its chances of being trifluoracetylated. This does indeed appear to be
the case for the carboxylestease with its content in the endoplasmic reticulum
being estimated to make up approximately 2% of total protein (Figure 5.10).
The other proteins that have been identified as being trifluoracetylated are all
found at high levels in the endoplasmic reticulum (Kenna et al ., 1993). These
proteins are GRP94 (lOOKda) (Thomassen et al., 1990), ERp72 (76kDa.)
(Pumford et al., submitted), calreticulin (63 kDa.) (Butler et al., 1992) and
protein disulphide isomerase (57 kDa.) (Kenna et al., 1990). An important
observation is that these proteins along with the carboxylesterase are all
found within the lumen of the endoplasmic reticulum. (Kenna et al. 1992).
These proteins all have at their C-terminus the KDEL (Lys-Asp-Glu-Leu), or
a related form of this, endoplasmic reticulum retention signal (Pelham, 1990).
The sequence derived from the human carboxylesterase cDNA reveals that at
its C-terminus there is the related KDEL motif, HIEL (His-Ile-Glu-Leu)
(Pelham, 1990). In the 24 amino acids preceding this there are six lysine
residues. The work of Harris et al. (1991) showed that trifluoracetylation of
hepatic proteins occured at lysine residues. It can be postulated that
perturbation of this retention signal, by trifluoroacetylation of the lysine
residue or of lysine residues near by (in the case of the carboxylesterase), may
prevent these proteins being retained within the lumen of the endoplasmic
reticulum. This may ultimately lead to the exportation of the protein(s) from
the endoplasmic reticulum and ultimately presentation to the immune
system. One study has shown that liver biopsies from halothane exposed
patients, who did not go on to develope hepatitis, contained trifluoroacetylated
proteins (Kenna et al., 1988). This work suggested that all pateints who have
undergone halothane anaesthesia produce trifluoroacetylated proteins. A
major question still to be answered is how immune sensitisation occurs.
Why this should occur in some individuals and not in others that are exposed
to halothane is unknown. Other factors that may be of importance include;
interindividual variability in the amounts of antigens generated, levels of
expression on the hepatocyte surface membrane, antigen-processing and
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presentation by antigen-presenting cells, immune recognition and/or specific
tolerance to TFA-protien antigens (Kenna et al., 1993). A summary diagram
of the above ideas are presented in Figure 5.16.
5.4 Summary.
The work in this chapter has described the purification and characterisation
of a human hepatic microsomal carboxylesterase. This work has also shown
that the human carboxylesterase is an autoantigen in 85% of patients tested
with the disease halothane hepatitis (Smith et al., 1993). The purified
carboxylesterase and the rabbit antisera produced will be important reagents
for the study of this protein both as a xenobiotic metabolising enzyme and as
an autoantigen in halothane hepatitis.
The initial characteristion of the enzyme suggested it to be similar to the rat
carboxylesterase form pi 6.0 (Mentlein et al., 1980; Harano et al., 1988), and to
have similarities to the human 'mid pi' form described by Ketterman et al.,
(1989). More recently, Kreutz et al., (1993) described the cloning and
baculovirus mediated expression of two almost identical carboxylesterases
from a liver cDNA library. The difference between these two carboxylesterses
is that one, termed hCEv, has two 3bp losses compared to the other, termed
hCE. This results in the loss of two amino acids. From the limited NH2-
terminal sequence, the specific activities towards p-nitrophenyl acetate and
malathione, the electrophoretic mobility and relative abundance it can be
presumed that the carboxylesterase purified here is one of those, or a
homogenous mixture of those described by Kroetz, et al. (1993). Using specific
oligonucleotides as probes Kroetz et al. (1993) showed that the mRNA for both
these proteins was present in human liver samples. From their study the
relative expression of the human isozymes appears to vary form individual to
individual. Separation of the two proteins by SDS-PAGE and subsequent
Western blot analysis will be very difficult since the two proteins differ in size
by only 200 Da. Why should humans have two proteins that are practically
identical? Maybe, these carboxylesterases are the product of a gene-
duplication event.
Much of the future work on carboxylesterases will probably focus on the
endogenous role of these enzymes. In rat adipose tissue a microsomal
carboxylesterase has already been shown to be fatty acid ethyl ester synthase
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Figure 5.16. Suggested mechanism of immune-mediated
hepatotoxicity. (From Kenna etal., 1993.)
(Tsujita and Okuda, 1992). A serine protease excreted from human alveolar
macrophages (Munger et al., 1991) has identical sequence to the
carboxylesterases cloned from a human liver cDNA library (Kroetz et al.,
1993).
The carboxylesterases may have some other important physiological role(s),
other than xenobiotic metabolism, that has still to be ascribed to them.
The role of the carboxylesterase as an autoantigen in halothane hepatitis has
been clearly established from the data presented within this chapter. At
present, the diagnosis of halothane hepatitis is largely a clinical one by
exclusion of other possible causes of liver damage (Zimmerman, 1978; Walton
et al., 1978; Ray and Drummond, 1991). The diagnosis can be confirmed by
testing for antibodies in patients' sera that react with trifluoracetylated liver
proteins (Kenna et al., 1984 and Kenna et al., 1988) but the assays described
are time consuming and technically demanding. The ELISA described here
offers promise as a quick, simple and sensitive diagnostic aid. In principle,
the assay might also identify patients sensitised to halothane and at risk of
hepatitis if re-exposed to this anaesthetic.
The carboxylesterase is only one of up to eight microsomal proteins that are
trifluoroacetylated by the oxidative metabolite of halothane. What the relative
importance of the carboxylesterase is as an autoantigen in comparison to the
other proteins will become clear when the other native proteins become
available. This work has served to highlight that autoantibodies are present
in the sera of patients with halothane hepatitis that are directed towards the
carboxylesterase and not just antibodies to TFA-carboxylesterase as previous
work has suggested (Satoh et al., 1989). This discrepency is probably due to
the fact that in the work discussd here a human protein was used compared
to one derived from rat liver microsomes (Satoh et al., 1989).
In halothane hepatitis the first immune response is most probably against
TFA-carboxylesterase. The TFA-carboxylesterase may then come into
contact with the immune system, after transport to the cell surface, through
perturbation of its C-terminal endoplasmic reticulum retention signal. After
this initial immune sensitisation a response to the whole protein may occur.
The other proteins that are trifluoracetylated may also go through this series
of events. Trifluoracetylation of microsomal proteins has been shown to
occur on lysine residues (Harris, 1991). The lysine residues that become
trifluoracetylated may be mapped on the carboxylesterase by
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trifluoracetylating the protein in vitro followed by sequence analysis of peptide
fragments obtained after proteolytic digestion of the protein.
The picture that is emerging from studies identifying trifluoracetylated
microsomal proteins is that the proteins are abundant, have a long half life
and are present within the lumen of the endoplasmic reticulum (Kenna et
al., 1993). However, are there other as yet unidentified, proteins
trifluoracetylated? For example , some data suggests that a P450 is
trifluoracetylated with the appearance of a TFA-P450 occuring quickly and
disappearing after 3 hours. This most probably represents the P450 that is
involved in the metabolism of halothane, namely CYP2E1 (Kenna,
unpublished). Other abundant endoplasmic reticulum proteins, e.g. epoxide
hydrolase, maybe modified by the trifluoroacetyl chloride metabolite of
halothane. Previous work has centered around Western blotting for
identification of antigens, but, as shown here for the human microsomal
carboxylesterase, conformational epitopes maybe lost through this technique
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ABSTRACT NADPH-cytochrome P450 oxidoreductase
transfers electrons from NADPH to cytochrome P450 and
catalyzes the one-electron reduction ofmany drugs and foreign
compounds. This enzyme is a flavoprotein containing the
cofactors FMN and FAD, which are essential for its function.
We have expressed the putative FMN and FAD/NADPH
binding domains of P450 reductase and show that these distinct
peptides fold correctly to bind their respective cofactors. The
FAD/NADPH domain catalyzed the one-electron reduction of
a variety ofsubstrates but did not efficiently reduce cytochrome
c or cytochrome P450 (as judged by the oxidation of the
CYP1A1 substrate 7-ethoxyresorufin). However, the domains
could be combined to provide a functional enzyme active in the
reduction of cytochrome c and in transferring electrons to
cytochrome P450. Both the reconstitution of the domains and
-the direct binding of cytochrome c to the FMN domain were
-ionic-strength dependent. The FMN domain containing the
-hydrophobic membrane anchor sequence was a potent inhib-
-itor of reconstituted monooxygenase activity. These data
strongly support the hypothesis that FMN/FAD-containing
■proteins have evolved as a fusion of two ancestral genes and
■provide fundamental insights into how this and structurally
=related proteins, such as nitric oxide synthase and sulfite
^reductase, have evolved and function.
The microsomal flavoprotein NADPH-cytochrome P450 ox¬
idoreductase (EC 1.6.2.4) shuttles electrons from NADPH
via its FMN and FAD prosthetic groups to cytochrome P450
(1). The reductase also has the ability to reduce a host of
exogenous electron acceptors, including cytochrome c, po¬
tassium ferricyanide, and 2,6-dichloroindophenol (DCIP) (2),
is well as therapeutically important compounds such as
nitomycin c (3) and the benzotriazine SR4233 (4). In addi-
ion, P450 reductase is also an electron donor to heme
oxygenase (5), the fatty acid elongation system (6), and
:ytochrome b5 (7) and initiates lipid peroxidation by the
ine-electron reduction of molecular oxygen (8). P450 reduc-
ase was the first protein found to contain FMN and FAD in
in equimolar ratio of 1:1 (9). Since its isolation, two other
;roups of proteins have been identified which contain these
—lavins as prosthetic groups: (/) the nitric oxide synthases,
nvolved in the production of the neurotransmitter, vasodi-
ator, and cytotoxic agent nitric oxide from L-arginine (10,
1), and (;/) the a subunit of the bacterial sulfite reductases,
vhich participate in the six-electron reduction of sulfite to
ulfide (12). In addition to this similarity, these proteins have
leen shown to share significant sequence identity, particu-
^rly within the suggested functional domains (12, 13).
Initial sequence comparisons of P450 reductase with other
—roteins reveal a striking homology with two distinct flavo-
■•roteins (14, 15). The N-terminal region of the reductase
shows homology with the FMN-containing bacterial flavo-
doxins. The C-terminal portion of the reductase is homolo¬
gous with the FAD-containing ferredoxin NADP+ reduc¬
tases. These observations led to the proposal that P450
reductase has evolved as a fusion of two ancestral proteins
(15).
We therefore set out to separate the proposed domains of
P450 reductase into discrete functional units by expressing
specific peptides in Escherichia coli. The peptides were
designed on the basis that exons or groups of exons within the
P450 reductase gene defined specific functional domains, as
has been observed for the steroid hormone receptors (16) and
the glyceraldehyde phosphate dehydrogenases (17). The abil¬
ity to dissect P450 reductase into functionally viable domains
would provide new avenues for studying the structure and
function of this and related proteins.
MATERIALS AND METHODS
Constructs. The cDNA for human NADPH-cytochrome
P450 oxidoreductase was obtained from a human skin fibro¬
blast cDNA library (kindly provided by S. M. Keyse, Impe¬
rial Cancer Research Fund, Dundee, UK) by PCR. Oligonu¬
cleotides for the 5' (incorporating an EcoRI site) and 3' ends
of the reductase cDNA were derived from the sequence
reported previously (18). After treatment with Klenow DNA
polymerase and digestion with FcoRI, the cDNA was ligated
into the EcoRl/Sma 1 site of pTZ19R (St. Albans, Hertford¬
shire, UK) and the sequence was confirmed. The human
cDNA was the template for further PCR amplifications.
Oligonucleotides were generated for the 5' and 3' ends of the
proposed exons shown in Fig. 1 in order to obtain cDNAs
encoding domains of P450 reductase. The exon/intron
boundaries were derived from the rat P450 reductase gene
(19). The 5' oligonucleotides were synthesized with an over¬
hanging Nde I restriction site whereas the 3' oligonucleotides
contained an Xho I site. After amplification and digestion, the
cDNAs were ligated into the unique Nde l/Xho I sites of the
expression plasmid pET15b (Novagen). The authenticity of
regions generated by PCR was confirmed by sequencing. The
plasmids were used to transform E. coli BL21(pLysS).
Purification of the Domains. Cloning into the Nde l/Xho I
sites of pET15b engineers a His6 linker and a thrombin
cleavage site onto the N terminus of the expressed protein.
Purification of the His-tagged domains on nickel-agarose
columns was carried out according to Novagen's recommen¬
dations. BL21 strains harboring the domain expression plas¬
mids were grown at 37°C overnight in LB broth containing
ampicillin (50 /ug/ml) and chloramphenicol (34 p,g/ml). Five
hundred milliliters of fresh LB broth was inoculated with 5 ml
of the overnight culture and the bacteria were grown at 37°C
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to an OD of 0.5-0.6. Isopropyl /3-d-thiogalactopyranoside
was then added (0.5 mM) and the culture was allowed to grow
for 2.5 hr before harvest at 5000 x g for 10 min. The pellet
from a 500-ml culture was suspended in 20 ml of binding
buffer (5 mM imidazole/500 mM NaCl/20 mM Tris-HCl, pH
7.9) and frozen at -70°C for 1 hr. Upon thawing the bacteria
were lysed, since the expression strain BL21 contains a
plasmid bearing T7 lysozyme. Sonication (MSE probe at full
power, 2 x 35 sec with 1 min of incubation on ice between
steps) was carried out to shear genomic DNA present in the
lysate. The extract was then centrifuged (39,000 x g for 30
min) to remove cellular debris and insoluble protein. Bacteria
were analyzed for domain expression by SDS/PAGE of
soluble and insoluble fractions (data not shown). The FMN/
anchor, FMN (no anchor), and FAD/NADPH domains (Fig.
1) produced soluble protein extracts. However, the FAD and
FAD/NADPH (small) domains were insoluble, as was the
FMN/FAD domain, with only a very small percentage pre¬
sent in the soluble fraction. The supernatant containing the
soluble domains was applied onto 2-ml nickel-agarose col¬
umns previously equilibrated with binding buffer. Columns
were washed with 10 volumes of binding buffer and then 10
volumes of wash buffer (binding buffer containing 20 mM
imidazole). The FMN (no anchor) and the FAD/NADPH
domains could be eluted from the nickel-agarose column by
increasing the imidazole concentration to 60 mM, while the
FMN/anchor region was eluted by increasing the imidazole
to 300 mM. Insoluble proteins were purified in a manner
similar to the soluble domains but in the presence of 6 M urea.
Attempts to renature the domains were unsuccessful. The
purity of the domains was determined by SDS/PAGE. The
insoluble domains were not used in any further experiments.
Purified soluble domains were extensively dialyzed against
10 mM potassium phosphate buffer (pH 7.7).
Protein was determined by the method of Lowry et al. (20).
Thrombin cleavage was performed in 20 mM Tris-HCl, pH
8.4/150 mM NaCl/2.5 mM CaCln with a domain/thrombin
weight ratio of 5000:1. Cleavage took place at 4°C and was
monitored by SDS/PAGE. One hundred percent cleavage
occurred after 10 min for the FMN (no anchor) domain and
after 4 hr for the FAD/NADPH domain. The His6 tag could
not be removed from the FMN/anchor domain. The cut
domains were separated from the His6 tag by passing the
sample through a nickel-agarose column.
Spectral Analysis. Absorption spectra were obtained with a
Shimadzu UV 2000 spectrophotometer. FMN and FAD
content was calculated after releasing the flavin from the
domains by boiling for 3 min in the dark, followed by
A ■K 1 Sit II
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Fig. 1. Organization of P450 reductase domains (A), exon orga¬
nization (£), and domains made for this study (C). Amino acids at the
ends of the domains are shown. Anc., membrane-anchoring domain;
S, substrate recognition sites. FMN-, FAD-, and NADPH-binding
domains are shown. Calculated molecular masses of the domains:
FMN/anchor, 31.1 kDa; FAD/NADPH, 49.7 kDa; FMN (no an¬
chor), 24.2 kDa; FAD/NADPH (small), 30.2 kDa; FMN/FAD, 61.3
kDa; FAD. 41.0 kDa.
centrifugation at 20,000 x g for 10 min to remove denatured
protein. The flavin concentration was determined at 450 nm
by using extinction coefficients of 12.2 mM^'-cm-1 for FMN
(21) and 11.3 mM_1-cm_1 for FAD (22).
Enzyme Assays. The one-electron reduction of cytochrome
c, potassium ferricyanide, DCIP, menadione, and 3-acetylpy-
ridine adenine dinucleotide phosphate was carried out in 50
mM potassium phosphate (pH 7.7) at 37°C (23). For recon-
stitution of reductase activity, the FMN (no anchor) and the
FAD/NADPH domains (0.1 nmol of each) were mixed in 10
mM potassium phosphate (pH 7.7) for 2 hr at 4°C before
assay. The FMN/anchor domain was used for the reconsti-
tution of P450 reductase activity. 7-Ethoxyresorufin O-de-
ethylation (EROD) was determined (24) with a Perkin-Elmer
LS-3 fluorescence spectrophotometer. Details of the recon-
stitution assays are in the figure legends. Rat CYP1A1 and
P450 reductase were purified as described (25, 26).
RESULTS
Expression and Purification of P450 Reductase Domains. E.
coli cells were transfected with expression plasmids encoding
the P450 reductase domains (Fig. 1). All the peptides tested
were expressed at high level (10-15% of total cell protein) but
not all were soluble (data not shown). The FAD and the
FAD/NADPH (small) domains were totally insoluble and
could be purified only under denaturing conditions. The
FMN/FAD domain was partially soluble but upon isolation
was very susceptible to proteolysis. The FMN (no anchor)
domain was predominantly soluble (up to 35 mg of purified
protein could be obtained from a 1-liter culture), with the
FMN/anchor and the FAD/NADPH domain less so (up to 5
mg of purified protein from a 1-liter culture).
The recombinant His-tagged proteins were purified to
homogeneity by nickel-agarose chromatography (Fig. 2). The
His6 tag was completely removed from the N terminus of the
FMN (no anchor) and FAD/NADPH domains. However, the
tag could not be removed from theterminus of the
FMN/anchor domain (data not shown).
Absorption Spectra of the Oxidized FMN and FAD/NADPH
Domains. The FMN/anchor, FMN (no anchor), and FAD/
NADPH domains purified from the bacterial supernatant
(under nondenaturing conditions) were yellow, indicating the
presence of flavin. To confirm this, UV/visible spectra were
recorded. The spectrum of the FMN (no anchor) domain had—
peaks at 370 and 453 nm and a broad absorption band between
570 and 630 nm (probably due to some reduced FMN being
present in this sample) (Fig. 3A). This spectrum was virtually
identical to that reported by Kurzban et al. (27) for the
FAD-depleted P450 reductase and similar to that predicted—
from the computer model of Oprian and Coon (28). The
spectrum of the FAD/NADPH domain had absorption max¬
ima at 382 and 454 nm (Fig. IB), similar to the FMN-depleted—
preparations of P450 reductase (29, 30). However, this spec¬
trum had more definition than the FMN-depleted reductase—
produced by site-directed mutagenesis (31). Analysis of fla¬
vin content showed that the FMN/anchor domain contained
0.67 mol of FMN per mol of protein, and the FMN domain,
0.63:1. The FAD/NADPH domain contained 0.70 mol ol—
FAD per mol of protein. When the FMN and FAD/NADPH—
domains were combined in a 1:1 ratio, a spectrum identical tc
that of native P450 reductase was obtained (Fig. 3 C and D).
The above data showed that the FMN and FAD domain!
could be expressed separately and could fold independent^
to bind their respective cofactors. To investigate whether the
FAD/NADPH protein could transfer electrons to the FMh
(no anchor) domain to produce an air-stable semiquinone
similar to the native P450 reductase (Fig. 3C), the twc
domains were mixed and an excess ofNADPH was added. /
spectrum characteristic of the air-stable semiquinone form o
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Fig. 2. Expression of P450 reductase domains in E. coli. The
cDNA sequences encoding the domains shown in Fig. 1 were
expressed in E. coli BL21(pLysS) using the pET15b vector. Domains
were purified to apparent homogeneity on nickel-agarose columns.
(A) Purification of the FMN/anchor domain. Std, molecular size
standards; On. soluble fraction applied to the column (15 /xg); FT,
flowthrough (15 /xg); 300 mM, domain eluted with 300 mM imidazole
after washing of the column with 60 mM imidazole (2 ixg). (B)
SDS/12% PAGE analysis of the other purified domains (1 /xg)
illustrated in Fig 1. FL - anc., full-length P450 reductase minus the
anchor domain.
native P450 reductase was obtained (Fig. 3 C and D). This
slowly reoxidized over a period of 4 hr, which is unlike intact
P450 reductase, where this intermediate is stable for up to 48
hr. This reduction occurs via electron transfer from NADPH
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Fig. 3. Absorption spectra of purified P450 reductase domains.
(A) FMN (no anchor) domain, 55 /xM. (B) FAD/NADPH domain, 50
iuM. (C) Native P450 reductase, 10 /xM: , oxidized; ,
air-stable semiquinone 24 hr after addition of 200 /xM NADPH. (D)
—Spectrum obtained on mixing the FMN (no anchor) (7.5 p-M) and
—FAD/NADPH (7.5 pM) domains: , oxidized; , reduced
spectrum 30 min after the addition of 200 /xM NADPH; , reduced
spectrum 4 hr after the addition of 200 pM NADPH.
D), which are characteristic of FMN semiquinone, indicates
that electrons are transferred from FAD to the FMN domain.
This is supported by the finding that the FAD semiquinone
rapidly reoxidized (25 min in a similar experiment using the
FAD/NADPH domain; data not shown) and that NADPH
did not directly reduce the FMN (no anchor) domain (data not
shown).
Interaction Between the FMN and FAD/NADPH Domains.
In view of the above observation, we determined whether the
two domains could bind directly to each other. The His-
tagged FMN (no anchor) domain was bound to a nickel-
agarose column and the FAD/NADPH domain (without the
His6 tag) applied. The FAD/NADPH domain became tightly
bound to the column, but only when the FMN domain was
bound. The FAD/NADPH domain could be dissociated from
the FMN (no anchor) domain and eluted by increasing the
ionic strength of the column buffer (Fig. 4), indicating that
ionic interactions were important for binding to occur.
In addition, the ability of the domains to bind cytochrome
c was studied. When cytochrome c was applied to the column
containing the immobilized FMN (no anchor) domain it was
retained on the column. This could also be eluted by increas¬
ing the ionic strength of the buffer (data not shown). In a
similar experiment with the FAD/NADPH protein immobi¬
lized on a nickel-agarose column, cytochrome c did not bind
(data not shown).
Functional Analysis of Domains and Reconstitution of Ac¬
tivity. The above data indicated that the FAD/NADPH and
FMN domains folded correctly and could interact to form a
complex with each other. We then established whether the
domains could couple to form a catalytically active unit. The
catalytic activity of the FAD/NADPH domain alone was also
assessed.
The FAD/NADPH domain could reduce a range of one-
electron acceptors and showed transhydrogenase activity in
the absence of the FMN domain but could not efficiently
reduce cytochrome c (Table 1). The activities measured were
to a varying degree decreased relative to native P450 reduc¬
tase. Activity toward these one-electron acceptors was not
significantly increased by the presence of the FMN (no
anchor) domain. However, cytochrome c reductase activity
was reconstituted when a combination of the FMN (no
anchor) and FAD/NADPH domains was used. The activity
of the reconstituted domains was found to be around 2% that
of the native enzyme.
To test for the reconstitution of cytochrome P450 monoox-
ygenase activity, the rat cytochrome P450 CYP1A1 was
incorporated into incubation mixtures containing the FMN/
anchor and FAD/NADPH domains. Activity was monitored
as the rate of EROD. In this case a functional monooxyge-
nase system could be reconstituted. Virtually no activity was
measured when the FMN/anchor domain was omitted, but
when it was replaced by the FMN (no anchor) domain some
FT 10 25 50 100 100 150
Fig. 4. Interaction of the FMN (no anchor) domain with the
FAD/NADPH domain. His-tagged FMN (no anchor) domain (2 mg)
was bound to a 1-ml nickel-agarose column and the FAD/NADPH
domain (0.1 mg/ml) was applied in 1 mM potassium phosphate (pH
7.7). This resulted in the binding of the latter domain. The concen¬
tration of the buffer passed through the column was then increased
from 1 to 150 mM in a stepwise fashion and the resulting eluates were
analyzed by Western blotting using an antibody to full-length P450
reductase. FT, flowthrough.
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Table 1. Specific activities of P450 reductase and domains
Specific activity (%)
























Specific activities are expressed as /xmol of substrate reduced per min per mg of protein, except for
menadione, where the oxidation ofNADPH was followed, and CYP1A1 activity, which was determined
as EROD activity and is expressed as nmol of resorufin produced per min per nmol of P450. All assays
were carried out in triplicate with SEM < 5%.
*3-Acetylpyridine adenine dinucleotide phosphate.
deethylation was measured (around 20% of that seen with the
FMN/anchor; data not shown). Also, when P450 was not
present no activity was measured. The reconstitution was
time dependent (Fig. 5A). Reconstitution of cytochrome c
reductase activity was also time dependent (data not shown).
The ability to reconstitute P450 reductase activity was ionic-
strength dependent (Fig. 5B).
To establish whether the FMN/anchor domain could in¬
teract with P450 to affect the coupling of P450 reductase to
P450, the effect of adding this domain to a reconstituted
system containing native P450 reductase and CYP1A1 was
investigated. Preincubation of CYP1A1 with the FMN/
anchor domain resulted in almost complete inhibition of
EROD activity (Fig. 6). Fifty percent inhibition was observed
at a domain/native reductase ratio of =4:1. The FAD/
NADPF1 domain had little effect on EROD activity, although
a reproducible slight decrease in activity was seen at the
lowest domain concentration tested. An interesting result
was observed when titrating the FMN (no anchor) domain
into the reconstituted system. This domain was found to
activate EROD activity up to 3-fold. This appeared to be
specific, as the denatured FMN domain or free FMN did not
cause this effect (data not shown).
DISCUSSION
We describe the dissection of an FMN/FAD-containing
flavoprotein, NADPH-cytochrome P450 oxidoreductase,
into structurally and functionally independent domains. This
provides strong experimental evidence to substantiate the
hypothesis that this protein has evolved from two distinct
ancestral genes (15). Indeed, many of the properties of the
ancestral proteins appear to have been retained and there is
no need for direct interaction between the two domains for
FMN and FAD binding. However, for stabilization of the
incorporated flavin in the protein (i.e., to maintain a 1:1 molar
ratio FAD or FMN to protein) and for efficient electron
transfer, interactions may be needed between the domains
and/or flavins.
The expressed FAD/NADPH domain could catalyze the
reduction of certain compounds, indicating correct folding of
both the FAD and NADPH binding regions. Certain reaction
rates were comparable to those of the native enzyme, indi¬
cating that the FAD/NADPH domain is at least in part
responsible for the one-electron reduction of many com¬
pounds, including redox cycling drugs. The much slower rate
of reduction of substrates such as menadione by the FAD/
NADPH domain indicates that for certain compounds this
region is not the major site of reduction. Previous work on the
FMN-depleted native P450 reductase also indicated that this
was the case (29, 30). The FAD/NADPH and FMN domains
could be reconstituted to form a complex active in the
reduction of cytochrome c and in donating electrons for
cytochrome P450-dependent monooxygenase reactions. This
fascinating finding demonstrated that electron transfer be¬
tween the domains, although not optimal, could be achieved.
Studies into why these interactions are so sensitive to ionic
strength, and studies into optimal domain size should identify
some of the structural and functional requirements needed for
efficient transfer between the peptides.
Comparison of the FMN-binding region of P450 reductase
with the flavodoxin from Desulfovibrio vulgaris shows that
highest homology lies within exons 4-6 (19). However, we
chose to express exons 2-8 and exons 3-8 as the FMN-
binding domain. In recent experiments we have expressed
only exons 4-6 but found that this protein did not bind FMN.
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Fig. 5. (A) Reconstitution of cytochrome P450 monooxygenase
activity. The FMN/anchor and FAD/NADPH domains (0.1 nmol)
were mixed in 10 mM potassium phosphate (pH 7.7) in a volume of
20 fx\ at 4°C. After various times the domains were incubated with
dilauroyl phosphatidylcholine (25 /xg) and CYP1A1 (37.5 pmol in 5
/xl) at 37°C for 5 min before assay EROD activity (24). (B) Effect of
ionic strength on the reconstitution of EROD. Domains were prein-
cubated, as described for A, for 2 hr in various concentrations of
potassium phosphate buffer at pH 7.7. Dilauroyl phosphatidylcholine
(25 /ug) and CYP1A1 (37.5 pmol in 5 /u.1) were then added and
incubated at 37°C for 5 min before assay for EROD.
0 0.5 1.0 1.5
Domain, nmol
Fig. 6. Inhibition of monooxygenase activity by the FMN/
anchor domain of P450 reductase. CYP1A1 (7.5 pmol) and 25 fxg of
dilauroyl phosphatidylcholine were incubated for 5 min with various
concentrations of the FMN/anchor (•) or FAD/NADPH (o) domain
(0.04-1.7 nmol) in 47.5 /xl at 37°C for 5 min. Native P450 reductase
(0.05 nmol in 2.5 /ul) was then added and the sample was incubated
for 5 min before measurement of EROD activity. Results (mean ±
SEM, n = 3) are expressed as percentage of the activity in the
absence of the domain; 100% = 6.34 nmol/min per nmol of P450.
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of spinach ferredoxin NADP+ reductase have revealed that
the minimal FAD/NADPH-binding region of the protein
should be contained within exons 12-16 (32). However,
expression of exons 12-16 yielded an insoluble protein which,
from its white appearance, did not bind FAD. In other cases,
even when insoluble products were formed, the color of the
protein suggested that flavin had been incorporated.
Expression of the FAD-binding region of P450 reductase,
excluding the proposed NADPH-binding domain (exons 15
and 16) (Fig. 1), generated an insoluble protein that did not
bind FAD. Alignment of this region with spinach ferredoxin
NADP+ reductase shows that exons 15 and 16, in addition to
containing important amino acids for NADP+ binding, con¬
tain residues involved in covering the face of the flavin
without hydrogen bonding to it (32). It has also been sug¬
gested that the large contact surface between the FAD- and
NADPH-binding domains would not allow them to be func¬
tionally separated (32). These observations would explain
why the FAD domain did not fold in the absence of the
NADPH domain.
The binding between the FMN (no anchor) and FAD/
NADPH domains, the interaction of the FMN (no anchor)
domain with cytochrome c, and the reconstitution of mono-
oxygenase activity were all ionic-strength dependent. These
findings are probably related to the highly charged nature of
P450 reductase, which contains 97 Asp and Glu residues and
74 Arg and Lys residues out of a total of 677 amino acids. The
direct involvement of the FMN (no anchor) domain with
cytochrome c binding and in its reduction is in agreement
with previous studies (29, 31, 33). Crosslinking studies of
native P450 reductase with cytochrome c indicate that amino
acids 207-215 of the reductase are involved in the binding
between the two proteins (33). These residues are located in
the FMN domain. Various amino acids within the FMN
domain have also been implicated in P450 interactions (34).
The FMN/anchor domain was found to be a potent inhib¬
itor of reconstituted monooxygenase activity. This could be
explained by the domain preventing the association of the
P450 to P450 reductase. This suggests a role for the hydro¬
phobic anchor in directing P450 reductase to the P450, as
suggested in earlier studies (23, 35). However, the His6 tag
and thrombin cleavage site could not be removed from this
domain. It cannot be ruled out that the His6 tag may affect the
association of the domain with the bilayer and that the
inhibitory effect we observe may be occurring outside the
bilayer. The FMN (no anchor) domain did not inhibit but
significantly increased monooxygenase activity. This could
be explained if the FMN (no anchor) domain can accept
electrons from the FAD of native P450 reductase and supply
electrons directly to P450.
Our data support the hypothesis that P450 reductase has
evolved as a fusion of two ancestral proteins (15). Indeed, we
may speculate that as two independent proteins the ancestors
of P450 reductase functioned as a dehydrogenase/electron-
transferase in a primitive organism. By fusion of the genes
encoding these ancient flavoproteins a more catalytically
efficient electron-transfer system was produced.
The ability to dissociate the protein into domains will be of
significant value for x-ray and NMR studies as well as in
understanding how the domains interact with each other and
with cytochrome P450 to form a functional electron-transfer
unit. Such studies will provide insights into the function of
structurally related proteins such as nitric oxide synthase and
sulfite reductase.
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Autoantibodies to hepatic microsomal
carboxylesterase in halothane hepatitis
Graeme C M Smith, J Gerald Kenna, David J Harrison,
David Tew, C Roland Wolf
Halothane hepatitis can be life-threatening, and this severe
adverse reaction may arise via an immune process. We have
detected autoantibodies to purified human liver microsomal
carboxylesterase in sera of 17 out of 20 patients with
halothane hepatitis (85%) but not in 9 halothane-exposed
controls and in only 2 (at low levels) of 33 patients with liver
disease due to other causes. Immunohistochemical studies
localised the carboxylesterase predominantly to the
centriiobular region of liver sections, which is consistent with
the area affected by halothane hepatitis. Human hepatic
microsomal carboxylesterase is a target antigen in halothane
hepatitis, and an immune response to this protein may be
involved in the liver damage observed.
Lancet 1993; 342: 963-64
Halothane causes two types of hepatotoxicity. The milder
form is characterised by minor increases in serum
transaminases, develops in 20% or so of patients, and has
been attributed to cytotoxic effects of halothane
metabolites.12 The severe form (halothane hepatitis) is
much rarer (1 in 10 000) but it can lead to massive hepatic
necrosis and death.1-2 Halothane hepatitis may arise
via an immune response to halothane-modified
(trifluoroacetylated) liver proteins2 and a similar
mechanism could underlie the very rare hepatotoxicity
caused by enflurane and isoflurane.3 Several of the
implicated trifluoroacetylated proteins have been purified
from halothane-treated rats and characterised
biochemically.2 One of them, a purified 59 kDa rat protein,
corresponds to a carboxylesterase isozyme.4 We have
purified the equivalent carboxylesterase isozyme from
pooled human livers (unpublished) and report here that
carboxylesterase autoantibodies are present in the sera of
patients with halothane hepatitis.
Sera from 20 patients with halothane hepatitis, defined clinically as
otherwise unexplained hepatitis within 28 days of halothane
anaesthesia, were studied. They were aged 32-60 (median 53) and
17 were female. All had had halothane anaesthesia before, on
between 1 and 8 occasions (median 2), and the interval between the
current and previous or latest prior exposure ranged from 7 days to
10 years (median 6 weeks). 13 patients had liver failure and 12 died.
Control sera were obtained from 9 patients who had received
halothane several times without liver damage; from 18 healthy
blood donors; and from 11 patients with fulminant hepatic failure
(6 paracetamol, 2 hepatitis B, 1 hepatitis A, 2 non-A, and non-B
hepatitis), 6 with autoimmune chronic active hepatitis, 4 with
alcoholic liver disease, 8 with primary biliary cirrhosis, and 4 with
jaundice due to flucloxacillin.
Purification and characterisation of human liver
carboxylesterase and production of a monospecific polyclonal
antiserum will be described elsewhere. Antibodies to
carboxylesterase were determined by enzyme-linked
immunosorbent assay.5 Sera were screened at a dilution of 1 in 100,
using a polyclonal sheep anti-human IgG coupled to horseradish
peroxidase (Scottish AntibodyProduction Unit, Lanark), diluted 1
in 1000, as secondary antibody. Sera were regarded as antibody
positive when optical density (OD) values at 492 nm were more
than 2 SD above the mean for the blood donors (OD> 0-211).
Immunohistochemical analysis was done on formalin-fixed,
paraffin-embedded liver tissue.6
Antibodies to human liver carboxylesterase were
detected in 17 patients with halothane hepatitis (85%)
but not in 9 halothane-exposed patients with no liver
disease (figure 1). Low levels were detected in 2 patients
with primary biliary cirrhosis but all the 31 other
patients with non-halothane liver disease were negative.
Immunohistochemical studies with rabbit polyclonal
antiserum revealed that the human liver carboxylesterase
was present throughout the liver but was concentrated in
the centriiobular region (figure 2). The pattern of damage
commonly observed in patients with halothane hepatitis is
also centrilobular.1 These findings suggest that an immune
response to human carboxylesterasemay have an important
role in the development and/or perpetuation of halothane
hepatitis.
Microsomal carboxylesterase is one of a group of at least
eight hepatic microsomal proteins that interact covalently
with trifluoroacetylchloride, the major reactive metabolite
produced in the livers of laboratory animals and patients
exposed to halothane at normal oxygen tensions.2,48
Furthermore, immunohistochemical studies with rabbit
antiserum specific for the covalently bound trifluoroacetyl
hapten show that, in livers of halothane-treated rats, the
trifluoroacetylated proteins are concentrated in the
centrilobular region.7 Presumably it is trifluoroacetylated
carboxylesterase that provides the immunogenic stimulus
that, in susceptible individuals, gives rise to an antibody
response.
We do not know why such an antibody response is seen in
patients with halothane hepatitis but not in halothane-
exposed patients in whom hepatitis does not develop.
All exposed patients metabolise halothane to
trifluroacetylchloride and produce trifluoroacetylated
protein antigens.9 Susceptibility factors may include
individual variability in the level of expression of the
cytochrome P450 isozyme responsible for bioactivation of
halothane (probably CYP2E12), in the level ofexpression of
the protein targets, in the presentation of antigens to the
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Figure 1: Detection of antibodies to carboxylesterase in
patients' sera by ELISA
Dotted line shows upper limit of normal control range.
2
Figure 2: Immunohistochemical staining of human liver section
with rabbit polyclonal antiserum to human liver
carboxylesterase
The carboxylesterase we used was purified from liver
obtained from a pool of individuals with no recent exposure
to halothane so the reactivity detected by ELISAmust have
been due to recognition of native, non-trifluoroacetylated
epitopes—ie, the patients' antibodies are true
autoantibodies. Experiments with immunoblotting8 have
indicated that the major epitopes on rat hepatic
trifluoroacetylated proteins which are recognised by
antibodies from patients with halothane hepatitis are the
trifluoroacetyl-hapten together with essential structural
features unique to the protein carriers.4-8 In general the
patients' antibodies did not recognise non-
trifluoroacetylated rat proteins.4-8 Sequence identity for
human and rat hepatic carboxylesterases is only 77%
(unpublished) so the non-trifluoroacetylated epitopes
recognised by the patient's antibodies may not be found in
the rat protein—or the epitopes may be conformational,
detectable by ELISA but destroyed by the harsh conditions
of immunoblotting.
The diagnosis of halothane hepatitis is largely a clinical
one, by exclusion of other possible causes of liver damage.
The diagnosis can be confirmed by testing for antibodies to
trifluoroacetylated liver proteins2-5-8 but the assays
described are technically demanding. A carboxylesterase
ELISA offers promise as a quick, simple, and sensitive test.
In principle, the assay might also identify patients
previously sensitised to lialolharie and aL risk of hepatitis if
re-exposed.
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